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Myxomatous mitral valve disease (MMVD) is the most common cardiac 
disease in dogs and the second most common cardiac valvular disease in 
humans. MMVD is particularly prevalent in small breed dogs (such as the 
Cavalier King Charles Spaniel (CKCS)) but by age 10, almost all dogs will have 
some form disease developing on the valve. Pathologically, there is a 
progressive deterioration in the organised structure of the valve extracellular 
matrix with an accumulation of proteoglycans and glycosaminoglycans, 
breakdown of collagen fibrils and loss of elastin and basement membrane 
components. Alongside this, there is an activation of quiescent valvular 
interstitial cells (VICs) into a myofibrotic phenotype, denuding of endothelial 
cells and endothelial-to-mesenchymal transition. Despite this knowledge of 
pathology and the clinical significance of MMVD, there is a lack of 
understanding of the underlying cellular and molecular mechanisms 
controlling the disease. This is particularly true of early disease development 
as the majority of previous studies have focused on comparing normal valves 
with end-stage disease.   
This project aimed to address this problem by examining the transcriptomic 
changes occurring in MMVD in the dog: across the entire pathogenesis of the 
disease, in regional development of the disease on the valve and in in vitro 
models of disease.  
Utilising the Whitney grading system (Grades 0-4), where Grade 4 represents 
severe disease, valves were collected (5 grades, n=6 per grade) from the entire 
spectrum of disease and in a mixture of dog breeds. Transcriptomic profiling 
(Affymetrix GeneChip™ Canine Gene 1.1 Sense Target (ST) Array) was 
performed and 1002 differentially expressed genes were identified across all 
iv 
grades of disease. Network analysis was used to cluster genes with similar 
expression profiles and establish trends of progressive up- or down-regulation 
over the course of MMVD. Gene enrichment analysis highlighted GO terms 
both associated with these trends and in a grade-specific manner. Pathway 
analysis established the top canonical pathways, upstream regulators and 
disease function networks associated with each grade of disease. As a whole, 
these results indicated dysregulation of metalloproteases (both up- and down-
regulation) and involvement of immune-related pathways as well as, most 
importantly, the repeated implication that TGFβ signalling is a controller in 
disease development. Furthermore, sample-to-sample analysis indicated 
CKCS, who have an earlier onset of disease than other dogs, had a slightly 
different transcriptomic profile compared to other valves, with analysis 
indicating a role for down-regulated calcium signalling and cell contractility 
in early disease development in this breed.  
Transcriptomic analysis comparing distinct diseased and normal areas of the 
same moderately affected valves (n=7) found 289 differentially expressed 
genes, including hallmarks of disease ACTA2 and 5HTR2B which were up-
regulated in the diseased sections of the valves. Comparison of the ‘normal’ 
tissue in this dataset with the whole normal valve dataset and dissection of 
comparable regions of normal valves and assessment by RT-qPCR indicated 
that the changes being measured were disease-specific and validated the 
approach used. Gene enrichment analysis of this dataset also implicated 
TGFβ1 as the top upstream regulator of disease.   
To further explore the role of TGFβ1 signalling in MMVD, VICs from normal 
(n=3) and diseased (n=3) valves were treated with 5ng/mL TGFβ1 and 10 µM 
SB431542 (TGFβ pathway inhibitor) respectively, with appropriate vehicle 
controls. Differential gene expression was identified comparing normal VIC to 
v 
normal VIC TGF-β1-treated (275 genes), diseased VIC to diseased VIC 
SB431542-treated (236 genes) and diseased VIC to normal VIC (902 genes). 
Normal VICs transformed to myofibrotic cells in the presence of TGFβ1, with 
increased αSMA (ACTA2) expression and a 5 fold increase in proteoglycan 
secretion (p<0.05), consistent with the pathology in vivo. Diseased VICs 
showed a significant 2 fold increase in TGFβ1 secretion compared to normal 
VICs, and in the presence of SB431542 reverted to a normal phenotype with a 
reduction in αSMA expression and 2.8 fold decrease in proteoglycan secretion 
(p<0.05).   
To summarise, this study provides insights into the molecular pathogenesis of 
MMVD from its early development to its end stage consequences and 
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Lay Summary 
Myxomatous Mitral Valve Disease (MMVD) is a common disease that affects 
both dogs and humans. The disease causes a gradual deterioration in the 
structure of a major heart valve to the point where the valve is no longer 
functional, so that blood can flow back towards the lungs. If left untreated 
MMVD can lead to death. Despite the prevalence of this disease in both species 
and the dire consequences that can result, there is a poor understanding of the 
underlying mechanism that causes the disease to develop. By studying the 
disease in dogs a full understanding of these mechanisms is achievable due to 
the ready availability of owner donated tissue that will encompass the entire 
development of the disease. By examining RNA (the intermediate step 
between DNA and proteins) from normal valves and those at different stages 
of the disease, a comprehensive assessment of MMVD can be carried out.  
In this project, whole valves spanning the entire course of disease, moderately 
affected valves dissected into diseased and normal tissue sections and cell 
culture assessment of valvular interstitial cells (the cells inside the valve 
responsible for their structure) had their RNA investigated.   
Analysis of the RNA from the tissue samples (both whole and dissected 
valves) indicated the involvement of factors that would cause a dysregulation 
and breakdown of the valve structure. Perhaps most importantly, however, 
TGFβ1 (a factor responsible for various cellular processes) was implicated 
consistently as the driving factor in disease development.  
Investigating TGFβ1’s effect on the valvular interstitial cells grown in culture 
in the laboratory, we saw that treating normal cells with this factor induced a 
disease-like state in the cells that shared many similarities with the diseased 
tissue. Likewise, treatment of diseased cells with a TGFβ pathway inhibitor, to 
viii 
block the effects of TGFβ, resulted in a reversal towards a more normal-
appearing cell.  
Collectively this study has shown that TGFβ1 plays a major contributing role 
in the development of MMVD. It is hoped that new drugs and treatments can 
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   Introduction 
1.1 Overview of Myxomatous mitral valve disease  
Myxomatous mitral valve disease (MMVD) is a progressive disorder which, 
over the lifetime of the affected individual, causes a deterioration in the left 
atrioventricular (mitral) valve to the point where it is no longer functional[1-9]. 
Spontaneously developing non-syndromic MMVD is primarily found in 
humans and dogs, although there have been indications that it can arise 
naturally in Fischer 344 rats and be induced by gene interference or surgical 
intervention in the mouse, pig, sheep and cow[1, 2, 10-18]. Disease typically 
presents clinically in older individuals and can result in valvular prolapse, 
regurgitation and backflow of blood into the left atrium, congestive heart 
failure and eventually death[2, 19-21]. It is the most common acquired cardiac 
disease of the dog, with almost all dogs developing some form of the disease 
over the course of their natural lifespan, and is a major cause of morbidity and 
mortality in this species[1, 2, 22-26]. MMVD occurrence in humans, both 
spontaneous and syndromic, is estimated at approximately 2%–3% of the 
global population and approximately 15% of those affected will require valve 
surgery[27-29]. Although key differences exist, there is a level of shared 
pathophysiology in spontaneous MMVD development between the dog and 
human so that research in both species is likely to be applicable to a broader 
disease understanding[1, 10, 11, 19, 22, 30]. Reference to MMVD has been present in 
the literature for well over a century and is even alluded to by Sir Arthur 
Conan Doyle in the adventures of Sherlock Holmes, for example when, in The 
Sign of Four, the neurotic Thaddeus Sholto confides that he has “grave doubts 
as to my mitral valve” [20, 31, 32]. However, despite the clinical significance and 
the long standing natural history of the disease, the underlying mechanisms 
for the development of disease in both species is poorly understood, especially 
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the events governing early disease development[1, 33]. Without this 
fundamental understanding, the advancement of new therapeutics that could 
halt the progress or reverse and cure MMVD has faltered. Currently, surgery 
is the only form of treatment in humans, whereas dogs almost exclusively only 
receive palliative treatment for the effects of the disease[20, 34, 35]. Research into 
the overall development of mitral valve pathology is therefore clearly 
warranted to allow for new perspectives and hypotheses to be generated that 
could eventually lead to improved outcomes in both humans and dogs. This 
study aims to investigate the biology of MMVD development in dogs.  
1.2 Features of the normal and pathological canine valve 
1.2.1 Normal valve structure 
The mitral valve consists of two leaflets the anterior and posterior, which are 
also commonly referred to as septal and parietal respectively in veterinary 
science. These are connected to the heart by the annulus fibrosus, a highly 
fibrous ring encircling the entire mitral valve, which is made of dense collagen 
and elastin and acts (amongst other functions) to anchor the valve leaflets in 
place[2, 36, 37]. The leaflets are also connected to papillary muscles in the left 
ventricle by the chordae tendineae which are thin fibrous chords again 
composed of elastin and collagen bundles[2, 36]. The chordae attach either to the 
valve leaflet edge (first order), preventing prolapse during left ventricular 
contraction, or to the ventricular surface close to the valve edge (second order), 
helping to maintain valve geometry[2, 38, 39]. The latter’s attachment results in a 
rough and irregular surface to the underside of the leaflets, while the atrial 
surface is smooth. There can be marked variation in chordae/papillary muscle 
organization, and such variation is regarded as normal[2]. Overall, the normal 
leaflet has a partially translucent appearance and is roughly divided into 
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proximal, mid- and distal zones, the latter also known as the ‘free edge’[2]. The 
features described here are highlighted in Figure 1-1. 
 
Figure 1-1. Healthy canine mitral valve. (A) Gross view of the valve after 
dissection. Note the presence of an anterior leaflet (AL), posterior leaflet (PL) 
and chordae tendineae (arrows) connecting the leaflets to the ventricular 
papillary muscles (PM). (B) Masson’s trichrome stain of the anterior leaflet 
of the mitral valve, highlighting its two surfaces (atrial and ventricular), the 
proximal/medial/distal areas, the presence of myocardium extending into 
the base of the valve (*), and the attachment of the chordae tendineae. Note 
that all of the chordae included are of second order. Arrowheads indicate 
chordae. Taken with permission from Markby et al (2017)[2]. 
Each leaflet has an atrial and a ventricular surface and a single layer of valvular 
endothelial cells (VECs), continuous with that lining the atrium and ventricle, 
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covers each surface[2, 40]. VECs are attached to a thin basement membrane layer, 
which consists of a mixture of fibronectin, laminin, a small amount of 
collagens I, III, IV and VI and the basement membrane-specific proteoglycan, 
heparan sulphate[1, 36]. In the mid-zone, there are three identifiable layers: the 
atrialis, the spongiosa and the fibrosa. The thin atrialis contains some valvular 
interstitial cells (VICs) and is rich in elastin and highly-organised mature 
collagen fibres (types I, III, IV and VI), which support valve movement 
through extension and recoil[1, 2, 41]. VICs in normal valves have 
overwhelmingly a quiescent phenotype and operate in a homeostatic role, 
discussed later (section 1.3.2)[1, 2, 41-45]. The spongiosa, which contributes to valve 
structure and compressibility, consists of loose collagen fibres (I and III) and 
small numbers of thin elastin fibres. These are embedded in a ground 
substance rich in glycosaminoglycans (GAGs) such as hyaluronan, and 
proteoglycans, including large proteoglycans like versican and small leucine 
rich proteoglycans (SLRPs) such as keratocan and decorin [1, 2, 36, 37, 41, 42, 46]. The 
majority of cells in the spongiosa, and throughout the whole valve, are 
quiescent VICs, but there is also the presence of a small number of mast cells 
as well as adipocytes, with extension of atrial myocardial cells into the 
proximal/ base end of the valve (as seen in Figure 1-1)[1, 2, 36, 44, 47-49]. These 
myocardial cells extend from the atrial myocardium for a variable length along 
the valve leaflets, and this decreases with age, with likely important functional 
implications in valve mechanics[2, 47]. Immediately beneath the spongiosa is the 
dense well-organized fibrosa layer with predominantly well-defined collagen 
bundles (types I, III and V) and scattered VICs[1, 2, 36]. The fibrosa is continuous 
with the annulus fibrosus and branches off to form the core of the chordae 
tendineae[2]. The thin sub-endothelial layer on the ventricular side has collagen 
fibres and occasional elastin, and is suggested to be an additional fourth layer 
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(ventricularis) similar to that seen in the aortic valve[2]. The fibrosa and the 
ventricularis have a tensile role, protecting against prolapse from the strong 
haemodynamic forces during left ventricular contraction[2, 41]. Towards the 
distal zone (free edge), the distinction between spongiosa and fibrosa, at least 
in some dogs, can become indistinct and the valve at this level appears to 
consist almost entirely of spongiosa covered by endothelium[2]. These features 
are schematised in Figure 1-2.  
 
Figure 1-2. Schematic diagram of the normal mitral valve. Taken with 
permission from Markby et al (2017)[1]. 
1.2.2 Whitney grading and gross pathogenesis of MMVD 
In canine MMVD, gross changes to the leaflets, including increasing 
nodularity, thickening and deformity, are thought to develop relatively slowly 
over the course of the dog’s lifetime[2]. These changes are often classified 
according to the Whitney grading system, proposed by J.C. Whitney in 1967, 
and are graded 0 to 4 with 0 being normal and 4 the most advanced form of 
the disease[2, 4, 9, 11, 19, 50]. This simple system is based on the degree of nodularity, 
thickening and deformity of the valve and allows quick and straightforward 
categorisation of the severity of valve pathology. Furthermore, this system is 
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clinically relevant with a close association of the assigned grade to the degree 
of cardiac murmur, a cardinal clinical sign of MMVD[2, 49]. Typically, the 
disease starts with small numbers of discrete nodules developing on the free 
edge of the leaflet with intervening areas of translucent leaflet (grade 1), 
progressing to the development of larger nodules (grade 2), coalescence of 
these nodules (grade 3), involvement of the chordae and, finally, gross 
distortion and ballooning of the leaflets with marked chordal thickening and 
eventual chordal rupture (grade 4). An alternative method has been proposed 
for assessing the disease grade on dogs. This is based on measuring the 
thickness of the nodules on valves with 1-2.5mm thick nodules being early 
disease and >2.5mm nodules being late-disease, however given the variability 
in nodule size across a valve and the time required to make such 
measurements this method has not been widely adopted[43, 51]. Gross and 








Figure 1-3. Whitney grading scheme for myxomatous valvular degeneration. 
Both the gross and haematoxylin and eosin stained histological 
presentations are illustrated. Histological images are all shown with the free 
edge (distal portion of the leaflet) on the right. Note the location of 
myxomatous nodules at the tip of the mitral leaflets. There is an increase in 
nodule size with grade, which results in marked distortion of the leaflet tip 
at higher grades. In grade 4, there is an evident thickening of chordae 
tendineae. Scale bar, 2 mm. Taken with permission from Markby et al 
(2017)[2]. 
Change in the thickness of the edge of the valve, associated with disease 
progression, has also been confirmed on histological samples, with the 
posterior leaflet being slightly thicker than the anterior leaflet in disease in the 
dog[2, 49]. Interestingly, while MMVD regularly affects both leaflets in the dog, 
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it mainly affects the posterior leaflet in humans[1, 5, 30, 52]. Additionally, in both 
canine and human disease, there is a lengthening of the valve with advancing 
disease as evidenced by the alteration in the ratio of the anterior-to-posterior 
leaflet length, but the anterior leaflet is always longer than the posterior leaflet, 
irrespective of disease severity[2, 49]. Chordal changes mirror those seen with 
the valve proper with swelling, thickening and eventual rupture, but chordal 
changes have not been reported in detail[2, 36]. 
1.2.3 Pathological valve structure and features 
Myxomatous degeneration is typified by a disorganisation and dysregulation 
of the extracellular matrix. In canine MMVD this is seen with an expansion of 
the spongiosa and loss of the fibrosa and atrialis. In areas of myxomatous 
degeneration, the expansion of the spongiosa involves an increased presence 
of GAGs, proteoglycans, disorganised collagen fibrils as well as increased 
retention of water and amorphous metachromatically-stained mucoid 
material[1-3, 11, 19, 36, 42, 49, 53-55]. In depleted areas of atrialis and fibrosa, there is a 
breakdown of the ordered collagen and elastin layers, contributing to the 
eventual valvular incompetency due to a loss in tensile strength and ordered 
structure[1, 49]. Overall, depending on the grade of disease, there are also 
changes in laminin, elastin and collagens IV and VI in the sub-endothelium, 
and elastin, fibronectin and collagens I and II deeper in the leaflet[2, 56].  
Alongside the breakdown of the valve extracellular structure, there are also 
cellular changes occurring during disease development. There is dysfunction 
and loss of basement membrane, which can also result in the loss and 
denuding of VECs[1, 2, 40]. Furthermore, it has been shown VEC loss can be 
exacerbated by the activation of endothelial-to-mesenchymal transition 
(EndoMT), a developmental pathway involved in the formation of valves, 
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which contributes to the VIC population[2, 57-59]. Perhaps most important of all 
is the activation of the VICs from a quiescent to a myofibroblast-like 
phenotype [1, 36, 40, 42, 43, 48, 60, 61]. It is the activation of VICs which is thought to play 
a pivotal role in the development of MMVD through the release of catabolic 
enzymes and the dysregulation of proteoglycan and collagen synthesis 
resulting in aberrant remodelling[1, 42, 43, 49, 60]. Further aspects of cellular changes 
will be described in more depth in section 1.3 and the pathological features are 
schematised in Figure 1-4. 
 
Figure 1-4. Schematic of pathological changes associated with MMVD. 
Taken with permission from Markby et al (2017)[1].  
1.2.4 Normal and pathological valve haemodynamics and biomechanics 
Despite their small size and relatively basic design, heart valves are critical for 
proper functioning of the heart. They experience a huge amount of stress over 
the course of an animal’s lifetime, in the form of haemodynamic shear stress 
(which is caused by the force of blood flow passing over the valve) and 
biomechanical flexure (the force exerted whilst the valve is opening and 
closing) and tension (the force during coaptation just prior to ventricular 
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ejection)[62]. Of all valves, the mitral valve is required to deal with the greatest 
stress due to the higher pressures involved in left ventricular ejection[15]. Under 
normal circumstances, the valve should adequately accommodate these forces 
due to the structure and composition of the valve (described in section 1.2.1)[15]. 
However, these forces do have an effect on the valvular cells in the long term. 
VEC phenotype differs not only in general from other vascular endothelial 
cells, but also on whether they are on the atrial or ventricular side of the valve, 
where there are marked differences in exposure to shear stress force[63-66]. VIC 
phenotype can also be mechanically manipulated, both in vitro and in vivo. 
Exposure both to forces, such as tension, or to pathological flail (chordae 
rupture causing prolapse) can transiently induce a more activated VIC 
phenotype with the production of extracellular matrix components to 
compensate[67-70]. The fact that valvular cells show a plasticity in response to 
these forces supports the hypothesis that these forces could, in part, be 
responsible for MMVD development[71]. However, while the role of these 
forces in the chronic progression of MMVD is yet to be fully elucidated, it is 
an important consideration in MMVD pathogenesis, especially for studies in 
vitro. 
1.2.5 Comparative pathology of canine and human MMVD 
Spontaneously developing non-syndromic MMVD regularly occurs in both 
the dog and the human, with the dog proposed as a candidate model of disease 
in humans[1, 10, 11, 22]. Although broadly speaking the previously described 
(section 1.2.3) pathological features of MMVD are similar in both the dog and 
human, some key differences do exist. Spontaneous disease in the dog has 
been characterised as likely to be a single disease with the features described 
above, but the reason behind disease development unknown. In humans, both 
spontaneous and syndromic MMVD have been identified and the valvular 
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disease can also be a consequence of other diseases (such as rheumatic fever 
and bacterial endocarditis)[1]. Examples of syndromic MMVD include Marfan 
syndrome (caused by mutation of the FBN1 gene), Loey-Dietz syndrome 
(caused by mutation of the TGFBR1, TGFBR2, SMAD3, TGFB2 or TGFB3 gene) 
and Ehlers-Danlos syndrome (caused by mutation of various genes including 
different collagens and ADAMTS2 with some of these resulting in valvular 
pathology)[72-79]. Human spontaneous MMVD can be separated into two 
diseases; Barlow’s disease and fibroelastic deficiency (FED)[1, 5, 21, 80-82]. Both 
include the development of myxoid lesions but differ in how they progress. 
FED is known to have relatively fast onset (months) affecting typically older 
individuals (>60 years old) and is a result of the deficiency in key connective 
tissue components including collagens, proteoglycans and elastin with 
chordae rupture being a common occurrence[1, 27, 80-82]. This deficiency results in 
prolapse typically of a single valve segment and it is at these areas of prolapse 
that myxoid degeneration can be found[81]. Barlow’s disease, in contrast, has a 
much longer pathogenesis (years-to-decades), typically becoming clinically 
significant earlier in life (30-50s) but can also affect older individuals[81]. Like 
MMVD in the dog, Barlow’s disease has an unknown aetiology but seems to 
predominantly involve a myxomatous degeneration affecting all layers of the 
valve and can be found in multiple segments at once[80-82]. Additionally, 
differences in microRNA expression between the two human conditions have 
been shown, indicating potentially different mechanisms controlling non-
syndromic MMVD in humans[83]. Parallels can be drawn with MMVD in the 
dog from certain aspects of both diseases, such as the later age onset in FED or 
the longer pathogenesis of Barlow’s[1]. However, important differences do 
exist including the preponderance for the development of fibrosis in particular 
and sometimes calcification in the human disease which is not observed in the 
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dog[1, 80, 81, 84]. Nonetheless, the level of similarity in the myxoid regions of the 
valve, such as the presence of activated VICs, between the dog and both 
human diseases would allow reciprocal and comparative research to be 
valuable as long as the caveats are taken into account when interpreting data[1, 
10, 30, 82].     
1.3 Cellular changes 
1.3.1 Valvular endothelial cells (VECs) 
Under normal circumstances, VECs play a critical role in acting as a barrier 
between the blood flow and the extracellular structure within the valve[63, 85]. 
They form a cobblestone-like smooth layer across the valve surface (Figure 
1-2), easing blood flow across the valve surface, with tight cell-to-cell contact 
facilitated by the cell-to-cell adhesion protein vascular endothelial cadherin 
(CDH5) (often used as a marker for VECs)[40, 57-59, 63]. Other adhesion molecules 
involved include platelet endothelial cell adhesion molecule (PECAM1/CD31) 
as well as the glycoprotein Von Willebrand factor (vWF)[57-59]. Aside from 
acting as a barrier VECs also play an important role in interacting with the 
forces and factors in the blood pool as well as with the VICs internally in the 
valve[86-89]. Both shear stress to VECs and interaction of VECs with circulating 
cytokines and platelets have been shown to induce phenotypic changes in 
VICs[40, 48, 63, 90-92]. VECs have been shown to play a role in maintaining the 
quiescent phenotype of VICs even when these cells are under stress or 
undergoing activation[93, 94]. As discussed in section 1.2.3, normal VECs play a 
critical role in early valve development. EndoMT is the process by which 
endothelial cells undergo a transformation into a mesenchymal phenotype[95]. 
This involves the loss of the VEC markers and the expression of the 
mesenchymal markers such as α-smooth muscle actin (αSMA) and hyaluronic 
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acid synthase 2 (HAS2) as well as an increase in the expression of matrix 
metalloproteinases (MMPs)[41, 57, 96-101]. In valvular development, these changes 
facilitate the migration of VECs undergoing EndoMT into the hyaluronan-rich 
cardiac jelly, which allows for the elongation and expansion of the valve 
leaflets and population of the inner valve stroma with VICs[41, 58, 59, 62, 97-100]. This 
process is under the tight control of several different factors including NOTCH, 
vascular endothelial growth factor (VEGF) and members of the transforming 
growth factor β (TGFβ) superfamily including TGFβ1, 2 and 3 and bone 
morphogenetic proteins (BMPs) 2 and 4[41, 85, 96-98, 102-107].  
Changes to the endothelium are clearly seen in MMVD. Scanning electron 
microscopy demonstrates areas of endothelial loss, cellular pleomorphism and 
increased numbers of surface micro-appendages[2, 40, 108, 109]. These changes are 
suggestive of basement membrane abnormalities, endothelial cell death and 
reactive changes in the endothelium in response to insult. Similar changes can 
be identified with transmission electron microscopy, with VIC accumulation 
in the immediate sub-endothelium[2, 48, 61]. Additionally, the denudation of the 
valvular surface allows for the interaction of circulating cells and cell 
fragments such as platelets, with the underlying valve structure and VICs[40]. 
Endothelial damage has also been detected with a clear reduction of 
expression in CD31 and vWF in canine MMVD, and further reduction as the 
disease progresses[2, 43, 57, 110]. The transition of VECs as part of EndoMT is also 
an important change in disease. It has been hypothesised for many years that 
repeated damage to the leaflet edge is likely to play a role in the 
aetiopathogenesis of canine MMVD and the localisation of lesions to the valve 
edge with demonstrable changes to the endothelium would support that 
assertion. Functional changes in canine valve endothelium have been 
identified, with increased nitric oxide (NO) synthase activity (i.e. expression 
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of NADH, NADPH reductase and diaphorase), increased endothelin (ET) 
receptor expression (associated with severity), sub-endothelial collagen 
degeneration and deposition of mucopolysaccharides[2, 109, 111, 112]. This suggests 
that NO and ET might contribute to the development of MMVD, as both have 
an effect on extracellular matrix production[112]. The migration and localisation 
of activated VICs towards the endothelium in MMVD may be a part of this 
process and would fit into the endothelial injury model of disease 
pathogenesis[2, 43, 44, 61]. 
1.3.2 Valvular interstitial cells (VICs) 
VICs are the prevalent cell type and can be identified in all internal layers of 
the valve[2]. They can exist as a heterogeneous population in normal valves 
with five identifiable phenotypes: (1) embryonic progenitor 
endothelial/mesenchymal cells, (2) quiescent VICs (qVICs), (3) activated VICs 
(aVICs), (4) progenitor VICs (pVICs) and (5) osteoblastic VICs (obVICs)[45]. The 
embryonic progenitor cells arise from VECs undergoing EndoMT in the 
developing heart[2, 107]. Once the valve is formed, qVICs predominate and are 
thought to maintain valve structure and function (i.e. normal life-long valve 
remodelling) and inhibit angiogenesis in the leaflets. The qVICs are presumed 
to become activated to become aVICs in response to disease and injury, and 
then the latter regulates the pathobiological responses of the valve[113]. These 
two cell types are distinguished typically by assessment of the expression of 
ACTA2/αSMA, MYH10/embryonic smooth muscle myosin (SMemb) and 
TAGLN/Transgelin (SM22α) (gene/protein) with aVICs showing increased 
expression of these markers compared to qVICs[2, 43, 60, 114-116]. However, 
although expression of a marker indicates the aVIC phenotype, not all aVICs 
will express all markers at the same time, indicating different levels of 
differentiation capacity[2, 43, 110, 117]. Interestingly, all three of these proteins play 
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a positive role in cell contractility and it has been suggested that aVICs 
increase their expression of these proteins in response to the loss of valvular 
competence and integrity in disease acting to increase tensile strength[60, 61, 118-
120]. In addition, SM22α also contributes to the migratory capacity of 
myofibroblasts[120]. Morphologically qVICs differ from aVICs in vitro. qVICs 
show an orthogonal, honeycomb-like organisation with an elongated 
morphology, and aVICs show a far more disorganised structure with varying 
morphologies including a large rhomboid (“fried egg”) and a hyper-elongated 
morphology[45, 113, 121]. Also, in comparison to qVICs, aVICs show differential 
expression of metalloproteases, such as the MMPs and members of the 
ADAMTS family (a disintegrin and metalloprotease with thrombospondin 
motif) and other extracellular remodelling components, which is thought aid 
in their response to valve injury[1, 2, 27, 33, 60, 122-125]. Small numbers of desmin-
positive VICs with chondroblast morphology (obVICs) can be seen in some 
diseased valves, but, as discussed in section 1.2.5, calcification is not a clearly 
identified feature of mitral valve disease in the dog[44, 45]. 
As stated in section 1.2.3, and importantly, there is a consistent phenotypic 
alteration of the VICs during MMVD pathogenesis from the quiescent to the 
activated (myofibroblast-like) phenotype. These αSMA-positive cells increase 
in number with disease progression and are located primarily in the sub-
endothelium, with a preference for the atrialis layer[2, 43, 44, 48]. Throughout the 
diseased valve stroma many cells express SMemb, while some co-express 
αSMA and SMemb, with this dual expression suggestive of heightened 
differentiation capacity[2, 43, 110]. Increased expression of Ki-67 suggests there is 
cellular proliferation, but what contribution cell migration might make to the 
increased cell numbers in the sub-endothelium is unknown[110]. The 
contribution from the endothelium via EndoMT should also be considered[2, 57]. 
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There are also data suggesting that aVICs in MMVD have an altered apoptotic 
mechanism with cells entering a pro-apoptotic state, but are not undergoing 
apoptosis[126]. The persistence of aVICs has been hypothesised as a mechanism 
for disease pathogenesis[45]. Irrespective of their origin or lineage aVICs are 
found to lie in areas of loose collagen bundles and can be seen to exude fibrillar 
collagen on electron microscopy, with many localised away from the central 
myxomatous areas and close to the valve edge[61, 108, 109, 127]. This change in cell 
phenotype and localisation coincides with disease progression with 
demonstrable temporal and spatial alteration in valve cellularity[43, 44, 110]. 
However, the increased numbers of SMemb-positive cells in the spongiosa, 
and to a lesser extent the fibrosa, suggests a distribution of aVICs throughout 
the entire depth of the affected valve[43]. The relative contributions of the 
SMemb and αSMA activated myofibroblast subpopulations to the overall 
disease process are unknown[2]. The SMemb-positive cells show a much 
greater expression of 5-hydroxytryptamine (5HT) compared with αSMA-
positive cells. This is of interest considering the putative role of 5HT/TGFβ 
signalling in disease pathogenesis which will be discussed more in-depth in 
sections 1.5.1 and 1.5.2[43]. In the more advanced stages of the disease, VICs can 
appear more like smooth muscle cells in that they form syncytia and anchor to 
collagen bundles, and it has been suggested that this is to compensate for the 
reduction in valve tensile strength caused by disease[61, 108]. Coupled with this 
regionalisation of stromal cells, there is a reduction in cell number in overtly 
myxomatous areas compared with normal spongiosa, but there is no further 
change in cell numbers as the disease progresses[44, 109]. However, in both 
human and canine mitral valve disease, there is an increase in total cell number 
through the entire depth of the valve[44, 60, 114]. A confounding factor in 
interpreting changes in cell number is the increased thickness of diseased 
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valves compared with normal, and when cell numbers are indexed to area, 
there is, in fact, a decrease in cell density[49]. It is clear that there is a 
congregation of cells towards the periphery, close to the overlying 
endothelium and in areas of endothelial loss[43, 44, 48]. Experimental ovine valve 
injury models show the same effect[12, 14, 49, 61]. 
1.3.3 Other cell types  
The exact identity of all cells present in myxomatous areas is not known, as 
some are both vimentin (VIC marker) and αSMA negative. However, in 
diseased valves, the majority of the cells throughout the valve are SMemb 
positive and this, coupled with αSMA expression in some cells and their 
spindle shape, indicates that they mostly have an interstitial phenotype[43, 44]. 
In human MMVD, some cells are CD34 and CD117 positive, suggesting a 
circulating fibrocyte, mast cell and/or stem cell lineage, but further work is 
needed to determine their precise phenotypes and to see if the same 
populations occur in dogs[128, 129]. Additionally, in recent studies an increased 
presence of macrophages and T-cells have been shown in human MMVD[130-
132]. Furthermore, an involvement in immune-related pathways has been 
reported in transcriptomic studies in both humans and dogs[33, 131]. In dogs with 
advanced disease, there is evidence of a marginal increase in the number of 
mast cells in affected valves[44]. However, there is no evidence of the 
involvement of the resident macrophage population in disease pathogenesis, 
or recruitment of inflammatory cells, as evidenced by the lack of expression of 
CD68, CD11c, CD45 and MAC387[43, 44, 133]. This again is despite increased 
expression of gene transcripts encoding for several inflammatory cytokines 
and adhesion molecules[33, 110]. Electron microscopy has also failed to identify 
inflammatory cells in the stroma of diseased canine valves[61, 108]. Finally, there 
are adipocytes and myocardial cells, especially in the proximal third of the 
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valve. These cells increase in the valve as the dog ages, but this appears to be 
independent of the development of MMVD[36, 47]. 
1.3.4 Valvular cells in culture 
Both VICs and VECs have been successfully cultured from a variety of 
different species including pig, sheep, mouse, rat, human and dog[42, 60, 88, 121, 134, 
135]. In vitro study has provided valuable insight into both normal and 
pathological functions in these cells. For example; the identification of both the 
different VIC phenotypes and the sub-phenotypes in the aVIC population 
(section 1.3.2), the role of TGFβ as a potent activator of VICs in human VICs 
(section 1.5.1), and the effects of cyclic strain have on valvular cell phenotype 
(section 1.2.4) were elucidated using cell culture [45, 60, 69, 70, 85, 113, 136]. However, a 
major drawback of this approach to understanding MMVD pathogenesis has 
been the spontaneous activation of VICs in culture[45, 113, 137]. This has made 
deciphering the role of different factors in disease progression difficult and is 
a caveat that should be taken into account when interpreting the results from 
these studies. For example, all ‘quiescent’ porcine VICs will have transformed 
into activated myofibroblastic aVICs by passage 3-5 making long-term 
comparisons in culture difficult[138]. More recently, a study on human aortic 
VICs in 2D culture established a low serum protocol which maintained the 
quiescent phenotype, so allowing further study of this cell type in culture[138]. 
Using this low serum approach, simple 2D cultures can be used to test the 
effect of molecules of interest and allow for more credible studies comparing 
VICs isolated from normal and diseased valves.  
1.4 Molecular and biochemical changes in MMVD 
Molecular and biochemical changes that have been associated with MMVD 
have a focus, unsurprisingly, on the alteration to the extracellular matrix, 
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which is the key feature of MMVD (sections 1.2.3 and 1.3). Assessment of these 
changes has been made through the focused study of specific gene and protein 
changes, performed by RT-qPCR, immunohistochemistry or western blotting, 
and broader studies through transcriptomic and proteomic analysis. 
Expectedly, given the pathogenesis of the disease, a great number of these 
studies have concentrated on the extracellular matrix. Activation of VICs has 
been shown to be associated with the increased production of extracellular 
matrix which supports the hypothesis that this cell type is crucial to the 
development of MMVD (section 1.3.2)[1, 2, 43, 44, 51, 85, 114, 139, 140]. The extracellular 
matrix derangement may in part be due to altered expression of matrix 
metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMPs), the ADAMTS 
family of metalloproteases as well as cathepsins (another form of protease)[27, 
30, 33, 46, 114, 141-145]. As measured by immunohistochemistry in the dog with 
advancing valvular disease there is a decreased expression of the gelatinase 
MMP2, an increase in the cell surface bound MMP14 and an increase in TIMP2 
and TIMP3[56, 124]. MMP14 is important in the degradation of collagens I, II and 
III and its presence in the valves of dogs with MMVD, but not in human 
diseased valves, probably reflects a dog-specific alteration in VIC phenotype[56, 
124, 141]. Mice with cardiac-specific transgenic expression of active MMP2 
developed marked mitral valve thickening and prolapse with a major loss of 
collagen bundles and a large accumulation of acidic GAGs, somewhat similar 
to the pathological changes observed in canine MMVD[56, 146]. MMP substrates 
can also include basement membrane components, and as mentioned 
previously (sections 1.2.3 and 1.3.1), disruption of the basement membrane is 
seen on transmission electron microscopy of diseased dog valves[48, 61, 147-149]. 
Interestingly, changes in gene expression (measured by microarray) for the 
MMPs and TIMPs in both human and canine MMVD do not always match 
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those seen on immunohistochemistry, possibly because of the transient nature 
of their expression. Of note in these microarray studies is an increase in TIMP1 
and MMP12 (an elastase) gene expression[27, 33, 150]. Nevertheless, any change in 
the balance of catabolic enzymes and their inhibitors would cause valve 
remodelling. Gene and protein expression changes implicated in basement 
membrane disarray have been reported, including alterations in expression of 
genes encoding nidogen 1 (NID1), laminins 1 and 2 (LAMA1 and 2), collagens 
(COL4 and COL6) and fibronectin[33, 46, 56]. Likewise, the cathepsin-encoding 
genes CTSK and CTSS are significantly up-regulated in diseased valves and in 
human MMVD aVICs, with these proteins having the same substrates as those 
altered in the basement membrane[33, 60]. While tissue protein expression of the 
ADAMTS peptidases has not been reported, there are interesting gene changes 
found in both human and canine MMVD[33, 131]. There is significant down-
regulation of ADAMTS2, ADAMTS19 and ADAMTSL4 in diseased canine 
valves with ADAMTS2 and ADAMTSL4 proteins having roles in procollagen 
maturation and fibrillin-1 binding respectively, whereas the function of 
ADAMTS19 is currently unknown[33, 151, 152]. Likewise, down-regulation of 
ADAMTS1, ADAMTS5 and ADAMTS9 has been observed in human valves[131]. 
These dysregulated proteases seen in diseased human valves are involved in 
the cleavage of the proteoglycans aggrecan and versican, as well as some other 
extracellular matrix components. The knockout ADAMTS5 and haplo-
insufficient ADAMTS9 mouse models, which target and clear the 
proteoglycans aggrecan and versican from the extracellular matrix, have also 
shown a MMVD phenotype[17, 18, 151]. Considering their function in pro-collagen 
maturation, deposition of the proteoglycan versican and regulation of fibrillin-
1 and elastin production (Marfan syndrome) these changes in ADAMTS gene 
expression fit extracellular matrix changes seen in valvular pathology.  
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Alterations in proteoglycan and GAG deposition are also a prominent feature 
of mitral valve disease (section 1.2.3), but have been reported only to a limited 
extent in the dog[49, 109]. Increased proteoglycan content in canine valves has 
been inferred indirectly by using cell maceration scanning electron 
microscopy[153]. Reduction in fibrillar connective tissue components in human 
myxomatous mitral valve disease coincides with increased expression of 
GAGs[49, 53, 54, 154-157]. However, the relative proportions of the different GAGs 
also change with age in normal human subjects, and this is a confounding 
factor when considering disease-associated changes in a disease that is age-
dependent[158, 159]. Proteoglycans and GAGs are necessary for the proper 
assembly of the extracellular matrix as they interact with other important 
structural proteins such as fibronectin and laminin and have a role in elastin 
fibrogenesis[160]. Hyaluronic acid is the most abundant GAG in mitral valves, 
but other proteoglycans particularly the SLRPs, are likely to have an equally 
important role in maintaining a healthy extracellular matrix[161]. SLRP gene 
transcripts have the highest signal intensity of all transcripts in normal and 
diseased canine valves and there is a significantly decreased expression of 
CHAD and KERA (encoding keratocan) in the canine valve[33]. Keratocan is of 
particular interest as it is important in collagen assembly. Decorin and 
biglycan are increased in the diseased canine valvular proteome and biglycan, 
decorin and the proteoglycan versican are increased in the extracellular matrix 
of human MMVD tissue[51, 55, 69, 161]. Decorin plays a critical role in collagen 
fibrillogenesis, while biglycan is found in both collagen- and elastin-rich 
regions and also influences elastic fibre formation[69, 162]. Elastin is particularly 
interesting as it has greater tensile strength than collagen and may contribute 
a disproportionately larger extent to valve mechanical integrity and 
strength[157]. An increase in elastic fibres has been reported in human and 
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canine myxomatous mitral valves, but the fibres are thinner than normal, are 
arranged into more distinct bundles, and the bundles are more widely 
separated than in normal leaflets[157]. The signalling pathways that drive all of 
these structural changes are complex and only partially understood. 
Global valve tissue transcriptomic profiling has identified a wide range of 
gene changes associated with MMVD in man and dogs[27, 125, 131, 150, 163]. In the 
dog, cluster analysis of all gene changes suggested that the most affected 
biologically relevant functions are inflammatory/immune response, cellular 
movement, cardiovascular development, extracellular matrix organization 
and epithelial-to-mesenchymal transition (EMT), as well as the endothelial 
function pathways, caveolar-mediated endocytosis signalling, endothelin-1 
signalling and epithelial adherens junctions remodelling[33, 150]. Caveolar-
mediated endocytosis regulates endothelial cell growth, endocytosis and cell 
migration and reduces TGFβ-induced fibroblast activation[164, 165]. In canine and 
human MMVD there is increased expression of genes encoding inflammatory 
molecules such as vascular cell adhesion molecule (VCAM) 1, intercellular 
adhesion molecule (ICAM) 1, selectin E (SELE), Toll-like receptor (TLR) 4, 
TLR8, interleukin (IL) 18 and IL6, which can trigger ECM changes and 
EndoMT/EMT[33, 91, 125, 150, 163]. There is now evidence of a moderate increase in 
some immune-related cells in both canine and human MMVD valves 
(although not localised to the myxoid regions) (section 1.3.3). However what 
contribution these may have to the expression of these factors or to disease is 
unknown[44, 132]. Likewise, aVICs themselves have been implicated in the 
expression of some immune/inflammation-related genes including IL6 and 
tumour necrosis factor (TNF)[45, 117]. Activation of low-density lipoprotein 
receptor (LDLR) has been reported in valves affected by MMVD, where this 
molecule is predicted to upregulate expression of a variety of inflammatory 
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mediators[33, 166]. An experimental mechanical endothelial shear stress model 
has been shown to generate reactive oxygen species (ROS) that act as 
intracellular secondary messengers and result in elevation of inflammatory 
cytokines, particularly ICAM-1[167]. The increase in expression of genes 
encoding IL6, IL1 and IL10, as well as the adhesion molecules VCAM1 and 
ICAM1, may represent a response to the endothelial damage associated with 
MMVD[40, 48]. Up-regulation of genes associated with oxidative stress has been 
identified in canine and human MMVD and the increase in inflammation-
associated cytokines might be in response to ROS generated by endothelial 
shear stress[27, 33, 125, 131, 163]. All of these protein functions are not unexpected 
considering what is known about valve pathology. Groups of gene changes, 
which on first examination might not appear to have related functions, clearly 
contribute to valve pathology by affecting VEC function, transition and loss, 
VIC activation, proliferation and migration, catabolism of the ECM and 
aberrant remodelling, without inducing a fibrotic response in the dog[1, 2]. 
1.5 Current Hypotheses for disease development 
Despite what is known about the pathological, cellular and molecular features 
of this disease the exact mechanism by which MMVD develops remains 
elusive. Many different effectors have been suggested, including ROS 
(including the metallothionein family), angiotensin II, BMPs, WNT/β catenin, 
TNF and shear/tensile stress[27, 30, 33, 42, 50, 71, 88, 90-92, 125, 131, 163, 168]. Perhaps most 
consistently, and convincingly, a role for TGFβ and/or serotonin (5HT) 
signalling has been shown for MMVD in both the dog and human[30, 60, 70, 71, 85, 





1.5.1 TGFβ signalling 
The TGFβ superfamily consists of thirty three different genes separated into 
sub-families including the BMPs, activin, nodal, growth and differentiation 
factors as well as TGFβ1, 2 and 3[178]. This superfamily is vital for many 
different cellular responses throughout the body[179]. Of particular interest in 
MMVD is the TGFβ1-3 sub-family[1, 2, 174]. These exogenous ligands exist in a 
latent form, bound to the latent TGFβ-binding proteins (LTBPs) in the 
extracellular matrix, where different stimuli, including proteolytic activity, 
mechano-sensing, integrins, thrombospondin-1 and ROS can release them in 
the active form[180]. Signalling is through TGFβ receptor 1 and 2 (TGFβRI and 
TGFβRII) dimerisation, as well as the potential involvement of endoglin 
(TGFβIII)[178, 179, 181, 182]. Both canonical (SMAD) and non-canonical (MAPK 
cascades (ERK and JNK/P38), JAK/STAT, PI3K/AKT and Rho-like GTPase) 
signalling can occur to induce a large variety of cellular processes many of 
which can be implicated in MMVD (summarised in Figure 1-5)[178, 179, 181-183]. 
With so many potential downstream targets, TGFβ signalling is under tight 
regulation and is also highly context specific to elicit the correct cellular 
response[178, 179]. Unsurprisingly, when this regulation is disrupted there are 
severe consequences, with TGFβ signalling already implicated in various 




Figure 1-5. Overview of aspects of TGFβ signalling. This schematic diagram 
highlights just some of the signalling mechanisms induced by TGFβ 
signalling and their consequences. Adapted and amalgamated from Shi and 
Massague (2003), Zhang (2009), Poniatowski et al (2015) and Meng et al 
(2016)[178, 181, 182, 185]. 
TGFβ signalling has been repeatedly implicated in MMVD. As mentioned 
earlier, in syndromic MMVD in humans, TGFβ signalling is directly affected 
in Loeys-Dietz syndrome as well as indirectly in Marfan syndrome[73-76, 130]. 
Exogenous TGFβ1 and TGFβ3 are potent activators of VICs in vitro and TGFβ1 
is regularly used to induce the aVIC phenotype for experimentation[45, 60, 85, 114, 
117, 136]. In tissue samples, up-regulation of TGFβ1, TGFβ3, TGFβRI and TGFβRII 
has been detected at the protein level in canine myxomatous valves with 
TGFB1 and TGFB2 increased at the gene level[122, 124, 126, 133, 174]. Likewise, in 
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human MMVD, increased TGFβ1 has been detected in spontaneous diseased 
valves alongside increased phosphorylated SMAD2/3 indicating downstream 
signalling[130, 176]. Additionally, in human transcriptomic studies, TGFβ2 has 
repeatedly been implicated as an important component of disease 
progression[125, 131, 168]. However, in similar studies in the dog a direct 
involvement is yet to be shown[33, 143, 186]. 
1.5.2 5HT signalling 
Serotonin or 5-hydroxytryptamine (5HT) is primarily considered a 
neurotransmitter important in the feeling of happiness, but has other 
important functions across the body including in cardiac development and 
function[169, 172, 187, 188]. 5HT is synthesised in the body through hydroxylation of 
tryptophan by the enzyme tryptophan hydroxylase (TPH)[189-191]. There are two 
isoforms of TPH termed TPH1 and TPH2, with TPH1 expressed in ‘peripheral’ 
tissues (gut, pineal gland etc.) and TPH2 expressed solely in the central 
nervous system[190, 191]. The majority of serotonin (90-95%) is synthesised by 
enterochromaffin cells in the gut by TPH1 and is released into the blood where 
it is taken up by platelets through the serotonin transporter (SERT) and 
circulated around the body[187, 189, 192]. Under normal circumstances in the 
cardiovascular system, 5HT can facilitate both vasodilation and 
vasoconstriction, depending on the receptors expressed on the vessel wall, as 
well as play an important role in platelet aggregation in response to a 
wound[187]. Signalling can either be through the 7 families of receptor or by 
direct uptake into the cell by SERT where it can then be metabolised by 
monoamine oxidase into 5-hydroxyindoleacetic acid[172, 187, 193].  
5HT was first implicated in MMVD development after it was found that the 
appetite suppressing drug fenfluramine, which induces the release of 5HT as 
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well as binding to the 5HTR2 family of receptors, induced MMVD in a small 
but significant proportion of patients[194-196]. This effect was also recapitulated 
in rats treated with 5HT for several months[197]. Additionally, this association 
was also made in carcinoid tumours (which can affect the enterochromaffin 
cells) were approximately 50% of patients developed hyper-physiological 
levels of 5HT in the blood and 50% of these patients showed heart-related 
lesions[198, 199]. Since these associations were discovered, analysis of 
spontaneous disease has further connected 5HT signalling with MMVD. VICs 
have been found to express TPH1, indicating that local synthesis of serotonin 
and potential autocrine signalling is possible, with an increase in TPH1 
expression found in MMVD valves from both dogs and humans as well as in 
VICs exposed to tensile strain[70, 133]. In conjunction with this, SERT was down-
regulated in myxoid valves, which may allow for reduced clearance of 5HT 
and longer activation of receptor signalling[133]. Following these studies, 5HT 
was found to be significantly increased in dogs with MMVD, both in platelets 
and in mitral valve tissue[200]. SERT has further been implicated in disease, 
through a study of Maltese dogs which indicated that genetic variation in the 
exons of this gene may be associated with MMVD development[201].  
The 5HT receptors that have been most widely associated with MMVD are the 
G-protein q coupled receptors 5HTR2B and to a lesser extent 5HTR2A[33, 131, 150, 
170, 171, 173, 202]. The up-regulation of 5HTR2B in canine MMVD has been a primary 
driver for the 5HT hypothesis since it was detected in the first transcriptomic 
study and has been consistently shown in studies following this as well as in 
humans and rats[33, 71, 133, 150, 170, 171, 202]. Additionally, increased phosphorylation 
of ERK1 and ERK2, a downstream signalling target of 5HTR2B (as well as 
other pathways), is detected in MMVD valve tissue and in VICs treated with 
5HT, demonstrating activation of 5HT signalling[71, 133, 171, 203]. However, 5HT 
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treatment of VICs, although capable of inducing cell proliferation and 
proteoglycan deposition is not capable of inducing a full aVIC phenotype on 
its own, at least in short-term culture[171, 203, 204].  This seeming lack of ability to 
fully induce disease phenotype has led to the speculation that 5HT produces 
disease phenotype by inducing TGFβ signalling[30, 71, 133]. 5HT induced TGFβ3 
expression in the embryonic avian heart and TGFβ1 in ovine aortic VICs[169, 205]. 
5HTR2B antagonism ablated TGFβ1-mediated porcine aortic VIC 
activation[206]. Furthermore, 5HT interacts with other pathways implicated in 
MMVD, such as angiotensin II signalling, and combined treatment with these 
factors induced MMVD in a mouse model and activated VICs in culture. The 
angiotensin type 1 receptor interacted with 5HTR2B directly[204, 207]. It may be 
the case that cross talk between various pathways is important in MMVD 
development.  
1.6 Prevalence and breed association for MMVD 
Almost all dogs will show some form of MMVD disease at necropsy if they 
live to an advanced age, with age being a major contributor to the prevalence 
of disease[4, 11, 50]. In Whitney’s study which classified the grades of disease, it 
was observed that 9% of one year old dogs had grade 1 disease and 35% of 
dogs under the age of five years of age had grade one or two disease[4, 9]. 
However, only 3% of these were thought to be clinically significant, and in the 
vast majority of cases, the disease will not reach a clinically significant point[4, 
9, 50, 208]. For MMVD to reach clinical significance in a dog it likely has to begin 
to develop earlier in life or the animal has to live for an exceptionally long time. 
It has been shown that 82% of dogs with Grade 1-3 disease will remain 
asymptomatic, defined as signs of mitral valve thickening with or without 
cardiac enlargement and the presence of a murmur without congestive heart 
failure or other signs of disease (described in section 1.7), for at least one year 
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before developing any clinical signs[209]. Indeed, it is worth noting that there 
appears to a large proportion of dogs that will remain asymptomatic and never 
develop clinically significant disease[210].  
Although all dogs can develop disease, it is typically associated with small 
breed dogs (with a higher incidence of clinical significance in males) with a 
particular predisposition in toy dog breeds including the Cavalier King 
Charles Spaniel (CKCS), Dachshund, Miniature Poodle, Miniature Pinscher 
and Whippet[24, 166, 211]. This predisposition is thought to be related to the earlier 
development of disease in these breeds of dog, with a study in CKCS 
indicating that on average, clinical signs develop 6 years earlier in CKCSs than 
in other breeds[24]. While the high prevalence of a disease in a specific breed is 
not uncommon, the high prevalence of disease in several breeds with a shared 
trait suggests that the shared trait, in this case size, may be involved in the 
development of the disease. This could be through either morphological 
similarities (including skeletal and chest cavity size) or genetic similarities that 
may or may not be due to a shared ancestor[212]. There are some indications in 
both dogs and humans that the physical morphology of smaller individuals 
and the effect this has on chest cavity size may be responsible for the increased 
prevalence of MMVD, but this is yet to be fully explained[212-215]. Examples of 
genes that have been associated with small size include the genes encoding 
insulin-like growth factor 1 (as well as other genes encoding proteins that are 
associated with this protein) and SMAD2 (implicating TGFβ signalling)[212, 216-
218]. GWAS studies aiming to determine variants that are specifically associated 
with MMVD have thus far been inconclusive. Three studies have been 
published; one in a cohort of CKCS associated two loci with MMVD, another 
in Whippets associated a different two loci and a third small study, again in 
CKCS, did not associate any variants significantly with MMVD[219-221]. This 
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indicates that MMVD is most likely polygenic and increased prevalence in 
these breeds may be multi-factorial.  
1.6.1 Cavalier King Charles Spaniels 
The breed that has been most associated with MMVD development is the 
CKCS[23, 24, 222, 223]. This is due to the early development of the disease with 10% 
of one year old dogs and 100% of dogs over 10 showing clinical signs[24]. This 
particularly high prevalence is likely to have arisen following inbreeding 
when, after the second world war, the breed numbers dwindled drastically. 
As a result, only 6 animals were used to propagate the breed resulting in a 
high level of homozygosity for alleles of genes involved in disease 
development. There are now 25 inherited diseases in this breed including 
(other than MMVD) syringomyelia, chronic fibrosing pancreatitis and 
cataracts[224]. In addition, CKCS have defects in platelet function (although 
there are conflicting reports of increased and decreased platelet aggregation in 
MMVD) and 50% of animals show macro-thrombocytopenia (giant platelet 
disorder)[225-227]. Dysfunction of platelets could be involved in the development 
of MMVD, especially considering their role as 5HT transporters and that forms 
of macro-thrombocytopenia in humans have resulted in early (3 years old) 
mitral valve surgery[228]. However, in addition to these defects, it has recently 
been shown that healthy CKCS have amongst 25 breeds, the highest level of 
circulating 5HT as well as showing greater elevated levels of circulating 5HT 
in CKCSs with MMVD, as with other breeds[200, 229]. Factors such as these could 
play a role in early MMVD development. Likewise, fundamental differences 
in CKCS valve morphology could be partly responsible for the disease. 
However, histopathological comparison of MMVD valves from CKCS and 
non-CKCS showed no difference, indicating a shared pathology in disease[110]. 
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It seems likely given the current evidence that multiple factors may be 
responsible for early disease development in this breed.  
1.7 Presentation and Diagnosis 
Diagnosis of canine MMVD often occurs late in the disease development as 
dogs with low-grade disease appear healthy. Late diagnoses can also be due 
to owners mistaking signs of exercise intolerance as part of the ageing process 
and hence delaying presentation of dogs for veterinary examination. The first 
sign that may be noticed by an owner is coughing, which can either be the 
result of bronchial compression from the enlarged left atrium and ventricle or 
due to pulmonary oedema from mitral regurgitation[230, 231]. Once these signs 
are present the dog likely has advanced disease. For a clinician, one of the 
principal indicators of disease is the presence of a systolic murmur which 
worsens over time as MMVD develops[231]. Ultimately diagnosis can be made 
based on a variety of different factors including physical assessment (presence 
of signs such as heart murmur, exercise intolerance etc.), history (history of 
murmur or predisposing factors) and thoracic radiographs (for the presence 
of enlarged heart)[230, 231]. The gold standard, however, for confirmation of 
MMVD is echocardiography with this also being used to determine prognosis 
as the disease develops and helps classify the severity of disease in the dog[231, 
232]. Classification is based on criteria set out by the American College of 
Veterinary Internal Medicine (ACVIM) (Table 1-1) and is used both to help 
distinguish whether an animal is asymptomatic (Stage A and B) and what 
treatment approach should be used[230, 231]. Broadly speaking, the same signs 
and diagnostic methods are also used in human disease, with particular 
emphasis given to echocardiographic assessment to distinguish what disease 
(i.e. FED, Barlow’s etc.) is causing MMVD and its severity. These factors 




Table 1-1. ACVIM classification summary with associated Whitney Grade 
of disease. Green colouration indicates asymptomatic stages, orange 
colouration clinically significant stages. Adapted from Hezzell (2018). 
In conjunction with these established diagnostic approaches, in the dog, the 
use of diagnostic and prognostic biomarkers has begun to be established. 
Typically this has been with the use of N-terminal pro-brain natriuretic 
peptide (NT-proBNP) and cardiac troponin I[234-236]. Both of these markers 
increase significantly in the blood of MMVD dogs. NT-proBNP in particular 
increases early in the disease (Stage B1) and continues to rise as disease 
progresses allowing it to be used prognostically[231, 234-237]. However, both 
markers have shown significant individual biological variability as well as 
breed variability making both interpretation and the use of reference intervals 
difficult[231, 234, 238]. Recently, attempts to find circulating microRNA biomarkers 
associated with MMVD have been made, but thus far results have been 
inconclusive in the four studies performed[239-242].  
1.8 Treatment 
Following diagnoses in humans, clinicians decide on the appropriate course 
of action depending on the individual patient’s medical circumstances. This 
can include: ‘watch and wait’ (where regular check-ups are scheduled until 
disease advances to a stage when surgery is required), lifestyle modifications, 
administration of drugs such as ACE inhibitors, mitral repair (using 
ACVIM Classfication Description Associated Grade
Stage A No evidence of disease but predisposed 0-2
Evidence of heart disease but no congestive heart failure 
B1: No echocardiogrpahic/radiographic evidence of disease 2
B2: echocardiogrpahic/radiographic evidence of left-sided heart enlargement 2/3
Stage C Evidince of congestive heart failure 3-4




technologies such as the MitraClip, which clips the flailing portions of valve 
together to prevent regurgitation) or mitral valve replacement (where all or 
part of the valve is removed and replaced with either a mechanical or 
bioprosthetic alternative)[243, 244]. Surgical approaches have likewise been 
attempted in the dog to a limited extent. Both mechanical and bioprosthetic 
valve replacement has been attempted with bioprosthetics showing the best 
clinical outcome[244-249]. However, given the nature of this open heart surgical 
procedure, a high level of expertise and an associated high level of cost is 
required[244]. Currently, there is only one team routinely performing such types 
of surgery on canines and is unlikely to become a common occurrence in the 
near future[250-253].  
Far more common practice in dogs is the use of palliative treatments to 
ameliorate the symptoms of MMVD by reducing cardiac load and to treat 
congestive heart failure. A range of drugs are used mainly to treat dogs in 
stage C and D of disease. This includes Benazepril and Spironolactone, an ACE 
inhibitor and aldosterone inhibitor respectively, that are used to reduce renin-
angiotensin-aldosterone system (RAAS) activation. Furosemide, an inhibitor 
of sodium and potassium reabsorption in the kidney, is prescribed to provide 
diuresis in congestive heart failure to alleviate pulmonary oedema[244, 254-256]. 
One of the most commonly used drugs is the phosphodiesterase III inhibitor 
and calcium sensitiser, Pimobendan[257-259]. Alongside its use for treatment for 
stage C diseased animals, recent studies have shown that this vasodilator may 
help to prolong the period of time an animal is in stage B2 by up to 15 months[35, 
260]. Likewise, a recent pilot study has found similar promising results for 
spironolactone treatment in extending canine life span[261].  
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1.9 Study aims and hypothesis  
Although drug therapies exist for dogs with MMVD, there are currently no 
treatments that can completely halt or reverse MMVD. This is due to a lack of 
understanding of the fundamental processes involved in the cellular and 
molecular development of the disease. Previous studies have elucidated some 
of the processes potentially involved but none have been able to fully establish 
pathways causal in disease development. This is primarily due to a focus on 
the comparison of late-stage diseased samples with normal samples, omitting 
the early disease groups. By examining tissue encompassing the entire 
pathogenesis of disease (Whitney grade 0-4), a better understanding should be 
achieved. Furthermore, taking this information and testing it in vitro could 
lead to a greater appreciation of the role, different cell types play in disease as 
well as targeting specific pathways of interest for therapeutic exploitation. As 
such, this thesis aims to:  
1) Investigate the molecular events occurring in each Whitney grade of 
disease. By studying disease in its entirety important pathways in 
disease development will be uncovered. 
2) Investigate the molecular events within early diseased valves. This will 
allow for causal pathways in disease development to be identified.  
3) Investigate the role of pathways of interest in VICs in culture. The 
proposition is that manipulation of the identified pathways will cause 
disease-related changes in VICs and elucidate the processes occurring 
in vivo.  
It is hypothesised that clear and discernible changes in gene expression will 
occur dependent on the Whitney grade of the disease and will be related 
to MMVD development. 
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   Materials and Methods 
2.1 Introduction 
This project as a whole aims to understand the molecular reasons why MMVD 
develops. The broad central dogma of molecular biology states:  
 
By studying the components of this model a researcher can begin to 
understand the molecular controls in a biological system. Transcriptomics, the 
study of the RNA repertoire in a sample, is a commonly used approach by 
researchers to investigate a biological system. It has the advantage of looking 
at the transcribed components of the genome giving a level of functionality 
over genomics (the study of DNA in a sample) but is less technically 
challenging and costly than proteomics (the study of all proteins in a 
sample)[262]. Two approaches for studying the transcriptome of a sample are 
gene expression microarray and RNA-sequencing (RNA-seq).  
Expression microarrays were the first approach developed that allowed for 
transcriptome-wide analysis of a sample to be performed. They work with a 
simple and elegant approach where specific sequences of nucleic acids, that 
each represent a transcript of a gene, are repeatedly printed on a glass surface 
called a chip[263]. Each cluster of nucleic acid representing a transcript is called 
a probe. Initially the probes were complementary DNA (cDNA) copies of RNA 
transcripts cloned into plasmid vectors; currently, the probes are synthetic 
oligonucleotides targeted along the gene of interest. When fluorescently 
labelled reverse-transcribed cDNA produced from total RNA is hybridised 
with this chip the level of fluorescence from a probe can be measured and 
quantified as a raw signal[263]. This raw signal can then be normalised to the 
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other samples and to normalisation probes included on the chip. Comparisons 
of the level of signal for all the probes on the chips can be performed. For 
example, the Affymetrix Canine Gene 1.1ST array contains 590,097 probes, 
each of 25 base pairs, to cover the 27,681 genes in the CanFam 2.0 database 
(representing 24 probes/gene) allowing for the vast majority of the dog 
transcriptome to be analysed at once.  
RNA-seq is a newer method that uses deep sequencing technologies to 
quantify the transcripts in a sample[264]. In this approach, fragmented RNA is 
converted into a library of cDNA which is then sequenced with the addition 
of specific linkers attached to the 5’ and 3’ ends of each fragment of cDNA. 
Sequenced fragments are then mapped back to the genome and the number of 
reads matching any part of the sequence of a specific gene is used to quantify 
the expression of that gene (the more reads the higher the expression)[264].  
Although both technologies ultimately allow for a comparison of the 
transcriptomes between samples, both have their advantages and 
disadvantages. As a sequencing technology, RNA-seq offers far more in-depth 
analyses as it can detect the presence of sequence mutations, splice variants 
and transcriptional regulation [265, 266]. In addition, as there is no need for a pre-
defined probe set, it is thought this approach is more suited to lesser studied 
organisms[267]. However, microarrays that do not rely on the original 3’ biased 
detection are able to be used to detect transcript variants and alternative 
splicing events and with the continued improvement in organism gene 
annotation, these discrepancies may be improving. Technically RNA-seq 
offers a greater dynamic range of detection with typically a lower background 
noise and no saturation point, unlike microarrays, which allows for the more 
accurate detection of lowly or highly expressed transcripts[264] (although the 
majority of transcripts will be unaffected by this). However, RNA-seq does 
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have its disadvantages particularly in the downstream analysis and 
bioinformatic interpretation of results which can be difficult and require large 
data storage capacities which is of particular concern with large or multiple 
datasets[264]. In contrast, as a longer standing approach the interpretation and 
analysis of microarray data has been simplified, requires less computing 
power and is approachable to most researchers. Moreover, at the time of 
starting this project, the cost of microarrays was substantially lower than 
RNA-seq allowing for a greater number of biological replicates to be run by 
this approach. For these reasons, microarray technology was chosen over 
RNA-seq to allow for analysis of multiple datasets by a relatively simple, 
validated and robust computational approach.  
2.2 Tissue collection and processing 
2.2.1 Tissue collection and disease grading 
Full owner consent was given for all tissue samples collected during the course 
of this PhD project and ethical approval given by the Roslin institute. The 
majority of samples were recruited from animal’s euthanised at the Hospital 
for Small animals (The Royal (Dick) School of Veterinary Studies, The 
University of Edinburgh, U.K.) for a wide range of medical and behavioural 
reasons and donated by the owner for research purposes. A small subset of the 
tissue samples collected were donated by Charles Rivers Laboratories (U.K.).  
Collection occurred typically within 1 hour of euthanasia by intravenous 
phenobarbital overdose. After excision of the heart, the mitral valve was 
exposed by cutting through the left atrium and down the left posterior wall to 
the apex. The left atrium, ventricle and mitral valve were then briefly and 
carefully washed with cold sterile phosphate buffered saline (PBS) to remove 
any excess blood. The degree of disease on the valve leaflet cusps was assessed 
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grossly by at least two investigators with a Whitney grade being assigned to 
score disease severity confirmed by a veterinary cardiologist (MVB DipPharm, 
PhD MRCVS, Chair of Veterinary Cardiopulmonary Medicine)[4]. When 
possible, a photograph was taken of the valve in situ. The mitral valve complex 
(posterior and anterior leaflet cusps and chordae tendineae) was removed 
from the heart by cutting along the annulus to detach the leaflet cusps. The 
chordae tendineae remained attached to the leaflet cusps and were removed 
where they attach to the papillary muscles of the left ventricular wall. The 
mitral valve complex was again washed in a bijou tube containing cold sterile 
PBS to remove any remaining blood before processing for future work.  
2.2.2 Tissue processing for RNA extraction, cell culture and dissection 
Tissue samples to be utilised for whole valve analysis of gene expression were 
immediately stored in cold RNAlater (Invitrogen, U.S.A.). Samples were either 
proceeded immediately to RNA extraction (detailed in section 2.3.1) or were 
incubated at 4ºC overnight before long term storage at either -20 or -70ºC. Prior 
to RNA extraction any excess annulus, the chordae tendineae and any atrial 
myocardium were removed, leaving only the leaflet cusps and the remnants 
of the chordal attachments. Tissue samples used for whole valve cell isolation 
and culture were stored immediately in a 50 mL falcon tube containing cold 
sterile PBS. The Falcon tube was then placed immediately on ice and 
transported for cell isolation and culture (detailed in section 2.3.2).  
A subset of normal valve samples and samples that were determined to have 
a Whitney score of grade 2 (areas of normal valve adjacent to visibly diseased 
areas) were used for regional analysis of gene expression. In this instance, the 
valve was stored in RNAlater as for whole valve analysis of gene expression. 
However, prior to RNA extraction valves were dissected into diseased and 
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normal areas of tissue. Valves were placed in a 10 cm3 petri-dish and kept in 
RNAlater for the duration of dissection. Valves were examined under a light 
microscope (Leica Mx8 stereomicroscope, Leica Biosystems, Germany) with 
backlighting allowing identification of diseased regions. All areas identified as 
diseased (typically along the free edge) were dissected from one end of the 
valve to the other in a methodical manner and stored immediately in 
RNAlater. The remaining tissue was assessed as normal and both tissue 
samples were then taken forward for RNA extraction. Four normal valves also 
underwent this process with areas from the free edge dissected and compared 
as described in Chapter 5. The method for tissue collection and processing are 
summarised in Figure 2-1. 
 
Figure 2-1. Summary of tissue collection process for valve tissue used for 
RNA extraction, cell culture and valve dissection. 
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2.3 RNA extraction and assessment  
2.3.1 RNA extraction from valve tissue 
Post processing, valve tissues (whole and dissected) were dried with tissue 
paper, separated into approximately 100 mg of tissue, placed in a clean 
Eppendorf tube and snap-frozen in liquid nitrogen. Tissues were 
disaggregated using a dismembranator (Braun Mikro Dismembranator, Braun 
Biotech International, Melsungen, Germany). The dismembranator equipment 
(steel ball lid and flask) was submerged in liquid nitrogen and allowed to 
freeze. Following this, 500 μL of Trizol reagent (Life technologies, U.S.A.) was 
pipetted into the dismembranator flask alongside 100 mg of frozen tissue and 
the steel ball before being sealed. This then oscillated in the dismembranator 
at 30 m/s for 120 seconds. Once macerated the combined frozen tissue/Trizol 
powder was thoroughly mixed with a further 500 μL of Trizol in a nuclease-
free screw-topped Eppendorf tube and incubated for 45 minutes at room 
temperature. Samples were then centrifuged for ten minutes at 13,400g and at 
4°C in an Eppendorf 5415R tabletop centrifuge (Sigma Aldrich, U.S.A.). The 
supernatant was carefully pipetted into a nuclease-free screw-topped 
Eppendorf tube and cell debris discarded. Two hundred microliters of 
chloroform (Fisher Scientific, U.S.A.) was mixed vigorously with the 
supernatant and then incubated at room temperature for 3 minutes, followed 
by centrifugation for 15 minutes as described previously. The aqueous phase 
was carefully pipetted, avoiding any phenol contamination from the 
interphase (illustrated in Figure 2-2), into a clean nuclease-free Eppendorf tube 




Figure 2-2. Illustration of the three phases in a phenol-chloroform 
extraction. 
RNA extraction and DNA digestion were then performed using the Qiagen 
RNeasy mini kit as specified in the manufacturer’s manual (Qiagen, 
Germany). The 1:1 ethanol-aqueous phase mix was pipetted, 700 µL aliquots 
at a time, onto the RNeasy mini column. The columns were then centrifuged 
at 8,000g for 15 seconds allowing the RNA in solution to bind to the column. 
The remaining solution was discarded. Three hundred and fifty microliters of 
buffer RW1 was then added to the column and centrifuged through the 
column, at 8,000g for 15 seconds, to wash out contaminants (such as proteins 
and carbohydrates). Eighty microliters of buffered DNAse I (Qiagen) was 
incubated on the column for 15 minutes at room temperature to minimise 
potential genomic DNA contamination. Another wash step with buffer RW1 
was then performed as described previously. Two washes with 500 µL per 
wash of buffer RPE (to remove potential salt contaminants) were then 
performed with the first using a 15 second centrifugation at 8,000g and the 
second requiring a longer 2 minute centrifugation at 8,000g. The column was 
then spun at 13,400g for 1 minute to remove any carryover solvents. Total RNA 
was eluted in 30 μL nuclease-free water in nuclease-free, labelled 1.5 mL 
Eppendorf tubes by centrifugation at 8,000g. In cases where more than one 100 
mg tissue segment was collected from a single valve, the RNA eluted from the 
separate columns was combined and stored at -70°C for downstream use. A 
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small number of samples used for transcriptomic analysis had been extracted 
as part of a previous project following the same protocol and stored at -70°C 
for no more than 2 years. These samples are indicated in the appropriate 
sections of Chapters 3 and 4. 
2.3.2 RNA extraction from cells 
Cells for RNA extraction were harvested by treating with TrypLE™ express 
(Thermo Fisher Scientific) for 5 minutes at 37ºC to dissociate cells from the 
flask surface. TrypLE™ express was inactivated with media and the cells were 
pelleted by centrifugation at 400g for 5 minutes in a Heraeus® Labofuge 400 
centrifuge (Thermo Scientific, U.S.A.). Cells were re-suspended in 1 ml of 
sterile chilled PBS and pelleted by centrifugation at 5,000g for 5 minutes with 
the Eppendorf 5415R tabletop centrifuge in a nuclease-free 1.5 ml Eppendorf 
tubes. These pellets were stored at -70°C pending RNA extraction. Pellets were 
thawed on ice and re-suspended in 350 µL of buffer RLT (from Qiagen RNeasy 
mini kit) and then passed through the QIAshredder (Qiagen) homogenisation 
column, by centrifugation at 5,000g, in order to lyse the cells. The flow-through 
was then mixed thoroughly with 1 volume (350 μL) of 70% ethanol. RNA 
extraction with the Qiagen RNeasy mini kit was performed as described in 
section 2.3.1, and the eluted RNA was stored at -70°C until needed.  
2.3.3 RNA quantification, quality assessment and quality control for 
microarray 
Quantification of RNA was performed by spectrophotometry in the 
NanoDrop™ 1000 (Thermo Scientific). Absorbance at 260 nm wavelength was 
measured in 1 µL of extracted RNA solution. Ratios of absorbance (260/280 
and 260/230) were also analysed to check for possible impurities that absorb at 
either 280 (proteins, carbohydrates etc.) or 230 (phenol for example) of the 
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sample. Ratios below 1.8 were viewed as contaminated and 2 as the ideal 
measurement.  
To assess degradation of RNA the ratio of ribosomal 28S and 18S RNA was 
measured in samples. This was performed using the Agilent RNA Screentape 
system and Agilent 2200 tapestation analyser (Agilent Technologies, U.S.A.), 
following the manufacturer’s instructions. This approach uses gel 
electrophoresis of the total RNA, quantifies the intensity of the 28S and 18S 
rRNA bands to calculate the 28S/18S ratio (with a ratio of 2 being regarded as 
minimally degraded). RNA integrity number (RIN), which scores the level of 
degradation on an arbitrary 1-10 scale, was then assigned with 10 being 
minimally degraded and ≥7 being taken as suitable for transcriptomic 
analysis[268]. In some cases, due to a lack of samples, the stringency of RIN ≥7 
was relaxed as described in Chapter 3 section 3.3.2 and Chapter 5 section 5.3.1.  
2.4 Cell isolation and culture conditions 
Following collection, valves being used for cell isolation were transported 
immediately, in sterile PBS, to a cell culture hood and put into a sterile 10cm3 
plastic dish. Excess annulus and chordae tendineae were excised. The 
remaining valve leaflet tissue was incubated for 10 minutes at 37ºC in a 3.5 cm3 
sterile plastic dish with 3-5 mL of pre-warmed collagenase II (Invitrogen) (600 
units/mL) dissolved in a low serum (2% v/v Fetal bovine serum (FBS)) 
Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies) 
supplemented with 150 units/mL Penicillin/streptomycin, 2 mM L-glutamine, 
50 ng/mL insulin and FGF-2 (10 ng/mL) which was added freshly to medium 
before use. Low serum medium with FGF-2 was used as this has previously 
been shown to prevent the activation of valvular interstitial cells (VICs) from 
a quiescent to an activated myofibrotic cell phenotype [138] and will be referred 
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to as DLF from now onwards. After incubation, the valve endothelial cells 
(VECs) were gently removed from the valve surface by rotating a sterile swab 
over the atrial and ventricular surfaces 5-6 times. The swab was dabbed in the 
collagenase medium to release the VECs; the remaining valve tissue was 
placed in 10-15 mL of the collagenase medium for VIC isolation. The VEC 
containing medium was then aspirated from the well and VECs were collected 
for use in other experiments not described in this thesis. VICs were isolated 
from the remaining valve tissue after VEC isolation. The leaflets were diced 
into the 10-15 mL of collagenase medium and incubated at 37ºC and 5% CO2 
for 18 hours. The valve tissue was then disrupted by pipetting and degraded 
tissue and cells were pelleted by centrifugation at 400g for 5 minutes in a 
Heraeus® Labofuge 400 centrifuge. VICs were re-suspended in DLF media 
and cultured in T75 flasks (Thermo Scientific) at 37ºC and 5% CO2. VIC media 
was changed every 48-72 hours during propagation.  
2.5 Affymetrix Canine Gene 1.1ST microarray analysis  
2.5.1 RNA processing and Affymetrix chip hybridisation 
The Affymetrix GeneChip™ Canine Gene 1.1 Sense Target (ST) Array plate 
was used for transcriptomic profiling of samples of normal canine mitral 
valves, each of the four whole valve disease grades, dissected valves 
comparing normal and adjacent diseased tissue and VICs cultures from both 
normal and diseased valves and under various treatment conditions. This was 
performed by Edinburgh Genomics (Edinburgh, U.K.). As informed by 
Edinburgh Genomics and summarised in Figure 2-3, 500 ng of total RNA was 
used per sample for analysis. Sample preparation was then performed using 
the WT Expression Kit (Invitrogen P/N4411974) and as described in the 
Ambion® WT expression kit manual (P/N 4425209 Rev. D) and the GeneChip™ 
WT Terminal Labeling and Hybridization User Manual (P/N 702808). First 
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strand cDNA synthesis utilised random primers with T7 promoter sequence 
to minimise rRNA contamination, which was followed by second strand 
cDNA synthesis. Following this, in vitro transcription was used to produce 
antisense RNA (aRNA) which was purified with magnetic beads and used in 
another first strand cDNA synthesis reaction with dUTP/dNTP mix. Sense 
strand cDNA was purified, again with magnetic beads, and following the 
Affymetrix terminal labelling kit protocol (Affymetrix P/N 900652), was 
treated with UTP-recognising endonucleases that fragmented cDNA. This was 
then labelled with Terminal deoxynucleotidyl Transferase (TdT) linked to 
biotin. 3 µg of this fragmented and labelled cDNA was hybridised to the 
Affymetrix GeneChip™ Canine Gene 1.1ST Array plate and scanned in the 
GeneTitan® multi-channel instrument (Thermo Fisher Scientific, U.S.A) 




Figure 2-3 Schematic workflow of sample preparation for microarray 
analysis. Adapted from Ambion® WT expression kit manual (P/N 4425209 
Rev. D) and the GeneChip™ WT Terminal Labeling and Hybridization User 
Manual (P/N 702808). 
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2.5.2 Post-hybridisation quality control and summarisation file creation 
CEL files supplied by Edinburgh Genomics were opened in the Affymetrix 
expression console (version 1.4.1.46) using the canine 1.1ST library files from 
Affymetrix. Robust Multi-array Average (RMA) was used to perform gene-
level normalisation and signal level summarisation[269]. Following this, quality 
control assessment was performed on the data set. This included assessment 
of hybridisation (spike in) controls, labelling (poly-A) controls and area under 
the curve (AUC) control, probe cell intensity boxplots, a signal histogram 
graph and, when possible, principle component analysis (PCA) plot. PCA plot 
creation was not possible in the initial microarray analysis (Chapters 3 and 4) 
due to a technical error made by Edinburgh genomics. Following this 
assessment, the datasets were exported with annotation as a text file or as a 
CHT file.  
2.5.3 Transcriptome analysis console  
Affymetrix transcriptome analysis console (version 3.1.0.5) was used to 
perform paired or unpaired one-way analysis of variance (ANOVA). 
Differentially expressed gene lists were created using the following criteria: P-
value <0.05, log signal intensity >2.8, >3.5 or >3.8 (referred to in each chapter 
as appropriate) and fold change of >1.5 or <-1.5. When possible, the Benjamini-
Hochberg false discovery rate (FDR) correction was applied (described in the 
individual chapters) uncorrected analysis was performed in Chapters 3, 4 and 
6 with this described in further detail in these chapters. Algorithm information 
for un-annotated transcript probes was found in TAC through an interface 
with the Affymetrix online browser. Probe sequence could then be copied and 
BLAST analysis performed on the online browser at http://www.ensembl.org 
to try and manually match the probe to a transcript. A transcript was 
considered matched to a probe sequence and could be manually annotated 
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when the E-score was <1x10-20 [33, 150] and other suggested transcripts did not 
meet these criteria. Gene lists could then be used for gene enrichment analysis. 
2.6 Gene enrichment analysis  
The following gene enrichment platforms were used to explore the 
transcriptome of the normal and diseased valves and cells. Their basis and 
function are briefly described. 
2.6.1 Miru  
Miru (version 1.4), now called Graphia Pro (Kajeka, U.K.), is a network 
analysis tool that allows for the visualisation of large data matrixes on 3D or 
2D graphs[270, 271]. Miru works to cluster data based on similarity, with nodes 
on the graph representing a data point and edges (the connecting lines 
between nodes) representing the relation between nodes past a selected 
threshold Pearson correlation coefficient, laid out with the Fruchterman-
Reingold algorithm. In a transcript-to-transcript analysis, nodes represent the 
expression of a gene across a sample set, and genes with similar expression 
patterns will be placed close to each other in the network layout. In a sample-
to-sample analysis, the data is transposed, and nodes represent the expression 
of all genes in a sample allowing the similarity of samples to be identified. Both 
the gene-to-gene and sample-to-sample analysis were performed with the 
Pearson correlation coefficient stated in each results chapter. To further 
delineate genes with similar expression in the network, Markov Clustering 
(MCL) with an inflation stated in each chapter and a minimum cluster size of 
5 genes was used. The similarity of expression can then be used to infer 
possible functional roles of these clustered genes. Cluster data could then be 
exported as a text file for further analysis.  
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2.6.2 Database for Annotation, Visualization and Integrated Discovery   
The Database for Annotation, Visualisation and Integrated Discovery (DAVID 
v6.8) (http://www.david.ncifcrf.gov) is a browser-based gene enrichment tool 
that takes gene lists and predicts the biological processes that are associated 
with the genes in the list using the gene ontology (GO) terms. Gene lists 
deriving from differential expression analysis (section 2.5.3) or Miru clustering 
(section 2.6.1) were uploaded to DAVID for analysis. Gene ontology (GO) 
terms were selected for biological processes (GOTERM_BP_DIRECT), cellular 
components (GOTERM_CC_DIRECT) and molecular function 
(GOTERM_MF_DIRECT) and summarised in the functional annotation chart 
with GO term, genes names associated with GO term, number of genes, P-
value of association and FDR value of association recorded. These were the 
only GO terms selected to try and remove redundancy from DAVID analysis. 
2.6.3 Ingenuity Pathway Analysis  
Ingenuity Pathway Analysis (IPA) (Qiagen) is a commonly used tool to 
analyse transcriptomic data. Differentially expressed gene lists were uploaded 
with related fold change to the online IPA server where core analysis was 
performed. This compared the submitted genes to all published literature and 
assigned reported attributes and pathways to them. From these canonical 
pathways, upstream regulators, disease and biological functions, as well as 
other factors were inferred by the software. These results were generated 
based on the number of genes in the submitted list that matched the genes 
reported in the literature to be involved in a certain process, with a statistical 
association calculated. Core analysis was performed with default settings on 
filtered gene sets. In some instances, gene names were not accepted by IPA 
and alternative names had to be submitted; some genes (often encoding novel 
proteins) were not accepted by IPA.   
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2.6.4 Gene list comparisons  
To identify genes that either shared or did not share differential expression in 
different datasets and in pathways the INDEX function provided by Microsoft 
Excel (Microsoft Corporation, U.S.A) was used. The function is as follows:  
=INDEX($Column of Gene list A$First cell of Gene list A:$Column of Gene 
list A$Final cell of Gene list A,MATCH($Cell of Gene list B,$First cell of Gene 
list A:$Column of Gene list A$Final cell of Gene list A,0)) 
This function was repeated to cover all cells for Gene list B. Venn diagrams 
based on the shared and differential genes were then produced in Microsoft 
Powerpoint (Microsoft Corporation). Genes that were identified as being 
matches in both datasets could then also be used for further gene enrichment 
analysis as described in sections 2.6.2 and 2.6.3.  
2.7 Real-time quantitative Polymerase Chain Reaction  
2.7.1 Complementary Deoxyribose Nucleic Acid synthesis  
Reverse transcription of mRNA to complementary DNA (cDNA) was 
performed using the Superscript™ III RT kit (Invitrogen) according to 
manufacturer’s recommendations with RNaseOUT recombinant RNase 
inhibitor (Invitrogen) treatment to remove RNase contaminants. For each 
reaction, 1 µg of total RNA was mixed with 1 µl random primers (Invitrogen), 
1 µl 10 mM dNTP mix (Invitrogen) and made to 10 µl with nuclease-free water 
in a nuclease-free micro-centrifuge tube. RNA secondary structure was 
denatured by incubating at 65°C for 5 minutes followed by 1 minute on ice. 
Four microliters of 5X first strand buffer (Invitrogen), 1 µL 100 mM DTT 
(Invitrogen), 1 µL RNaseOUT recombinant RNase inhibitor (Invitrogen) and 
1 µL of Superscript III reverse transcriptase (RT) (200 units/µL) (Invitrogen) 
were added to each reaction tube, mixed by pipetting and briefly centrifuged. 
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Reactions were incubated at 25°C for 10 minutes, 50°C for 50 minutes and 85°C 
for 5 minutes. Synthesised cDNA was then separated into 5 µL aliquots and 
either used immediately for amplification by PCR or stored at -20°C.  
2.7.2 Primer design 
Expression levels determined by microarray were validated using Reverse 
transcription quantitative PCR (RT-qPCR). For genes of interest and reference 
genes, exon sequence transcripts were found using CanFam 3.1 genome 
assembly (http://www.ensembl.org). The cDNA sequence was copied into 
primer3 browser-based primer design tool (http://www.primer3.ut.ee) and 
parenthesis ([]) were inserted in the sequence at intron junctions (so that 
primers were located outside the bracketed area) to enable intron spanning 
primer selection. Parameters for primer design were kept as standard except 
that GC content set to 40-60% and product length set to 70-250bp. Primers of 
optimum suitability were selected from those suggested by primer3 and were 
BLAST searched against the CanFam 3.1 genome assembly to check for off-
target binding sites. Primer sequence and amplicon size are provided in the 
following chapters. Suitable primers were ordered from Eurofins Scientific 
(Luxembourg). 
2.7.3 RT-PCR 
As an initial screen of the suitability of primers standard reverse transcription 
PCR (RT-PCR) was performed to allow for analysis of PCR product by gel 
electrophoresis (checking expected product length, primer dimerization and 
off-target products) and sequencing. Using the Hotstar Taq polymerase kit 
(Qiagen) a master mix containing; 3 µL 10X buffer, 1 µL 10 mM MgCl2, 1 µL 
10 mM dNTPs mix (Invitrogen) and 20.25 µL nuclease-free water per sample 
was made and mixed in a nuclease-free Eppendorf tube. This master mix was 
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pipetted (25.25 µL per tube) into thin-walled PCR tubes, and 1.5 µL of 10 mM 
forward and reverse primer mix, 3 µl of cDNA (section 2.7.1) and 0.25 µL 
Hotstar Taq polymerase was added and mixed; reaction tubes were briefly 
centrifuged before PCR. PCR reactions were performed using the G-storm 
thermal cycler (Labtech international, U.K.) and reaction conditions were as 
follows: 15 minutes 95°C, 32 cycles of 95°C for 30 seconds, 60°C for 30 seconds 
and 72°C for 20 seconds with a final extension at 72°C for 10 minutes. Samples 
were either stored at -20°C or used immediately for gel electrophoresis.  
2.7.4 Gel electrophoresis  
cDNA samples and a 100bp ladder (Promega, U.S.A.) were prepared for 
loading by mixing 5 µL with 1 µL 6X blue/orange loading dye (Promega). 
UltraPure™ Agarose (Invitrogen) was used to prepare a 2% gel by dissolving 
powder by heating in 1X TAE (40 mM Tris base, 2 mM sodium EDTA, pH 7.2 
with glacial acetic acid solution. To visualise DNA, 1 µL/10 mL Gel red™ 
(Biotium, U.S.A.) was mixed with agarose prior to pouring the gel. When set, 
the gel was placed in a Horizon gel electrophoresis system gel tank (Life-
technologies, U.S.A.) and covered with 1X TAE solution. Following this 
samples were loaded onto the gel and the tank was attached to the Bio-Rad 
model 200/2.0 power supply and run at 75 V (constant voltage) for one hour 
before visualisation and image capture under UV light on the Gel logic 200 
imaging system (Kodak, U.S.A).  
2.7.5 RT-qPCR and relative gene expression quantification 
RT-qPCR was performed using the Takyon 2X low Rox SYBR green mastermix 
dTTP blue (Eurogentec, Belgium) following the manufacturer’s 
recommendations. Positive assays were performed in triplicate with a no-
template control for each sample on clear 96-well plates. Per well, 10 µL of 
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Takyon™ mastermix (see Eurogentec for reagent list), 4 µL of forward and 
reverse primer mix (final concentration 100 nM for each primer), 3.5 µL 
nuclease-free water and 2.5 µL cDNA (1:10 dilution of synthesised cDNA; 
section 2.7.1) were mixed. The plate was centrifuged at 453g for 3 minutes in 
the Eppendorf 5810R centrifuge (Thermo Fisher Scientific). qPCR was 
performed on the Stratagene MxPro MX3000p (Agilent Technologies) under 
the following conditions: 95°C activation for 10 minutes, 40 cycles of 10 
seconds at 95°C, 20 seconds of primer specific temperature annealing and 20 
seconds at 72°C. Results were analysed using MxPro version 4.1 software 
(Agilent Technologies) and Microsoft Office Excel 2013. In brief, a gene’s 
expression was measured at the cycle at which the fluorescence from the SYBR 
green mastermix became detectable above the background Rox fluorescence. 
The relative expression for genes of interest was calculated using ΔΔCt 
method with normalisation to the reference genes MRPS25, GAPDH and 
RPL32 geomean expression. The primer sequence, amplicon size, primer 
efficiency and TMºC (see section 2.7.6) for reference genes are given in Table 
2-1.  
 
Table 2-1 Reference gene primer sequences used for normalisation in this 
thesis.  
2.7.6 Primer efficiency  
To determine the suitability and optimum annealing temperature for each 
primer, primer efficiency reactions were performed. cDNA samples diluted 
1:10, 1:100 and 1:1000, were set up in triplicate for each primer on 96 well plates 
Gene Symbol Forward Primer Sequence Reverse Primer Sequence Product Length Optimum TM ºC Primer Efficiency %
GAPDH 5'GGGAAGATGTGGCGTGAC3' 5'GAAGGCCATGCCAGTGAG3' 123 59 102.1
MRPS25 5'TCTTGGGGAAGAACAAGGAA3' 5'AGTGGGCTGGGTGAGAAAG3' 72 60 107.6
RPL32 5'GCAGCATTGAAGTTAACCGC3' 5'TCTCCTTGCACACACCTTCTCA3' 147 60 103
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which allowed for the generation of a standard curve in MxPro version 4.1. Ct 
values were plotted on the Y-axis and cDNA dilution was plotted on a 
logarithmic scale on the X-axis. The slope generated from this was converted 
from Log to standard and efficiency rate calculated. All primers fell between 
90 and 110% which is generally accepted as a suitable range. 
2.8 Western blotting 
2.8.1 Cell protein extraction 
Cells were harvested either by displacement with TrypLE Express (Thermo 
Fisher Scientific) or by cell scraping, after which any excess media was 
removed and cells were suspended in 1 mL cold PBS in a 1.5 mL Eppendorf 
tube. Cells were pelleted by centrifugation at 2300g in the Eppendorf 5415R 
tabletop centrifuge. Supernatant was removed and the cells were either snap 
frozen and stored at -70ºC or processed immediately. Cells were lysed using 
urea lysis buffer (7 M urea (Sigma-Aldrich), 0.1 M DTT (ITW, U.S.A.), 0.05% 
(v/v) Triton X-100 (Sigma-Aldrich), 25 mM NaCl and 20 mM HEPES pH 7.6 
(Sigma-Aldrich)) by mixing 30-100 µL with the cell pellet and incubating on 
ice for 15 minutes and then centrifuged for 15 minutes at 16,000g in an 
Eppendorf 5415R tabletop centrifuge. The protein-containing supernatant was 
then either stored at -70ºC or used immediately for analysis.  
2.8.2 Protein quantification 
Protein concentration was quantified using the quick start Bradford assay 
(Bio-Rad.). An eight-point dilution series of bovine serum albumin (BSA) (Bio-
Rad) ranging from 2 mg/mL to blank dH2O was made and pipetted in 
triplicate on a clear-bottomed 96 well plate in 5 µL aliquots. Protein samples 
were diluted 1:10 and then 5 µL aliquots were pipetted in duplicate onto the 
96 well plate. 250 µL of 1X Bradford reagent (Bio-Rad) was added to wells 
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containing standard or sample and incubated at room temperature for 5 
minutes. Absorbance was measured at 595 nm on the Victor3 V1420 Multilabel 
Plate Counter (Perkin Elmer, U.S.A.). Samples were quantified against the 
standard curve generated from absorbance reading from the BSA dilution 
series. Calculations were performed using Microsoft Office Excel software.  
2.8.3 Gel Electrophoresis 
Thirty micrograms of protein from the sample lysates was resolved by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Typically, 
10% resolving gels were used in protein analysis. Gels were prepared using 
the Bio-Rad Protean III mini-gel system. After assembly of the gel casting 
apparatus, resolving gels were made with the following constituents 10% gels; 
10% acrylamide/bis-acrylamide (National Diagnostics, U.S.A.), 375 mM Tris 
(pH 8.8) (Fisher Scientific), 0.1% SDS, 0.1% ammonium persulphate (APS) 
(Sigma-Aldrich) and 0.04% tetramethylethylenediamine (TEMED) (Sigma-
Aldrich). APS and TEMED were added just before pouring to initialise 
polymerisation. Resolving gel was poured to leave an appropriate gap for the 
comb and 5% stacking gel. As the gel set, isopropanol (Fisher scientific) was 
poured on top of the resolving gels to create a level interface and to remove 
air bubbles. The stacking gel was made as follows; 5% acrylamide/bis-
acrylamide, 126 mM Tris-HCl (pH 6.8), 0.1% SDS, 0.1% APS and 0.1% TEMED 
and was poured on top of the resolving gel once it had set and isopropanol 
had been removed. A well-forming comb was inserted into the stacking gel 
and the apparatus left for 20-30 minutes at room temperature. Following the 
stacking gel setting, the gel was removed from the casting stand, the comb was 
detached and the gel was placed in the running module and covered in SDS-
PAGE running buffer (25 mM Tris, 0.1% (w/v) SDS and 192 mM glycine 
(Sigma-Aldrich) in dH20). Prior to loading, the samples were heated at 95ºC 
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for 3 minutes to denature protein structure. Pre-stained protein ladder (Bio-
Rad and GE Healthcare, U.K.) was added to at least one well and used to 
indicate protein size. Electrophoresis was performed at 180-200 volts for 45-60 
minutes using the PowerPac Basic (Bio-rad).  
2.8.4  Transfer 
Following protein separation by electrophoresis, proteins were transferred 
onto Hybond enhanced chemiluminescence (ECL™) nitrocellulose 
membranes (GE Healthcare) using the mini trans-blot module (Bio-Rad). To 
correctly assemble the module, the following protocol was used: one sponge 
then one piece of blotting paper, the resolving gel, the nitrocellulose 
membrane, one piece of blotting paper, the final sponge. These were put 
together and submerged in 1X transfer buffer (25 mM Tris, 192 mM glycine 
and 20% methanol (Fisher Scientific) in dH2O). The assembled cassette was 
inserted into the transfer holder ensuring the correct current direction was 
followed so that the protein transferred from the gel to the membrane. An ice 
block was placed in the transfer tank to prevent overheating and the tank was 
filled with transfer buffer. Transfers were performed for 1 hour at 100 volts.  
2.8.5 Immunoblotting  
To detect proteins of interest, the nitrocellulose membrane was removed from 
the cassette and washed for 5 minutes in 0.1% PBS Tween 20 (Scientific 
Laboratory Supplies, U.K.). Blocking was then performed with 5% milk 
powder (Sigma-Aldrich) 0.1% PBS Tween for 1 hour at room temperature. The 
primary antibody (mouse anti-αSMA (Sigma-Aldrich) 1:1,000 dilution, rabbit 
anti-SM22α (Abcam, U.K.) 1:2,000 dilution or mouse anti-β-actin (Abcam) 
1:20,000 dilution) was diluted in blocking buffer and incubated with the 
membrane overnight at 4ºC. The membrane was then washed with 0.1% PBS 
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Tween for three X five minute washes and then incubated for 1 hour at room 
temperature with a horseradish peroxidase (HRP) conjugated secondary 
antibody directed against the primary antibody species (rabbit anti-mouse 
HRP (DAKO, Denmark) 1:1000 dilution and pig anti-rabbit HRP (DAKO) 
1:2000 dilution) diluted in blocking buffer. The membrane was then washed 
as previously before application of Amersham™ ECL™ Western Blot 
Detection Reagent (GE Healthcare, Cat No. RPN2209) to allow for 
visualisation of the protein bands. This was incubated with the blots for 1-2 
minutes before the membrane was placed in cling film with all air bubbles 
removed and then into a film cassette. To visualise the protein bands 
radiographic film (GE Healthcare) was loaded into the cassette in a dark room 
and incubated with the membrane for between 1 second to 2-3 minutes 
depending on the antibody. Radiographic films were developed in a SRX-
101A radiographic processor (Konica Minolta, U.K.).   
2.9 Enzyme-Linked Immunosorbent Assays  
2.9.1 Tumour Necrosis Factor 
A DuoSet canine tumour necrosis factor (TNF) Enzyme-Linked 
Immunosorbent Assay (ELISA) (R&D Systems, U.S.A.) was used to analyse 
the level of TNF secreted from VICs into media. Prior to the assay being 
performed, the capture antibody supplied with the kit was diluted 1:180 in 
PBS and used to coat the necessary number of wells in a high protein-binding 
capacity Maxisorp 96 well plate (Nunc, Denmark).To run the standard 
dilution series 50 µL of antibody was applied per well in triplicate. Once 
coated, plates were incubated overnight at room temperature, washed 5X with 
0.05% PBS Tween 20 (Scientific Laboratory Supplies) in the Skanwasher 400 
(Molecular Devices, U.S.A.), with all solution being completely aspirated off 
after the final wash. Reagent diluent (10% BSA) (R&D Systems) was diluted 
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1:10 with PBS to make a working solution. Three hundred microliters per well 
was used as a blocking buffer with a 1 hour incubation period at room 
temperature. Following this, the plate was washed as indicated previously. A 
dilution series of TNF standard was produced by first diluting 65 ng/mL 
recombinant canine TNF 1:65 in reagent diluent to get a 1000 pg/mL top 
standard. A 2 fold 7 point serial dilution series was then set up by diluting this 
standard in reagent diluent. 50 µL of sample media or standard dilution series 
was then pipetted into coated wells in triplicate and incubated for 2 hours at 
room temperature. The plate was then washed as previously. Stock 18 µg/mL 
biotinylated goat anti-canine TNF detection antibody was diluted 1:180 in 
reagent diluent for a working solution at 100 ng/mL. 50 µL of this per well was 
then pipetted onto the plate and incubated for 2 hours at room temperature 
before being washed as previously. Stock Streptavidin-HRP was then diluted 
1:200 with reagent diluent and 50 µL per well was added to the plate, the plate 
was then protected from light with foil and incubated at room temperature for 
20 minutes whilst being shaken gently on a Wellmix microplate shaker 
(Thermo Fisher Scientific). Following washing the plate as previously 
described, 50 µL of 1 step ultra TMB ELISA Highly Sensitive Substrate 
Solution (Thermo Scientific) was added to each well, protected from light and 
incubated using the Wellmix at room temperature for approximately 20 
minutes or until a colour change was detected in the wells containing the TNF 
standard dilution series . Following this 25 µL of 1 M H2SO4 (sulphuric acid) 
was pipetted into each well using a multi-channel pipette, to stop the substrate 
solution reaction. Optical density at both 450 nm (wavelength of interest) and 
540 nm (wavelength used to correct for imperfections on the plate by 
subtracting from the 450 nm reading) were read on the Cytation 3 imaging 
reader (BioTek, U.S.A.). Results were then exported to Microsoft office excel 
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and secreted TNF in each sample was calculated using the standard dilution 
series.     
2.9.2 Interferon gamma 
To detect interferon gamma (IFNγ) secreted into the media from VICs a 
DuoSet canine IFNγ ELISA (R&D systems) was utilised. This used the protocol 
described in 2.9.1 including the same dilution factors. However, the standard 
used was recombinant canine IFNγ and the capture antibody and detection 
antibody were targeted against canine IFNγ.  
2.9.3 Transforming Growth Factor β1 
A Human Quantikine® TGFβ1 ELISA (R&D Systems) was used to analyse 
secreted TGFβ1 from canine VICs as the dog and the human TGFβ1 share 
100% homology at the protein level (http://www.ensembl.org). The ELISA was 
performed following the manufacturer’s protocol. Prior to the assay being 
performed, all reagents were prepared as required. This included diluting 
calibrator diluent RD5-53 1:4 with dH2O, making a 1:25 dilution of wash buffer 
concentrate with dH2O and making 1 M HCl and 1.2 M NaOH/0.5 M HEPES 
solution. A dilution series of TGFβ1 standard (1:2 dilution at each step) from 
2000 pg/mL to 31.3 pg/mL was performed with calibrator diluent RD5-53. To 
activate all latent TGFβ1 in the supernatants and expose the antibody-binding 
epitope, 20 µL of 1 M HCl was added to each 100 µL of the samples. Samples 
were then incubated for 10 minutes at room temperature and then neutralised 
with 20 µL of 1.2 M NaOH. Pre-coated microplate strips were treated with 50 
µL of assay diluent RD1-73 with enough strips prepared for all samples and 
standards to be run in duplicate. Fifty microliters of standard or activated 
sample was added to each well and incubated at room temperature for 2 
hours. All wells were gently aspirated and washed 3X with assay wash buffer 
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and 100 µL of TGFβ1 conjugate was then added to each well and the samples 
incubated at room temperature for 2 hours. All wells were washed as 
described above and 100 µL of substrate solution was added to each well. 
Wells were then protected from light and incubated at room temperature for 
30 minutes. Finally, 100 µL of assay stop solution was added to each well and 
the optical densities for both 450 nm and 540 nm wavelengths were read on 
the Cytation 3 imaging reader. Results were then exported to Microsoft Office 
Excel and secreted TGFβ1 in each sample was calculated against the standard 
dilution series.  
2.9.4 Transforming Growth Factor β2 
A mouse/rat/canine/porcine TGFβ2 Quantikine® (R&D Systems) was used to 
analyse secreted TGFβ2 from canine VICs. The ELISA was performed 
following manufacturers instructions and followed the same protocol 
described in section 2.9.3 with the exception that the standard used was 
recombinant TGFβ2 and the capture and detection antibodies were targeted 
against TGFβ2. To activate all latent TGFβ2 in the supernatants and expose the 
antibody-binding epitope, 20 µL of 1 M HCl was added to each 100 µL of the 
samples. 
2.9.5 Transforming Growth Factor β3 
A human TGFβ3 (98% homology between human and canine TGFβ3 
(http://www.ensembl.org)) DuoSet ELISA (R&D Systems) was used to analyse 
secreted TGFβ3 from canine VICs. The ELISA was performed following 
manufacturers instructions and followed the same protocol described in 
section 2.9.1 with the exception that the standard used was recombinant 
TGFβ3 and the capture and detection antibodies were targeted against TGFβ3. 
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To activate all latent TGFβ3 in the supernatants and expose the antibody-
binding epitope, 20 µL of 1 M HCl was added to each 100 µL of the samples. 
2.10 Proteoglycan assay  
To assess proteoglycan changes in VIC media supernatants the sulphated 
glycosaminoglycan quantification assay (AMS Biotechnology Ltd, U.K.) was 
used following the manufacturer’s instructions. Stock 100 µg/mL chondroitin 
sulphate was diluted 1:5 with the DLF media used to propagate VICs to obtain 
a 20 µg/mL top standard. A 2 fold 7 point dilution series was made from the 
top standard, again diluting in media. One hundred microliters of either 
standard dilution series or sample supernatant was pipetted in triplicate into 
wells of a clear 96 well plate. One hundred µL of assay dye was then added to 
each well, gently swirled to mix, and the optical density was measured at 515 
nm on a Synergy HT plate reader (BioTek). Results were then exported to 
Microsoft Office Excel and secreted proteoglycan in each sample was 
calculated against the standard dilution series. 
2.11 Cell culture treatment conditions 
2.11.1 TGFβ1 and SB431542 cell culture conditions 
To analyse the effect of TGFβ1 signalling and the TGFβ pathway in VICs, a 
microarray gene expression study was carried out on 3 biological replicates of 
quiescent VICs (qVICs) and VICs derived from diseased valves (aVICs) (all 
passage 3). All cells were grown in T25 cell culture flasks for the duration of 
the experiment. This approach was used to ensure that a high quantity and 
quality of RNA would be obtained from all samples. VICs were seeded at a 
density of 200,000 cells per flask. Cells were maintained in 5ml of DLF media 
(described in section 2.4) per flask. qVICs were treated with 5 ng/mL 
recombinant human TGFβ1 (Gibco Life Sciences, U.S.A.) dissolved in 4 mM 
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HCl, 0.1% BSA (Sigma-Aldrich) (concentration chosen upon personal 
communication with Dr. Karen Tan as well as previously being shown to 
induce activation in aortic VICs[117, 272]). aVICs were treated with 10 µM 
SB431542 (Sigma-Aldrich) dissolved in Dimethyl Sulfoxide (DMSO) (Sigma-
Aldrich) (concentration chosen upon personal communication with Dr. Karen 
Tan). Control plates for all qVICs and aVICs were run concurrently, passage 
matched and with vehicle treatment of DMSO (1 µL/mL), and 4 mM HCl, 0.1% 
BSA (1 µL/mL) added. In addition, to account for vehicle effects in the 
treatment groups, DMSO (1 µL/mL) was added to the TGFβ1-treated qVICs 
and 4 mM HCl, 0.1% BSA (1 µL/mL) was added to the SB431542 treated aVICs. 
A diagram of the experimental approach is shown in Figure 2-4. 
 
Figure 2-4 Summary of the experimental design used to derive samples for 
microarray analysis of TGFβ signalling in VICs.   
Following 72 hours of treatment of the qVICs and 96 hours of treatment for the 
aVICs, cells were processed for storage and RNA extraction as described in 
section 2.3.2 with the exception that cells were counted on a haemocytometer 
prior to pelleting for storage. This was performed for later normalisation of 
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proteoglycan data from these cells (see Chapter 6). All cell media was stored 
in appropriately labelled bijou tubes at -20ºC for future analysis.  
2.11.2 5HT and LY272015 cell culture conditions 
To investigate the role of serotonin (5HT) signalling in VICs the following 
protocol was used. qVICs and aVICs were cultured in 35 mm2 plastic cell 
culture dishes over the course of the experiment (qVICs ranged between 
passage 3-5, aVICS were all passage 3). As two time points (4 and 7 days) and 
both RNA and protein were being sampled, each primary cell culture was set 
up in quadruplicate with cells being cultured for 4 days seeded at 150,000 cells 
per well and cells cultured for 7 days seeded at 50,000 cells per well. Culture 
wells were supplemented with 5 mL DLF media and treatment every 48 hours. 
qVICs were treated with 1µM 5HT (Sigma-Aldrich) dissolved in sterile dH2O 
(concentration was chosen upon personal communication with Dr. Karen Tan 
and for previous use in the literature[171]). aVICs were treated with either 100 
nM or 1 µM of the selective 5HTR2B antagonist LY272015 (Santa Cruz 
Biotechnology, U.S.A.) dissolved in DMSO (100 nM selected as this 
concentration had previously been reported in the literature [171, 273] and 1 µM 
selected to check the effect of a high dose). To control for the effect of vehicle, 
media was supplemented to 1 µL/mL DMSO in the 5HT treated qVICs and the 
lower dose LY272015 treatment. As a control, DMSO treated (1 µL/mL) qVICs 
and aVICs were propagated concurrently with the treatment groups.  
Cells were harvested after appropriate treatment times (see section 2.3.2) and 
went on to either have RNA (section 2.3.2) or protein (section 2.8.1) extracted. 
Media from day 7 cells intended for protein extraction was stored in 
appropriately labelled bijou tubes at -20ºC and used for proteoglycan analysis 
normalised to protein concentration (see Chapter 6).  
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2.12 Cell microscopy and image capture 
Photomicrographs of cells were taken using a Zeiss Axiovert 40 CFL inverted 
microscope (Zeiss, Germany) at x10 magnification. Images had 100 µM scale 
bar attached in Axiovision software (version 4.7.2) and were exported as JPEG 
files.  
2.13  Statistical analyses 
Microarray statistical analysis was performed in the transcriptome analysis 
console as stated in section 2.5.3, all other statistical analysis was performed in 
Minitab17. When the data had a normal distribution, parametric tests were 
performed. Otherwise, a non-parametric test was performed. 2-sample T-tests, 
paired sample T-tests or Mann Whitney U-tests were performed with 













   Grade dependent changes in MMVD 
3.1 Introduction  
As discussed in Chapter 1, myxomatous mitral valve disease (MMVD) causes 
a progressive deterioration in the structure and function of the mitral valve. 
The gross anatomy and histological features of the disease have been well 
characterised with a grading system (Whitney grading)[4]. This has been 
implemented to distinguish, broadly, the development of disease from early 
to end-stage (Chapter 1 section 1.2.2).  
However, the molecular mechanisms underpinning and controlling disease 
development in the dog remain poorly understood. One reason for this is that 
the majority of previous studies have examined changes between normal 
(Grade 0) and end grade (Whitney grade 4) disease. This is particularly true of 
transcriptomic studies where presently only three studies (two microarrays, 
one RNAseq) in the dog have been performed and all have compared normal 
to highly diseased valves [33, 143, 150]. Although these studies have been 
informative in highlighting the fundamental transcriptomic differences 
between normal and diseased valves, they fail to distinguish which of these 
pathways may be causal and which may be consequential. To ascertain this 
requires contextualising transcriptomic changes as the disease progresses. 
Furthermore, by virtue of the natural history of the disease, these studies have 
compared older MMVD-affected dogs with younger disease-free dogs. The 
pathology of the condition (discussed in Chapter 1 section 1.2) means that it is 
unfeasible to propose a study into MMVD where the control group will be 
completely devoid of myxomatous lesions and be of the same age as an end 
grade diseased group[22]. This makes data analysis difficult as age cannot be 
removed as a confounding factor[22]. Tackling this problem can be partly 
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achieved by assessing disease in a grade-dependent manner. Although there 
will still be a difference between the control and end grade groups, the age of 
lower grade and control groups are likely to overlap, allowing for a distinction 
of which pathways solely associated with disease and those associated with 
senescence. 
Another consideration is the effect of breed on the development of MMVD. 
All breeds of dog will likely develop some form of the disease by 10 years of 
age, however, the vast majority of these will not reach clinical significance[3, 4, 
50]. As discussed in Chapter 1 section 1.6, it is well established that various 
small breed dogs, such as the Cavalier King Charles Spaniel (CKCS) and 
dachshund, are predisposed to developing the disease at an early age, making 
the eventual development of clinical symptoms more likely[24, 166, 222]. Although 
previous studies have looked at potential genetic variants responsible for this, 
none have been successful in establishing a single responsible variant [201, 219-221]. 
Previous microarray studies have both included at least one group containing 
just one breed with Oyama et al using exclusively beagles in their control 
group and Lu et al comparing beagles to CKCS [33, 150], allowing a possible breed 
bias to be introduced.  
With this in mind, the aim of this study was to investigate the transcriptomic 
changes occurring as MMVD progresses. To minimise artefacts and bias 
related to age, breed and secondary effects of late disease, multiple breeds in 
control and grade 1-4 groups were used. This allows broader statements about 
the development of MMVD in the dog as a whole. Although new information 
about various aspects of end grade disease was expected, this study was 
particularly interested in separating cause and consequence pathways 
involved in the development of the disease.  
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3.2 Materials and methods  
3.2.1 Tissue collection 
For full details on tissue collection, see Chapter 2 section 2.2. Thirty valves 
were collected with full owner consent for this study. The description of these 
dogs is summarised in Table 3-1. Disease grade was assessed grossly by two 
investigators and scored using the Whitney grading system [4].  
 
Table 3-1 Description of the dogs used in this study. 
Sample ID Date sampled Dog Breed Gender Age Whitney grade
B2G0 05/06/2015 BEAGLE MALE 4y 0
B4G0 05/06/2015 BEAGLE FEMALE 4y 0
PBT1G0 20/11/2015 PITBULL TERRIER' TYPE MALE 2y9m 0
PBT3G0 01/04/2016 'PITBULL TERRIER' TYPE MALE 1y9m 0
PBT2G0 27/11/2015 'PITBULL TERRIER' TYPE MALE 3y 0
B26G0 26/10/2015 BEAGLE MALE 3y 0
B5G1 09/04/2015 BEAGLE FEMALE 4y1m 1
B3G1 09/04/2015 BEAGLE MALE 3y10m 1
B1G1 09/04/2015 BEAGLE MALE 4y1m 1
MG1 25/09/2015 MASTIFF MALE 5y 1
SBT1 30/10/2015 STAFFORDHSIRE BULL TERRIER FEMALE 6y 1
SBT2G1 24/06/2016 STAFFORDHSIRE BULL TERRIER FEMALE 10y 1
B3G2 09/04/2015 BEAGLE MALE 3y2m 2
B6G2 09/04/2015 BEAGLE FEMALE 3y2m 2
RG2 23/10/2015 ROTTWEILLER MALE 5y 2
ABDG2 05/02/2016 AMERICAN BULLDOG MALE 6y 2
CG2 19/02/2016 BORDER COLLIE MALE 5y 2
SBTG2 01/04/2016 STAFFORDHSIRE BULL TERRIER FEMALE 7y 2
BTG3 29/01/2016 ENGLISH BULL TERRIER FEMALE 10y 3
WHTG3 06/11/2015 WEST HIGHLAND TERRIER MALE 10y 3
811M_024 16/01/2013 CAVALIER KING CHARLES SPANIEL MALE 12y 3
811M_019 20/12/2012 CAVALIER KING CHARLES SPANIEL MALE 11y 3
811M_023 16/01/2013 CAVALIER KING CHARLES SPANIEL MALE 12y 3
811M_017 20/02/2013 CAVALIER KING CHARLES SPANIEL FEMALE 10y 3
CKCSG4 21/03/2014 CAVALIER KING CHARLES SPANIEL MALE 16y 4
JRG4 30/10/2015 JACK RUSSEL TERRIER FEMALE 11y 4
C1G4 19/02/2016 BORDER COLLIE MALE 13y 4
811M_016 20/12/2012 CAVALIER KING CHARLES SPANIEL FEMALE 12y 4
811M_007 22/05/2012 CAVALIER KING CHARLES SPANIEL MALE 14y 4
C2G4 08/07/2016 BORDER COLLIE MALE 13y 4
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3.2.2 RNA extraction, quantification and quality control for microarray 
The extraction protocol followed for whole valve RNA extraction is detailed 
in Chapter 2 section 2.3.1. Almost all RNA extractions were performed by 
myself, with the exception of CKCS samples with the sample ID beginning 
811M which were extracted by Dr. Chie Chien Lu prior to the start of this study. 
Quantification and quality control assessment of RNA for microarray analysis 
was performed as described in Chapter 2 section 2.3.3.  
3.2.3 Affymetrix Canine Gene 1.1ST microarray analysis 
For this study, microarray analysis was performed using two 16 well 
Affymetrix Canine Gene 1.1ST chips. RNA processing, hybridisation, post-
hybridisation quality control, summarisation file creation and differential 
gene expression analysis was performed as described in section 2.5 of Chapter 
2. Unless otherwise stated, this study relaxed the Benjamini-Hochberg false 
discovery rate (FDR) correction to allow the inclusion of a greater number of 
genes for gene enrichment analysis.  
3.2.4 Gene enrichment analysis  
The network analysis tool Miru (version 1.4) was utilised as described in 
Chapter 2 section 2.6.1. In this study, a pairwise gene-to-gene comparison was 
made using a Pearson correlation with the Fruchterman-Reingold algorithm 
threshold set at r=0.87 to allow the maximum number of nodes (genes) with 
the smallest number of edges (connections between genes). This calculation 
governs how nodes are plotted on the 3D graph, determining the stringency 
of the association of gene expression patterns with one another (topology). 
Markov clustering (MCL) inflation was set at 4.3.  
The tools Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) and Ingenuity Pathway Analysis (IPA) were used as stated in 
69 
 
Chapter 2 sections 2.6.2 and 2.6.3; default settings were used throughout. Gene 
list comparison was performed as outlined in Chapter 2 section 2.6.4. 
3.2.5 cDNA synthesis and RT-qPCR 
To validate the microarray analysis RNA samples were synthesised into 
complementary DNA (cDNA) and real-time quantitative polymerase chain 
reaction (RT-qPCR) was performed. For this analysis, all RNA samples except 
811M_016 were reverse transcribed into cDNA as stated in Chapter 2 section 
2.7.1. Sample 811M_016 was excluded due to a lack of remaining RNA. 
Primers used for validation are listed in Table 3-2 and were designed and 
optimised following the protocol summarised in Chapter 2 section 2.7.2-2.7.6.  
 
Table 3-2 Primers designed and optimised for the validation of whole valve 
microarray data. 
RT-qPCR of the samples was performed following the protocol outlined in 
Chapter 2 section 2.7.7 with the optimum TMºC (Table 3-2) for each primer 
being used as the annealing temperature.  
Gene Symbol Forward Primer Sequence Reverse Primer Sequence Product Length Optimum TM ºC Primer Efficiency %
ACTA2 5'CGGCTACTCCTTTGTGACG3' 5'CGTGGCCATCTCGTTCTC3' 100 58 102.2
HTR2B 5'CCAATCCAGGCCAATCAAAG3' 5'CAGGTGATGTTGCTTGGGTT3' 143 59 104.8
TAGLN 5'GACATGTTCCAGACCGTCGA3' 5'CAATGACGTGCTTTCCCTCC3' 199 59 106.7
ACTG2 5'TGCCAACAATGTCCTTTCCG3' 5'GCCTCCAATCCAGACTGAGT3' 148 60 93
SLIT3 5'CTGACAAGGACAACGGCATC3' 5'CCCATCATTCACCGTCTCCA3' 146 60 101
CDKN2A 5'CATGTTGGCTCAGAATCGGG3' 5'CTCACGTCCAAGGCACAAAA3' 125 60 90.6
SLC10A6 5'GCTGTTGGATGGGTTTCTCA3' 5'TCCAAGAAAGCACCAGTCTCT3' 147 58 101.7
CILP 5'TGCTCCAATTATACCGTGCG3' 5'CAGAACACTTGCTCCAGGGA3' 100 62 106.1
MMP12 5'GACACAATTCATGGACCCTGG3' 5'TCAAATACGTCAGGTCCTTGGA3' 129 63 110
ADAMTS5 5'GTTCCCAAATATGCAGGCGT3' 5'AGCTTCGAACCAATGATGCC3' 191 59 101.6
ADAMTS19 5' GGACGGTGAGGTGTACTAAC 3' 5'ACTGCATTCCTTTACCACAGG 3' 150 59 100.2
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3.3 Results  
3.3.1 Breed, gender and age analysis 
The 30 tissue samples obtained for analysis in this study were from 11 different 
breeds of dogs (Table 3-1) with 2 or more different breeds of dog in each 
Whitney grade of disease. 10 females and 20 males were included in the study 
(Table 3-1) with at least 1 female being included in each Whitney grade of 
disease. The average age of the dogs in each grade of disease (n=6 per grade) 
is summarised in Figure 3-1. A significant difference in age of at least P-value 
<0.05 was reached between all groups with the exception of between normal 
and grade 1 and grade 1 and grade 2 valves. 
 
Figure 3-1 Average age of dogs sampled for microarray analysis. Significant 
differences between Whitney grades of disease are shown by * symbols 





3.3.2 RNA quality assessment 
Post-extraction, the RNA concentrations from all RNA samples from the 30 
valves were quantified. These along with 260/280 and 260/230 absorbance ratio 
readings and RNA integrity number (RIN) were recorded (Table 3-3). RNA 
concentration ranged from 192.3-1315.6 ng/µL. Absorbance ratios were all 
within the acceptable reference range (1.8-2.2) for both 260/280 and 260/230, 
indicating that the extractions did not contain contaminants. Gel 
electrophoresis images generated by the Agilent 2200 bioanalyser (Figure 3-2) 
visualised the 28S and 16S rRNA in each sample. The intensity for each of these 
was then semi-quantified and a ratio of 28S:16S was used to create the RIN for 
each sample[268]. The majority of samples passed the accepted RIN cut-off of >7 
for microarray analysis. Samples MG1, C1G4 and 811M_007 had RINs below 
7 (5.9, 6.5 and 6.3 respectively). Upon personal communication with Chieko 
Kontani (Edinburgh Genomics), it was decided that these samples would be 




Table 3-3. Concentration, 260/280 and 260/230 absorbance readings and RIN 
for each valve sample. 
 
Figure 3-2. Gel electrophoresis images visualising the 28S (indicated by the 
top arrow) and 16S (indicated by the bottom) rRNA intensity in each sample. 
The RIN for each sample is shown and colour coded with >8 given a green 
colour, 6.5-8 given a yellow colour and <6.5 given a red colour. 
Sample ID RNA concentraion [ng/µl] 260/280 260/230 RIN
B2G0 330.7 2.07 1.92 8.2
B4G0 416 1.96 1.99 8.5
PBT1G0 416.7 2.07 2.08 7.6
PBT3G0 307.6 2.13 1.98 8.2
PBT2G0 876.4 2.05 2.15 8.5
B26G0 825.2 2.02 2 7.7
B5G1 424.4 2.04 2.02 9.1
B3G1 372 2.03 2.15 7.9
B1G1 848.2 2.05 2.03 8.3
MG1 228.8 2.07 2.04 5.9
SBT1 652.2 2.06 1.98 7.6
SBT2G1 541.1 2.06 1.98 8.6
B3G2 281.1 2.08 1.9 9.3
B6G2 1026.6 2.03 2.15 8.7
RG2 631.2 2.11 2.31 7.8
ABDG2 998.9 2.09 2.04 8.4
CG2 826.4 2.03 2.05 8.2
SBTG2 522.9 2.1 2.22 7.7
BTG3 627.6 2.09 2.17 8.3
WHTG3 439.9 2.07 2.19 7
811M_024 303.5 2.05 2.16 8.6
811M_019 465.7 2.01 2.19 8.8
811M_023 351.6 2.06 2.04 7.2
811M_017 192.3 2.06 2.13 7.6
CKCSG4 806.5 2 2 7.9
JRG4 974 2.06 2.2 8.6
C1G4 1315.6 1.97 1.81 6.6
811M_016 265.7 2.07 2.18 8.9
811M_007 541.6 2.1 1.99 6.3
C2G4 1175.6 1.97 1.98 8.3
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3.3.3 Microarray post-hybridisation quality control  
Post-hybridisation analysis was performed to assess the gene expression data 
from the microarray analysis of the submitted samples. All wells on the array 
showed the correct concentration of spike in and labelling controls indicating 
that the arrays had been performed correctly. After Robust Multi-array 
Average (RMA) and gene-level normalisation, log expression signal was 
plotted (Figure 3-3) in box plots with the majority of samples showing a 
similar profile relative to one another. Samples MG1 and 811M_007 showed a 
larger amount of variation compared to any other samples (highlighted in 
red). These two samples had the lowest RINs out of all samples.  
 
Figure 3-3. Post-RMA signal intensity boxplots for each sample. 
Highlighted in red are samples MG1 and 811M_007, which show the largest 
variation. 
The sample-to-sample analysis in Miru (r=0.97) (Figure 3-4) highlighted 
samples 811M_007 and MG1 as clustering away from the main group of 
samples. This difference was also apparent in the PCoA plot (Figure 3-5). In 
transcript-to-transcript expression analysis, 9951 nodes (transcripts) were 
plotted with the two largest clusters being grouped based on the differential 
expression in samples 811M_007 and MG1 (Figure 3-6) (Pearson correlation 
r=0.85, MCL inflation 2.2). These samples had the lowest RINs of any samples 
and, as shown by these analyses, this was causing a detrimental effect on 
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microarray analysis of all samples. Therefore, these two samples were 
removed from the dataset for subsequent analyses.  
 
Figure 3-4. Sample-to-sample analysis of whole valve RNA submitted for 
microarray analysis. Normal valves are coloured green, grade 1 brown, grade 
2 black, grade 3 blue and grade 4 red. Highlighted are samples 811M_007 





Figure 3-5. PCoA plot indicating the level of similarity in transcript 
expression between samples. Normal valves are coloured green, grade 1 
brown, grade 2 black, grade 3 blue and grade 4 red. Highlighted are samples 
811M_007 and MG1 are separated from the other samples. 
 
Figure 3-6. Bar charts of the average gene expression in the largest two gene 
clusters from transcript-to-transcript analysis of all 30 samples submitted 
for microarray analysis. Y-axis shows averaged normalised intensity. The 
yellow bar chart on the left highlights that the genes in this cluster are only 
highly expressed in the MG1 sample. The red bar chart on the right 




After outlier removal, sample-to-sample analysis in Miru (r=0.97) showed a 
distribution with normal and lower grade valves clustering towards one side 
of the plot and higher grade 3 and 4 diseased valves clustering to on the other 
(Figure 3-7). This highlights a difference transcriptomically in these samples. 
Additionally, there is a slight breakaway group of grade 3 and 4 diseased 
valves away from the main cluster (highlighted in the red circle); this will be 
investigated further in Chapter 4. 
 
Figure 3-7. Sample-to-sample analysis with outliers removed showing 
samples coloured by grade of disease. (Normal samples are coloured green, 
grade 1 brown, grade 2 black, grade 3 blue and grade 4 red. Highlighted by 
a red circle is a set of grade 3 and 4 disease samples clustering away from 
the main group of samples. 
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Signal intensity distribution for each of the remaining samples was analysed 
and presented as a log2 signal histogram (Figure 3-8). This shows log signal 
intensity from 0-13.89 with a similar distribution pattern for all samples being 
exhibited, with an initial peak at 1.8 log signal (which is indicative of the 
inherent background signal associated with microarray). This peak declines 
and a plateau in the expression of genes is seen between 3.8-8 log signal 
intensity before a decline in genes expressing above this signal intensity until 
no genes being expressed at a greater intensity than 13.89. This figure shows 
that to remove the effect of background on this dataset genes expressed below 
3.8 log signal intensity should be removed. 
 
Figure 3-8. The Log2 signal line graph for samples. Each line represents a 
sample with the X-axis plotting signal intensity and Y-axis plotting the 
number of probes on the array with that signal intensity. The higher the line 
is on the Y-axis, the greater the number of probes are showing that signal 
intensity. A uniform pattern of expression can be seen here. 
3.3.4 Differential expression of genes  
With post-hybridisation quality control and outlier removal completed, 
differential expression of genes was calculated in the Affymetrix 
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Transcriptome Analysis Console. In total 1002 genes were differentially 
expressed (>1.5 or <1.5 fold change, p-value <0.05, >3.8 log2 signal intensity) in 
at least one grade of disease when compared to normal valve samples. This 
comprised 461 genes upregulated and 541 genes downregulated relative to 
normal valves. When expression in each grade of the diseased valves was 
compared to expression in normal valves, grade 1 valves had 71 differentially 
expressed genes, grade 2 had 59, grade 3 had 673 and grade 4 had 507 (full 
gene list can be found in Appendix I: Chapter 3 Tables S1-4). These results 
were exported as volcano plots (Figure 3-9). Points on these plots were 
generally equally distributed between up and down-regulated genes with 46 
transcripts up-regulated and 25 down-regulated in grade 1, 39 up-regulated 
and 20 down-regulated in grade 2, 290 up-regulated and 383 down-regulated 
in grade 3 and 258 up-regulated and 248 down-regulated genes in grade 4. 
These gene lists were exported to Microsoft Excel and log2 signal intensity was 




Figure 3-9. Volcano plots of each stage of disease compared against 
transcript expression in normal valves. A – grade 1; B – grade 2; C – grade 3; 
D – grade 4. The X-axis shows fold change value and Y-axis shows the P-
value. Central vertical line shows 0 fold change with negative fold changes 
relative to normal on the left and positive fold changes on the right. Red are 
up-regulated transcripts (>1.5 fold) green are down-regulated transcripts (<-
1.5 fold) and grey are transcripts which do not meet criteria for differential 
expression. 
Higher stringency analysis was performed for all grades of disease, with the 
inclusion of a false discovery rate (FDR) of Q-value <0.1 as well as the criteria 
included above. Under these criteria, a total of 88 genes were differentially 
expressed with 18 being altered in grade 3 (12 up-regulated and 6 down-
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regulated) and 70 being altered in grade 4 (37 up-regulated and 33 down-
regulated). No genes were differentially expressed compared to normal in 
grades 1 and 2 with a FDR correction applied. Full gene lists for grades 3 and 
4 with the FDR correction applied are shown in Table 3-4 and Table 3-5. 
 
Table 3-4. Differentially expressed genes between grade 3 and normal 
valves with high stringency criteria (FDR Q-value <0.1). 
Gene Symbol Description Fold Change ANOVA p-value FDR q-value 
NT5E 5-nucleotidase, ecto (CD73) -2.93 0.000065 0.088017
TANC2 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 -1.72 0.000049 0.080518
CCDC65 coiled-coil domain containing 65 -1.69 0.000126 0.098682
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 -1.64 0.000031 0.075599
Uncharacterised -1.6 0.000144 0.098682
LOC102152842 zinc finger protein 512-like -1.51 0.000028 0.075599
LOC480571 septin-4 1.51 0.000045 0.080518
UBTD1 ubiquitin domain containing 1 1.55 0.000004 0.068246
FAM174A family with sequence similarity 174, member A 1.58 0.000118 0.098682
ACYP2 acylphosphatase 2, muscle type 1.63 0.000135 0.098682
Uncharacterised 1.79 0.000047 0.080518
BNC2 basonuclin 2 1.82 0.000064 0.088017
NOV nephroblastoma overexpressed 1.87 0.00001 0.068246
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 1.94 0.000032 0.075599
PLCXD3 phosphatidylinositol-specific phospholipase C, X domain containing 3 2.98 0.000145 0.098682
CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 5.34 0.000009 0.068246
LRRN1 leucine rich repeat neuronal 1 6.1 0.000143 0.098682




Table 3-5. Differentially expressed genes between grade 4 and normal 
valves with high stringency criteria (FDR Q-value <0.1). 
Gene Symbol Description Fold Change ANOVA p-value FDR q-value
Uncharacterised -3.75 0.000157 0.073688
NKAIN2 Na+/K+ transporting ATPase interacting 2 -3.68 0.000092 0.060638
CILP cartilage intermediate layer protein, nucleotide pyrophosphohydrolase -3.64 0.000052 0.052298
NT5E 5-nucleotidase, ecto (CD73) -2.99 0.000172 0.074864
TMEFF2 transmembrane protein with EGF-like and two follistatin-like domains 2 -2.73 0.000001 0.030355
ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary) -2.65 0.000353 0.083815
WIF1 WNT inhibitory factor 1 -2.6 0.000472 0.094419
MIR218-1 microRNA mir-218-1 -2.6 0.000258 0.080548
KCNQ5 potassium channel, voltage gated KQT-like subfamily Q, member 5 -2.07 0.000405 0.090038
LRP1B low density lipoprotein receptor-related protein 1B -2.01 0.000487 0.094419
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 -2 0.000027 0.039052
IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2 -2 0.000219 0.076063
TMEFF2 transmembrane protein with EGF-like and two follistatin-like domains 2 -1.95 0.000026 0.039052
Uncharacterised -1.94 0.00021 0.076063
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 -1.93 0.000008 0.039052
AFF2 AF4/FMR2 family, member 2 -1.9 0.000428 0.090038
PTGFR prostaglandin F receptor (FP) -1.86 0.000404 0.090038
OVGP1 oviductal glycoprotein 1, 120kDa -1.85 0.000258 0.080548
SCIN scinderin -1.84 0.000199 0.076063
ARGLU1 arginine and glutamate rich 1 -1.84 0.000386 0.08795
SNTB1 syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1) -1.73 0.000163 0.074067
KCNQ5 potassium channel, voltage gated KQT-like subfamily Q, member 5 -1.71 0.000311 0.081427
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 -1.67 0.000316 0.081427
PDGFRL platelet-derived growth factor receptor-like -1.65 0.000258 0.080548
SNTB1 syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1) -1.63 0.000408 0.090038
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 -1.6 0.000293 0.081323
MPP6 membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) -1.59 0.000131 0.071504
SCARA5 scavenger receptor class A, member 5 -1.59 0.000005 0.039052
TYW3 tRNA-yW synthesizing protein 3 homolog (S. cerevisiae) -1.58 0.000245 0.078947
MOB3B MOB kinase activator 3B -1.52 0.000048 0.051544
LOC489911 zinc finger protein 688-like; zinc finger protein 785; zinc finger protein 764 -1.52 0.000064 0.056956
ERBB4 erb-b2 receptor tyrosine kinase 4 -1.51 0.000023 0.039052
SRSF2 serine/arginine-rich splicing factor 2 -1.51 0.000106 0.060638
FAM174A family with sequence similarity 174, member A 1.51 0.000349 0.083815
CDR2 cerebellar degeneration-related protein 2, 62kDa 1.51 0.000363 0.084496
RAI14 retinoic acid induced 14 1.55 0.000007 0.039052
CYR61 cysteine-rich, angiogenic inducer, 61 1.58 0.000152 0.073688
LOC479476 arachidonate 12-lipoxygenase, 12S-type 1.59 0.000038 0.046206
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.62 0.000088 0.060638
NOV nephroblastoma overexpressed 1.65 0.000097 0.060638
NME1 non-metastatic cells 1, protein (NM23A) expressed in 1.65 0.000192 0.076063
COL4A1 collagen, type IV, alpha 1 1.66 0.000276 0.081323
LOC100856638 uridine phosphorylase 1-like; uridine phosphorylase 1 1.68 0.000217 0.076063
ADAM22 ADAM metallopeptidase domain 22 1.7 0.00014 0.072075
BNC2 basonuclin 2 1.72 0.000337 0.083815
LBH limb bud and heart development 1.77 0.000451 0.09208
Uncharacterised 1.77 0.00011 0.061186
GAP43 growth associated protein 43 1.78 0.000269 0.081323
ARNTL2 aryl hydrocarbon receptor nuclear translocator-like 2 1.79 0.000028 0.039052
ATP8B1 ATPase, aminophospholipid transporter, class I, type 8B, member 1 1.82 0.000099 0.060638
GPER1 G protein-coupled estrogen receptor 1 1.87 0.000416 0.090038
ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 1.88 0.000015 0.039052
MFSD2A major facilitator superfamily domain containing 2A 1.9 0.000346 0.083815
CLEC3A C-type lectin domain family 3, member A 1.95 0.000028 0.039052
Uncharacterised 2.1 0.000298 0.081427
BMP6 bone morphogenetic protein 6 2.19 0.000275 0.081323
KCNMB1 potassium channel subfamily M regulatory beta subunit 1 2.25 0.000159 0.073688
ANGPT1 angiopoietin 1 2.33 0.000017 0.039052
NTRK3 neurotrophic tyrosine kinase, receptor, type 3 2.4 0.000014 0.039052
NLGN4X neuroligin 4, X-linked 2.51 0.000522 0.096567
LRRC3B leucine rich repeat containing 3B 2.73 0.000137 0.072075
TPM2 tropomyosin 2 (beta) 2.83 0.000059 0.054713
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled 3.11 0.000226 0.076063
Uncharacterised 3.2 0.000069 0.057543
CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 3.23 0.000014 0.039052
Uncharacterised 3.44 0.000205 0.076063
CCL13 chemokine (C-C motif) ligand 13 3.82 0.000329 0.083815
LRRN1 leucine rich repeat neuronal 1 3.89 0.000098 0.060638
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 4.34 0.000038 0.046206
CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 5.07 0.000011 0.039052
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3.3.5 Gene Network analysis  
To understand expression trends throughout all grades of disease, the average 
gene expression level for each of 1002 differentially expressed genes (without 
FDR correction) found between all 4 grades of disease and normal valves were 
entered into Miru. Transcript-to-transcript analysis using a Pearson 
correlation coefficient of r=0.87 and default Markov Clustering (MCL) with 
inflation 2.2, pre-inflation 2.2 and a minimum cluster of 5 nodes only produced 
12 clusters. The majority of genes were clustered as being either upregulated 
or downregulated in grade 3 and 4 of disease (395 and 457 genes respectively) 
without allowing for more specific trends in the data to be observed (Figure 
3-10A). Optimisation of MCL clustering with an inflation of 4.3, pre-inflation 
of 2.2 and minimum cluster 5 produced 26 clusters of genes which could be 
investigated to find more specific trends in gene expression throughout all 
grades of disease (Figure 3-10B).  
 
Figure 3-10. Miru cluster optimisation. (A) Default Miru MCL clustering of 
1002 differentially expressed genes showing 12 clusters of genes with down-
regulated genes on the right side of the plot (the majority of nodes red) and 
upregulated on the left side of the plot (the majority of nodes yellow. (B) 
Optimised MCL clustering (inflation of 4.3) of differentially expressed 
genes with 26 clusters identified. 
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The largest 5 gene clusters from the optimised MCL plot of differentially 
expressed genes were examined. Cluster 1 contained 233 genes (Figure 3-11A) 
and had an average signal profile where the gene changes between normal 
and grades 1 and 2 were not distinguishable, whereas grades 3 and 4 showed 
a distinct down-regulation, grade 3 slightly more so than 4, in comparison to 
the other graded valves (Figure 3-11B). Genes were submitted to DAVID 6.8 
with 59 GO terms being associated with these genes. The 10 most significant 
terms listed (Table 3-6) were topped by proteinaceous extracellular matrix.  
 
Figure 3-11. Miru clustering of differentially expressed genes – Cluster 1. 
(A) The position of Cluster 1. (B) Average signal profile of the 233 genes in 
Cluster 1. 
 




Cluster 2 contained 206 genes (Figure 3-12A) with an average signal profile 
indicating up-regulation of these genes in grade 3 and 4 valves (particularly 
grade 3) in comparison to normal, grade 1 and grade 2 valve groups (Figure 
3-12B). 66 GO terms were associated with the genes from this cluster with 3 of 
top 10 (Table 3-7) connected to immune-related GO terms indicating that the 
involvement of immune-related pathways is important in late-stage disease.  
 
Figure 3-12. Miru clustering of differentially expressed genes – Cluster 2. 
(A) Miru clustering highlighting the position of Cluster 2. (B) Average 
signal profile of the 206 genes included in cluster 2. 
 
Table 3-7. Functional analysis chart of the top 10 GO terms associated with 
cluster 2. 
Cluster 3 contained 147 genes (Figure 3-13A) with an average signal profile 
showing a progressive decrease in gene expression. Grade 1 and 2 valves 
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showed a slight decrease in gene expression in comparison to normal valves 
and a larger decrease in signal was seen in grade 3 and 4 valves in comparison 
to other valves (Figure 3-13B). 30 GO terms were associated these genes. A 
recurring theme in the top 10 GO terms (Table 3-8) involves G-protein coupled 
receptor (GPCR) signalling related terms. In general clusters 3-5 illustrated 
gene trends which changed more gradually throughout disease in comparison 
to clusters 1 and 2. 
 
Figure 3-13. Miru clustering of differentially expressed genes – Cluster 3. (A) 
Miru clustering highlighting the position of cluster 3. (B) Average signal 
profile of the 147 genes in cluster 3. 
 
Table 3-8. Functional analysis chart of the top 10 GO terms associated with 
cluster 3.  
Cluster 4 contained 96 genes (Figure 3-14A) with an average signal intensity 
profile which increased in grade 3 and 4 of disease (Figure 3-14B). 24 GO terms 
Category Term Count P-Value FDR
GOTERM_MF_DIRECT Heparin binding 6 1.53E-04 0.17588
GOTERM_CC_DIRECT Cell surface 9 0.00102 1.09886
GOTERM_BP_DIRECT Adenylate cyclase-activating GPCR signaling pathway 4 0.00114 1.58043
GOTERM_MF_DIRECT G-protein coupled peptide receptor activity 3 0.00221 2.5091
GOTERM_MF_DIRECT Calcium ion binding 10 0.0043 4.83464
GOTERM_CC_DIRECT Integral component of membrane 34 0.00787 8.23544
GOTERM_BP_DIRECT Adenylate cyclase-inhibiting GPCR signaling pathway 3 0.01624 20.4417
GOTERM_CC_DIRECT Basolateral plasma membrane 4 0.01766 17.6233
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 5 0.01796 17.8929
GOTERM_BP_DIRECT Phospholipase C-activating GPCR signaling pathway 3 0.02121 25.8816
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were related with all genes in cluster 4. GO terms in the top 10 GO terms 
associated with cluster 4 included osteoblast- and bone-related GO terms 
(Table 3-9).  
 
Figure 3-14. Miru clustering of differentially expressed genes – Cluster 4. 
(A) Miru clustering highlighting the position of cluster 4. (B) Average signal 
profile of the 96 genes in cluster 4. 
 
Table 3-9. Functional analysis chart of the top 10 GO terms associated with 
cluster 4. 
Cluster 5 contained 80 genes (Figure 3-15A) with an average signal intensity 
profile which increased in a progressive manner reaching its peak in grade 4 
disease (Figure 3-15B). 26 GO terms were assigned to these genes including 




Figure 3-15. Miru clustering of differentially expressed genes – Cluster 5 (A) 
Miru clustering highlighting the position of cluster 5. (B) Average signal 
profile of the 80 genes in cluster 5.  
 
Table 3-10. Functional analysis chart of the top 10 GO terms associated with 
cluster 5. 
To analyse trends for progressive down- and up-regulation of genes over the 
entire course of the disease, all clusters showing a down-regulation pattern or 
an up-regulation pattern were averaged and GO term analysis was performed. 
Collectively, these analyses indicated that genes that are changed significantly 
in one grade of disease follow a progressive pattern for change across all 
grades of disease. The down-regulated clusters contained 211 genes (Figure 
3-16A) with the average signal intensity for genes in these clusters decreasing 
Category Term Count P-Value FDR
GOTERM_MF_DIRECT Metalloendopeptidase activity 5 6.63E-04 0.70482
GOTERM_BP_DIRECT Stem cell differentiation 3 0.00327 4.53441
GOTERM_BP_DIRECT Heart development 4 0.00708 9.58508
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 4 0.0132 17.1765
GOTERM_BP_DIRECT Positive regulation of endothelial cell proliferation 3 0.01437 18.5586
GOTERM_BP_DIRECT Neutrophil chemotaxis 3 0.01496 19.2449
GOTERM_BP_DIRECT Positive regulation of T cell differentiation in thymus 2 0.02315 28.2675
GOTERM_CC_DIRECT Collagen type IV trimer 2 0.02559 23.4714
GOTERM_BP_DIRECT Regulation of behavior 2 0.02696 32.1325
GOTERM_BP_DIRECT Response to hypoxia 3 0.02955 34.6459
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by more than 2-fold by grade 4 disease (Figure 3-16B). 27 GO terms were 
associated with these clusters with the top 10 GO terms shown in Table 3-11. 
 
Figure 3-16. Analysis of all down-regulated genes. (A) The down-regulated 
genes in the network layout. (B) The average signal intensity for the 211 
down-regulated genes in these clusters.  
 
Table 3-11. Functional analysis chart of the top 10 GO terms associated with 
the clusters associated with down-regulation in disease. 
The up-regulated clusters contained 116 genes (Figure 3-17A) with the average 
signal intensity for genes in these clusters increasing by more than 2-fold by 
grade 4 disease (Figure 3-17B). 24 GO terms were associated with these 




Figure 3-17. Analysis of all up-regulated genes. (A) Miru clustering of all 
genes showing a trend for up-regulation over the course of the disease. (B) 
Average signal intensity for the 116 genes in these clusters.  
 
Table 3-12. Functional analysis chart of the top 10 GO terms associated with 
the clusters associated with up-regulation in disease. 
3.3.6 DAVID 6.8 gene enrichment between grades  
The differentially expressed genes from each grade of disease (without FDR 
correction) were submitted to DAVID 6.8 for gene ontology enrichment. Due 
to the relatively low number of genes that were differentially expressed in 
grade 1 and 2 valves both up- and down-regulated genes had to be submitted 
together whereas the differentially expressed genes for grade 3 and 4 valves 
could be separated into GO terms associated with up- and down-regulation. 
The functional analysis charts for the GO terms associated with genes 
Category Term Count P-Value FDR
GOTERM_MF_DIRECT Metalloendopeptidase activity 5 0.00149 1.64773
GOTERM_BP_DIRECT Stem cell differentiation 3 0.00523 7.25952
GOTERM_BP_DIRECT Heart development 4 0.01365 17.9351
GOTERM_BP_DIRECT Positive regulation of endothelial cell proliferation 3 0.0226 28.0176
GOTERM_BP_DIRECT Positive regulation of cell proliferation 5 0.02338 28.8392
GOTERM_BP_DIRECT Neutrophil chemotaxis 3 0.0235 28.9738
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 4 0.02495 30.4709
GOTERM_CC_DIRECT Dendrite 4 0.02929 26.9821
GOTERM_BP_DIRECT Positive regulation of T cell differentiation in thymus 2 0.02935 34.8472
GOTERM_CC_DIRECT Collagen type IV trimer 2 0.0319 29.0338
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differentially expressed in grade 1 valves are shown in Table 3-13. Nine GO 
terms were identified with the majority of terms suggesting that early 
pathogenic gene changes are related to membrane and extracellular matrix. 
 
Table 3-13. Functional analysis chart summary of grade 1 related GO terms. 
Functional analysis chart only identified two GO terms related for the genes 
differentially expressed in grade 2 valves (Table 3-14). 
 
Table 3-14. Functional analysis chart summary of grade 2 related GO terms. 
The functional analysis for grade 3 valve differentially expressed genes could 
be separated into up- and down-regulated genes, with 92 GO terms associated 
with up-regulated genes and 85 GO terms associated with down-regulated 
genes. The top 10 suggested terms are shown in Table 3-15.  
Category Term Count PValue FDR
GOTERM_BP_DIRECT Regulation of ryanodine-sensitive calcium-release channel activity 2 0.0116 13.89
GOTERM_BP_DIRECT Defense response to virus 3 0.0202 22.903
GOTERM_BP_DIRECT Myoblast migration 2 0.0231 25.855
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 3 0.0822 56.851
GOTERM_CC_DIRECT Integral component of membrane 16 0.0891 59.898
GOTERM_CC_DIRECT Extracellular space 6 0.0892 59.946
GOTERM_BP_DIRECT Negative regulation of protein kinase B signaling 2 0.0895 69.813
GOTERM_BP_DIRECT Branching involved in ureteric bud morphogenesis 2 0.0948 71.993




Table 3-15. Functional analysis chart summary of grade 3 valves. GO terms 
associated with up- and down-regulated genes. 
Functional analysis of the genes differentially expressed in grade 4 valves, 
likewise, was separated into terms associated with up- (107 GO terms) or 
down-regulated (40 GO terms) genes. The functional analysis chart of top 10 
GO terms for both up- and down-regulated genes are shown in Table 3-16.  
Category Term Count PValue FDR
GOTERM_BP_DIRECT Inflammatory response 16 1.08E-07 1.70E-04
GOTERM_BP_DIRECT Positive regulation of angiogenesis 9 2.93E-05 0.0460492
GOTERM_BP_DIRECT Cell-cell signaling 8 5.68E-05 0.0890522
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 10 1.57E-04 0.2467334
GOTERM_BP_DIRECT Immune response 11 3.30E-04 0.5164762
GOTERM_BP_DIRECT Positive regulation of transcription from RNA polymerase II promoter involved in smooth muscle cell differentiation 3 7.10E-04 1.1086158
GOTERM_BP_DIRECT Neutrophil chemotaxis 6 8.47E-04 1.3217166
GOTERM_BP_DIRECT Regulation of cell growth 5 8.56E-04 1.3356317
GOTERM_MF_DIRECT Chemokine activity 5 0.0010917 1.3991207
GOTERM_BP_DIRECT Positive regulation of inflammatory response 5 0.0018038 2.7944106
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 19 1.42E-09 1.75E-06
GOTERM_BP_DIRECT Semaphorin-plexin signaling pathway 7 3.73E-06 0.0059178
GOTERM_CC_DIRECT Extracellular space 35 9.50E-06 0.0116947
GOTERM_MF_DIRECT Semaphorin receptor binding 6 1.70E-05 0.022432
GOTERM_MF_DIRECT Calcium ion binding 25 3.54E-05 0.0467482
GOTERM_MF_DIRECT Chemorepellent activity 6 7.12E-05 0.0938346
GOTERM_BP_DIRECT Negative regulation of axon extension involved in axon guidance 6 7.99E-05 0.1265495
GOTERM_BP_DIRECT Regulation of heart rate by cardiac conduction 6 9.74E-05 0.1543246
GOTERM_MF_DIRECT Heparin binding 9 1.53E-04 0.201529






Table 3-16. Functional analysis chart summary of grade 4 valves. Up-
regulated genes associated with GO terms and down-regulated genes 
associated with GO terms. 
Functional analysis was performed on the differentially expressed genes from 
the grade 3 and 4 valves with the higher stringency FDR cut off gene sets. Both 
the up- and down-regulated genes in these datasets had to be submitted 
together for each valve. The 18 genes differentially expressed in grade 3 valves 
only indicated one GO term associated with disease, negative regulation of 
inflammatory response (Table 3-17). The 70 genes differentially expressed in 
grade 4 valves had 19 GO terms associated with disease (Table 3-18) with 
several of the same GO terms (e.g. positive regulation of ERK1 and ERK2 
cascade, proteinaceous extracellular matrix) found in the GO term analysis of 
the less stringent gene lists.   
 
Table 3-17. Grade 3 valve GO term from FDR cut off gene set. 
Category Term Count PValue FDR
GOTERM_BP_DIRECT Neutrophil chemotaxis 8 4.16E-06 0.00659
GOTERM_CC_DIRECT Extracellular space 29 8.42E-06 0.01006
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 11 1.11E-05 0.01758
GOTERM_MF_DIRECT Heparin binding 9 2.02E-05 0.02544
GOTERM_BP_DIRECT Cell-cell signaling 8 2.91E-05 0.04611
GOTERM_MF_DIRECT Integrin binding 5 8.47E-05 0.10658
GOTERM_BP_DIRECT Positive regulation of angiogenesis 8 1.14E-04 0.18042
GOTERM_BP_DIRECT Inflammatory response 11 1.96E-04 0.31029
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 10 4.46E-04 0.53226
GOTERM_BP_DIRECT Positive regulation of endothelial cell proliferation 6 4.77E-04 0.75468
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 11 1.86E-05 0.02146
GOTERM_BP_DIRECT Receptor localization to synapse 3 0.00115 1.67606
GOTERM_CC_DIRECT Integral component of plasma membrane 19 0.00205 2.34731
GOTERM_CC_DIRECT Extracellular matrix 6 0.00557 6.25627
GOTERM_BP_DIRECT Adenylate cyclase-activating GPCR signaling pathway 4 0.00638 8.98655
GOTERM_MF_DIRECT G-protein coupled peptide receptor activity 3 0.00808 9.66805
GOTERM_MF_DIRECT Calcium ion binding 14 0.00905 10.7702
GOTERM_BP_DIRECT Positive regulation of phosphatidylinositol 3-kinase signaling 4 0.01439 19.1963
GOTERM_CC_DIRECT Cell surface 10 0.01516 16.191
GOTERM_CC_DIRECT Basolateral plasma membrane 5 0.0197 20.5581
Upregulated
Downregulated
Category Term Count PValue FDR




Table 3-18. Grade 4 valve GO terms from FDR cut off gene set. 
3.3.7 Ingenuity Pathway Analysis  
The low stringency (no FDR correction) differentially expressed gene lists for 
each grade of disease was submitted into Ingenuity Pathway Analysis (IPA). 
Mapped genes were used for further analyses while unmapped genes were 
unable to be correctly identified and so not used for further analyses (Table 
3-19).  
 
Table 3-19. Mapped, unmapped and total number of genes submitted into 
IPA for each grade of disease. 
Canonical pathway analysis of each grade of disease showed an increasing 
number of pathways associated with disease (P-value <0.05) as the disease 
Category Term Count P-Value FDR
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 5 4.40E-04 0.59452
GOTERM_BP_DIRECT Negative regulation of cell death 3 0.00263 3.50626
GOTERM_BP_DIRECT Positive regulation of phosphatidylinositol 3-kinase signaling 3 0.00782 10.09
GOTERM_BP_DIRECT Negative regulation of inflammatory response 3 0.00987 12.5661
GOTERM_BP_DIRECT Negative regulation of apoptotic process 4 0.0201 24.0395
GOTERM_BP_DIRECT Positive regulation of cell proliferation 4 0.02416 28.1944
GOTERM_BP_DIRECT Wound healing, spreading of cells 2 0.02529 29.3118
GOTERM_MF_DIRECT Heparin binding 3 0.02607 23.665
GOTERM_BP_DIRECT Regulation of blood coagulation 2 0.03358 37.0342
GOTERM_BP_DIRECT Angiogenesis 3 0.03818 40.9749
GOTERM_BP_DIRECT Positive regulation of cell migration 3 0.04679 47.7491
GOTERM_MF_DIRECT Integrin binding 2 0.05142 41.712
GOTERM_BP_DIRECT Negative regulation of endothelial cell apoptotic process 2 0.05535 53.7549
GOTERM_BP_DIRECT Cell adhesion 3 0.06053 57.0748
GOTERM_CC_DIRECT Cell surface 4 0.07811 55.4765
GOTERM_BP_DIRECT Positive regulation of cell adhesion 2 0.08189 68.5664
GOTERM_BP_DIRECT Cellular iron ion homeostasis 2 0.08451 69.7574
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 3 0.08569 58.9895
GOTERM_BP_DIRECT Inflammatory response 3 0.09059 72.3672
Grade of disease Mapped genes Unmapped genes Total genes
1 66 10 76
2 42 17 59
3 628 41 669
4 458 34 492
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progresses. The genes differentially expressed in grade 1 disease had eight 
canonical pathways attributed to them. Analysis of the genes differentially 
expressed in grade 2 disease showed an association of twelve pathways. 
Ninety-three pathways were associated with the differentially expressed 
genes in grade 3 disease. Finally, fifty-two pathways were associated with the 
differentially expressed genes in grade 4 disease. A summary of the top three 
canonical pathways associated with the differentially expressed genes in each 
grade of disease is shown in Table 3-20. This highlights the strength of the 
association of the gene list with the pathway (P-value) and the number of 
genes up- or down-regulated in each pathway. There was considerable 
overlap between the pathways for grade 3 and 4.  
 
Table 3-20. Summary of top three canonical pathways associated with each 
grade of disease. The number of genes up- and down-regulated in each 
pathway as well as the total number of genes changed in each pathway is 
shown. The P-value score shows the association of the gene list to the 
pathway (the lower the value indicates the stronger the association). 
Grade of disease Canonical Pathway Up-regulated genes Down-regulated genes Genes changed in pathway P-value
GPCR-Mediated Integration of Enteroendocrine Signalling 2 0 2/61 0.016218
Lipid Rafts in the Pathogenesis of Influenza 0 1 1/6 0.019055
Melanocyte Development and Pigmentation Signaling 1 1 2/91 0.033884
Aryl Hydrocarbon Receptor Signaling 2 1 3/115 0.002138
Glycerol-3-phosphate Shuttle 0 1 1/3 0.006761
Glycerol Degradation I 0 1 1/4 0.008913
Hepatic Fibrosis / Hepatic Stellate Cell Activation 10 15 25/183 3.16E-11
Agranulocyte Adhesion and Diapedesis 8 13 21/189 5.13E-08
Axonal Guidance Signaling 20 14 34/450 8.91E-08
Hepatic Fibrosis / Hepatic Stellate Cell Activation 3 14 17/183 2.29E-07
Agranulocyte Adhesion and Diapedesis 2 14 16/189 1.78E-06







The upstream regulator analysis provided by IPA suggests which upstream 
transcriptional regulators are involved in the gene changes observed in a gene 
list. An increasing number of molecules were associated with each grade of 
disease and a stronger association for the top suggested molecules was also 
seen as the disease progresses. With a P-value cut-off (<0.05) 156 molecules 
were associated with the genes differentially expressed in grade 1 valves. 254 
molecules were suggested as potential top upstream regulators in grade 2 
disease. 1873 molecules were associated with the genes differentially 
expressed in grade 3 disease. 1961 molecules were suggested as potential 
upstream regulators for genes differentially expressed in grade 4 disease. 
Table 3-21 summarises the top three upstream regulators associated with the 
differentially expressed genes in each grade of disease. Each regulator has the 
molecule type, the association of the gene list with the molecule (P-value) and 
prediction as to whether the molecule’s pathway is being activated or 
inactivated (Z-score). Of particular note is the repeated association of the 
molecules Transforming Growth Factor β1 (TGFβ1) and Tumour Necrosis 
Factor (TNF). 
 
Table 3-21. Summary of the top three upstream regulators associated with 
the differentially expressed genes lists for each grade of disease. For each 
upstream regulator, the molecule type, Z-score and P-value are given. 
Disease state Upstream Regulator Molecule Type Activation Z-score P-value
P2RY2 GPCR 0.0007
Lithium Chemical drug 0.00124
Bucladesine Chemical toxicant 1.131 0.00167
Mma_DMAG Chemical 0.00067
TNF Cytokine 0.826 0.00089
HOXB13 Transcription regulator 0.00122
TGFβ1 Growth factor 1.316 3.01E-22
TNF Cytokine 2.361 8.03E-18
LPS Chemical drug 3.874 3.00E-15
TGFβ1 Growth factor 2.589 6.22E-18
TNF Cytokine 3.313 1.17E-14







Forty-five downstream genes of TGFβ1 and TNF signalling pathways were 
shared in grade 4 diseased samples (Figure 3-18). Image networks produced 
for TGFβ1 (Figure 3-19) and TNF (Figure 3-20) indicate that, respectively, only 
28 of 90 and 28 of 85 of the genes differentially expressed in grade 4 valves that 
are downstream targets for these molecules were inconsistent with previously 
published articles (yellow interrupted line). 
 
Figure 3-18. Venn diagram illustrating the number of genes shared between 
TGFβ1 and TNF pathways suggested by IPA upstream regulator analysis. 
The left orange circle shows the number of genes differentially expressed 
in grade 4 samples associated with TGFβ1 and not shared with TNF, in the 
right purple circle are the number of genes associated with TNF and not 
shared with TGFβ1 and in the centre brown area the number of shared genes 




Figure 3-19. The network of genes that are differentially expressed in grade 
4 valves that are downstream of TGFβ1 signalling. TGFβ1 is shown to have 
its effect from the extracellular space on the genes in their cellular location. 
Genes are coloured red and green to represent up- or down-regulation in the 
dataset. Dotted lines connecting TGFβ1 to these genes show the expected 
effect of TGFB signalling: orange - activation, blue - inhibition, yellow -




Figure 3-20. The network of genes that are differentially expressed in grade 
4 valves that are downstream of TNF signalling. TNF is shown to have its 
effect from the extracellular space on the genes in their cellular location. 
Genes are coloured red and green to represent up- or down-regulation in the 
dataset. Dotted lines connecting TNF to these genes show the expected 
effect of TGFB signalling: orange - activation, blue - inhibition, yellow -
result inconsistent and grey – effect not predicted. 
Network analysis for the genes differentially expressed in each grade of 
disease highlights the disease and functional annotations assigned to each 
dataset. Four disease and function networks were associated with the genes 
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differentially expressed in grade 1 valves (Table 3-22). The top network in this 
analysis is visualised in Figure 3-21  
 
Table 3-22. Summary of disease and function networks associated with 
differentially expressed genes in grade 1 disease. Underlined is the network 
that is visualised in Figure 3-21. 
 
Figure 3-21. Schematic of the Cellular movement, haematological system 
development and function, hypersensitivity response disease and function 
network. Genes are shown in their protein cellular location with red 
indicating up-regulation, green down-regulation and un-coloured showing 
no change in the dataset. 
Top disease and function
Cellular Movement, Hematological System Development and Function, Hypersensitivity Response
Cell Death and Survival, Cellular Development, Cellular Function and Maintenance
Cancer, Gastrointestinal Disease, Organismal Injury and Abnormalities
Cell Cycle, Cell Morphology, Cell-To-Cell Signaling and Interaction
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Genes differentially expressed in grade 2 disease likewise were associated 
with four disease and function networks (Table 3-23). The Cancer, organismal 
functions, organismal injury and abnormalities network is schematised in Figure 
3-22.  
 
Table 3-23. Summary of disease and function networks associated with 
differentially expressed genes in grade 2 disease. Underlined is the network 
that is visualised in Figure 3-22. 
 
Figure 3-22. Schematic of the Cancer, organismal functions, organismal 
injury and abnormalities disease and function network. Genes are shown in 
their protein cellular location with red indicating up-regulation, green 
down-regulation and un-coloured showing no change in the dataset. 
Top disease and function
Cancer, Organismal Functions, Organismal Injury and Abnormalities 
Cell Death and Survival, Hematological System Development and Function, Gene expression 
Cell Cycle, Developmental Disorder, Hereditary Disorder
Connective Tissue Disorders, Developmental Disorder, Gastrointestinal Disease
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Genes differentially expressed in grade 3 disease were associated with ten 
disease and function networks (Table 3-24). The Skeletal and muscular system 
development and function, cardiovascular system development and function, organ 
morphology network is schematised in Figure 3-23 as this was amongst the top 
networks and appeared to have biological relevance to disease.  
 
Table 3-24. Summary of disease and function networks associated with 
differentially expressed genes in grade 3 disease. Underlined is the network 
that is visualised in Figure 3-23. 
 
 
Top disease and function
Cellular Function and Maintenance, Skeletal and Muscular System Development and Duncftion, Tissue Development 
Skeletal and Muscular System Development and Function, Cardiovascular System Development and Function, Organ Morphology
Cancer, Organimsal Injury and Abnormalities, Tissue Morphology
Cellular Assembly and Organisation Cellular Function and Maintenance, Cellular Development




Figure 3-23. Schematic of the Skeletal and muscular system development and 
function, cardiovascular system development and function, organ 
morphology disease and function network. Genes are shown in their protein 
cellular location with red indicating up-regulation, green down-regulation 
and un-coloured showing no change in the dataset. 
 
Genes differentially expressed in grade 4 disease were associated with ten 
disease and function networks (Table 3-25). The Cardiovascular system 
development and function, organismal development and embryonic development 
network are schematised in Figure 3-24 as this was amongst the top networks 




Table 3-25. Summary of disease and function networks associated with 
differentially expressed genes in grade 4 disease. Underlined is the network 
that is visualised in Figure 3-24. 
 
Figure 3-24. Schematic of the Cardiovascular system development and 
function, organismal development and embryonic development disease and 
function network. Genes are shown in their protein cellular location with 
red indicating up-regulation, green down-regulation and un-coloured 
showing no change in the dataset. 
Top disease and function
Cell Cycle, Cellular Development, Cellular Growth and Proliferation
Auditory Disease, Developmental Disorder, Hereditary Disorder
Cardiovascular System Development and Function, Organismal Development, Embryonic Development
Cell-To-Cell Signalling and Interaction, Hematological System Development and Function, Immune Cell Trafficking
Cell Death and Survival, Embryonic Development, Cellular Assembly and Organisation 
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A noticeable effect in this analysis was that the milder grade 1 and 2 disease 
samples had considerably weaker associations (P-value) in all forms of 
analysis compared with the more severe grade 3 and 4 disease samples. This 
is due to the lower number of differentially expressed genes in each of these 
grades and the smaller fold change difference seen in these samples (as 
indicated in Table 3-19). As such, the results from the grade 3 and 4 diseased 
valve samples are more statistically credible. Additionally, there seems to be a 
level of agreement in the results returned for grade 3 and 4 diseased valve 
samples. This is exemplified by both the canonical pathway analysis and top 
upstream regulator analysis (Table 3-20 and Table 3-21) suggested the same 
top two pathways. 
To investigate the effect of the more stringent (Q-value >0.1) FDR correction 
applied to the genes differentially expressed in grade 4 disease. Grade 3 
disease analysis was not performed due to the low number (18) genes 
differentially expressed when this correction is applied. Of the 64 genes 
accepted by IPA from the differentially expressed gene lists for grade 4 valves, 
61 were mapped and 3 unmapped. Similarly, to the grade 1 and 2 analysis, the 
associations with this dataset are much lower than analysis without the FDR 
correction.  
Eighteen canonical pathways were associated with this dataset (P>0.05) with 
the top five of these pathways shown in Table 3-26. These pathways differ 
with the canonical pathways associated with grade 4 disease without the FDR 
correction; however, the top suggested canonical pathway is the top canonical 




Table 3-26. Summary of the top five canonical pathways associated with 
genes differentially expressed in grade 4 of disease with the FDR correction 
(Q-value <0.1) applied. The number of genes up- and down-regulated in 
each pathway as well as the total number of genes changed in each pathway 
is shown. 
The top five upstream regulators associated with the FDR corrected grade 4 
disease dataset are shown in Table 3-27. In total 1201 molecules were 
associated with this dataset (P-value <0.05). The top suggested upstream 
regulator was TGFβ3 with TGFβ1 being the thirty-ninth upstream regulator 
(Z-score 0.672, P-value 0.000178). The gene interaction networks suggested by 
IPA for each of these factors are schematised in Figure 3-25 and Figure 3-26 
respectively. TGFβ3 shows an interaction with three extracellular and two 
nuclear localised proteins, which are all increased in this dataset, in agreement 
with published literature as determined by IPA. TGFβ1 interacts with thirteen 
genes in the dataset but five of these changed their expression contradictory 
to what has been previously shown in the published literature. Although 
TGFβ3 had more genes whose expression was consistent with reports in the 
literature, TGFβ1 had not only more genes but the highest number of genes 
associated with it out of all pathways. Collectively this indicates an important 
role for both of these molecules in MMVD. 
 
Canonical Pathway Up-regulated genes Down-regulated genes Genes changed in pathway P-value
Aryl Hydrocarbon Receptor Signaling 1 2 3/115 0.007244
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 0 2 2/44 0.01
Melanoma Signaling 0 2 2/53 0.014454
Cell Cycle: G1/S Checkpoint Regulation 0 2 2/60 0.018197




Table 3-27. Summary of the top five upstream regulators associated with the 
differentially expressed genes lists for grade 4 disease with the FDR 
correction (Q-value>0.1) applied. For each upstream regulator, the molecule 




Upstream Regulator Molecule Type Activation Z-score P-value
TGFβ3 Growth factor 2.156 1.00E-05
GRN510 Chemical reagent  1.17E-05
S100A11 Other  1.17E-05
ZFYVE16 transporter  1.17E-05




Figure 3-25. The network of genes that are differentially expressed in grade 
4 disease with FDR correction (Q-value >0.1) that are downstream of TGFβ3 
signalling. TGFβ3 is shown to have its effect from the extracellular space on 
the genes in their cellular location. Genes are coloured red to represent up-
regulation in the dataset. Dotted lines connecting TGFβ3 to these genes are 




Figure 3-26. The network of genes that are differentially expressed in grade 
4 disease with FDR correction (Q-value >0.1) that are downstream of TGFβ1 
signalling. TGFβ1 is shown to have its effect from the extracellular space on 
the genes in their cellular location. Genes are coloured red and green to 
represent up- or down-regulation in the dataset. Dotted lines connecting 
TGFβ1 to these genes show the expected effect of TGFB signalling: orange - 





Network analysis for the genes differentially expressed in this dataset was 
then performed using IPA. Six disease and function networks were associated 
with the genes differentially expressed in grade 4 disease with the FDR 
correction applied (Table 3-28). The top network in this analysis is visualised 
in Figure 3-27. This schematic also has the TGFβ signalling canonical pathway 
overlaid on it to show where this pathway would interact with the network.  
 
Table 3-28. Summary of disease and function networks associated with 
differentially expressed genes in grade 4 disease. Underlined is the network 
that is visualised in Figure 3-27. 
Top disease and function
Cancer, Organismal Injury and Abnormalities, Cellular Development
Lipid Metabolism, Small Molecule Biochemistry, Molecular Transport
organismal Injury and Abnormalities, Post-Translational Modification, Cell Cycle
Cell Morphology, Cancer, organismal Injury and Abnormalities




Figure 3-27. Schematic of the Cancer, organismal injury and abnormalities 
disease and cellular development network. Genes are shown in their protein 
cellular location with red indicating up-regulation, green down-regulation 
and un-coloured showing no change in the dataset. The canonical pathway 
TGFβ signalling is overlaid on this network indicating with black lines 
which genes it would interact within this network. 
3.3.8 RT-qPCR validation of microarray analysis 
To validate the microarray results RT-qPCR was performed on selected genes 
that were significantly altered in at least one grade of disease. These genes 
included known hallmarks of disease (ACTA2 and 5HTR2B), 
metalloproteinases (MMP12, ADAMTS5 and ADAMTS19) and genes that 
changed in multiple grades of disease with high fold change differences 
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(SLC10A6, CDKN2A, ACTG2, SLIT3 and CILP). The microarray results for 
these genes are shown in Table 3-29 and the corresponding RT-qPCR results 
are shown in Table 3-30. Almost all results were in agreement between 
microarray and RT-qPCR with differences highlighted in yellow in the two 
tables. Results that did not agree all showed a significant difference in RT-
qPCR but not by microarray. The direction of fold change movement matched 
for all genes.  
 
Table 3-29. Microarray fold change and P-value per grade of disease 
compared to normal valve samples for genes selected for microarray 
validation. Highlighted in yellow are instances where the significance of 
these results does not match with RT-qPCR validation.  
Fold change P-value Fold change P-value Fold change P-value Fold change P-value
ACTA2 1.91 0.171 1.59 0.078 4.43 <0.001 3.24 0.001
HTR2B 1.2 0.53 1.2 0.387 2.14 0.002 3.11 <0.001
ADAMTS5 0 0.23 1.13 0.137 -1.81 0.035 -1.45 0.097
SLC10A6 1.1 0.544 -1.01 0.535 -2.01 <0.001 -1.67 0.003
CDKN2A 1.09 0.163 1.14 0.036 5.34 <0.001 3.23 <0.001
ACTG2 1.75 0.406 2.75 0.109 4.57 0.001 4.18 0.008
SLIT3 1.82 0.016 1.97 0.003 1.57 0.239 1.99 0.018
CILP 1.05 0.83 -1.16 0.556 -5.86 0.002 -3.64 <0.001
MMP12 1.52 0.809 2.92 0.097 2.87 0.02 3.77 0.038
ADAMTS19 -1 0.338 -1.33 0.155 -1.84 <0.001 -1.79 0.02
Gene name




Table 3-30. RT-qPCR fold change and P-value per grade of disease compared 
to normal valve samples for genes selected for microarray validation. 
Highlighted in yellow are instances where the significance of these results 
do not match with microarray data. Normalised to GAPDH, MRPS25 and 
RPL32. 
3.4 Discussion 
As outlined in section 3.1, this study primarily aimed to investigate the 
transcriptomic changes occurring in each Whitney grade of MMVD, 
examining a mix of breeds to make broad statements about the disease 
development and extrapolate cause and consequence pathways in disease. To 
do this, Affymetrix Canine 1.1ST arrays were utilised to analyse six samples of 
diseased valves per grade and compare them to six normal valve samples 
(thirty valves in total) with at least two breeds and both genders represented 
in each group. This builds and extends on previous microarray studies in the 
dog, from Oyama et al and Lu et al, which only examined normal and late-
stage disease valves with n=4 and n=3 independent replicates used, 
respectively[33, 150]. Additionally, these studies did not use multiple breed 
groups, which may cause breed specific gene changes to be detected in the 
Fold change P-value Fold change P-value Fold change P-value Fold change P-value
ACTA2 3.41 0.102 2.69 0.1 9.55 0.001 9.09 0.001
HTR2B 1.97 0.186 1.82 0.245 3.45 0.038 3.75 0.027
ADAMTS5 1.38 0.116 1.12 0.357 -1.83 0.036 -1.85 0.113
SLC10A6 -1.49 0.198 -1.64 0.013 -2.67 0.005 -6.25 0.003
CDKN2A 4.99 0.049 4.07 0.002 10.84 0.001 12.6 <0.001
ACTG2 6.05 0.068 6.94 0.001 15.75 <0.001 14.97 <0.001
SLIT3 3.35 0.002 4.07 0.001 1.876 0.14 5.2 0.001
CILP -1.32 0.213 -2.71 0.001 -5.9 0.005 -14.27 0.014
MMP12 3.67 0.085 4.6 <0.001 12 <0.001 10.72 <0.001
ADAMTS19 -1.54 0.102 -2.32 0.005 -3.67 0.001 -9.01 <0.001
Gene name
Grade 1 Grade 2 Grade 3 Grade 4
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dataset[33, 150]. Examining a mixed breed population and various grades of 
disease in the present study minimised some aspects of these biases in the 
dataset. One aspect that could not be completely eliminated is the effect of age. 
As summarised in Figure 3-1, there were significant differences between 
almost all groups except between grade 0/normal valve samples and grade 1 
valves and between grade 1 valves and grade 2 valves, reflecting the age-
dependent natural history of the disease[22]. This is something to be wary of 
when interpreting these results as the disease-related gene changes observed 
in the grade 3 and 4 valves may be an effect of age independent of disease. 
However, finding age (and breed) matched controls for a disease as prevalent 
as MMVD would be impractical[22].  
An important factor to be aware of in any transcriptomic study is the quality 
of the RNA samples being examined. Low-quality RNA can compromise the 
results of downstream analysis nullifying findings[268]. The quality of RNA can 
be affected either by contamination of the sample or the breakdown of the 
RNA into smaller fragments. The presence of contaminants can be measured, 
as discussed in Chapter 2 section 2.3.1, and RNA breakdown can be quantified 
with RIN analysis. In this study, it was found that the vast majority of samples 
showed no contamination and little breakdown in RNA. However, as 
summarised in section 3.3.3, two samples in the microarray dataset were 
found to have degraded RNA that had a detrimental effect on the downstream 
analysis. These samples were removed from the dataset. This resulted in the 
grade 1 and 4 groups having five rather than six samples, however, this still 
represented an improvement on previous studies in the dog [33, 150].  
As summarised in section 3.3.4, FDR correction resulted in a high degree of 
exclusion of differentially expressed genes. This contrasts with the previous 
studies in dogs were Oyama et al and Lu et al were able to establish 229 and 
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591 differentially expressed genes respectively with an FDR correction[33, 150]. 
Although in this study some genes were differentially expressed in the grade 
3 and 4 diseased valve samples with an FDR correction applied, they only 
numbered 18 and 80 respectively. A reason for the lack of differential 
expression seen in grade 1 and 2 diseased valve samples could be related to 
how the disease develops in a region dependent manner[2, 4, 9]. Outside of the 
diseased areas of the grade 1 and 2 valves there is ostensibly normal tissue, 
which could be dampening any detectable gene changes[2]. In grade 3 and 4 
diseased valves, the noticeably lower number of differentially expressed genes 
when using the FDR correction compared with the earlier studies could be, in 
part, because of the mixed breed approach used in this study[33, 150]. A 
variability in the baseline of expression of genes between breeds of dog within 
the same grade of disease could account for high standard deviation within 
the grade of disease. This, in turn, would make comparisons less likely to yield 
significant changes especially with the FDR correction applied. Of the five 
human transcriptomic studies performed on spontaneous mitral valve 
diseases (with four independent studies and one repeated analysis), two did 
not use an FDR correction, two used unconventional FDR approaches and one 
used an FDR correction of Q-value <0.1[27, 125, 131, 163, 171]. This supports the results 
presented here as the human population is genetically far more heterogeneous 
than a breed of dog so greater variability between individuals is expected, as 
is the case when mixing different dog breeds in the same group[274]. In future 
studies, two approaches could be used to allow for FDR correction to be 
applied to a dataset. The first would be to analyse samples from one breed of 
dog only. This would come with the caveat that any changes that were 
observed could be breed specific and would have to be confirmed in other 
breeds. The second would be to increase the number of valves in a mixed breed 
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analysis. The only publication describing human valve samples that were able 
to apply a standard FDR correction and still have over 2000 differentially 
expressed genes used n=11 valves for normal and affected groups[131]. Using 
similar numbers in a canine study would likely discount the variability 
between breeds. As important data could still be gathered from the datasets 
relaxed stringency analysis was performed and will be discussed going 
forward.  
With the FDR requirement relaxed, differentially expressed genes were 
detectable in all grades of disease, with 1002 genes being differentially 
expressed in at least one grade of disease when compared to normal valve 
samples (section 3.3.4). When comparing these 1002 genes to the 592 
differentially expressed genes in the study from Lu et al 125 genes were shared 
(data not shown) including genes such HTR2B, CDK1NA and BMP6 which 
were also differentially expressed in the study of Oyama et al[33, 150]. Remarkably, 
this study is the first instance were ACTA2, the gene that encodes αSMA, was 
shown to be up-regulated in a microarray study (including both dog and 
human)[33, 125, 131, 150, 163, 171]. This is of interest as increased ACTA2/αSMA is seen 
as a hallmark of VIC activation into a myofibrotic phenotype and 
consequentially a hallmark for MMVD and is regularly used in other studies 
to indicate MMVD phenotype[45, 60, 121]. Although this result contrasts with 
previous transcriptomic data, in the context of the wider literature the up-
regulation of ACTA2 in this study is consistent with up-regulation of 
ACTA2/αSMA noted by both RT-qPCR and immunohistochemistry in a 
disease severity dependent manner[33, 43, 57].  
As stated, the aim of this study was to try to identify gene and pathway 
transcriptomic changes that are causal in disease development. To do this it is 
important not just to focus on differently expressed genes in individual grades 
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of diseased valves, but also to identify trends in gene expression across all 
grades of disease. In this study, the tools Miru and DAVID were utilised to 
achieve this, as summarised in section 3.3.5 and 3.3.6.  
GO term analysis consistently, both in Miru clusters and in by grade analysis 
(with or without FDR correction), showed that proteinaceous extracellular 
matrix was associated with down-regulated genes and inflammatory response 
and positive regulation of ERK1 and ERK2 cascade was associated with up-
regulated genes. The down-regulation of some aspects proteinaceous 
extracellular matrix is expected in the context of disease, with the 
accumulation of proteoglycans and glycosaminoglycans in the matrix. 
Without an increase in the expression of these components seen in disease, it 
is proposed that a down-regulation of the proteinaceous proteins is required 
for this change to occur[17, 18, 125]. For example, genes highlighted in this GO term 
include members of the ADAMTS family of genes, specifically ADAMTS2, 5 
and 19. Down-regulation of ADAMTS2 and 5 have previously been associated 
with disease phenotype. Mutation in ADAMTS2 has been seen in Ehlers-
Danlos syndrome with these patients having an increased risk of mitral valve 
prolapse. A knockout mouse lacking ADAMTS5 developed myxomatous 
mitral valve disease as the down-regulation of this gene resulted in the 
deposition of proteoglycans[17, 78]. Furthermore, both ADAMTS5 and 19 have 
been shown to change in previous transcriptomic studies on MMVD with 
down-regulation of ADAMTS5 reported in human valves and down-
regulation of ADAMTS19 being shown in the Lu et al study[33, 131, 163]. Likewise, 
up-regulation of immune response and ERK1 and ERK2 cascade are also noted 
in the DAVID analysis of grade 3 and 4 disease samples. The activation of VICs 
during disease progression into a myofibrotic phenotype is likely to cause the 
release of cytokines and other immune-related factors, and ERK1 and ERK2 
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cascade signalling (amongst various roles) have been shown to be involved in 
αSMA production in myofibrotic VICs[45, 117, 275, 276]. In addition, ERK1 and ERK2 
cascade is a downstream signalling component of both non-canonical TGFβ 
signalling and 5HT signalling both of which (as discussed in Chapter 1 
sections 1.5.1 and 1.5.2) have previously been implicated in MMVD[171, 178, 203]. 
The results presented here are in support of these hypotheses. 
Genes that showed a more gradual up-regulation during disease associated 
with GO terms including metalloendopeptidase activity, stem cell 
differentiation and heart development. The up-regulation of 
metalloendopeptidase activity may be counter-intuitive given the down-
regulation of proteinaceous extracellular matrix; however, in the context of a 
disease where alteration of the extracellular matrix is fundamental, divergent 
expression of such genes is to be expected. For example, the down-regulation 
of ADAMTS5, which cleaves a proteoglycan called aggrecan, results in 
accumulation of the latter, contributing to the increased proteoglycan 
deposition seen in MMVD valves[17]. In contrast, concurrent up-regulation of 
MMP12, which encodes an elastase degrading elastin in the extracellular 
matrix, would be predicted as MMVD valves demonstrate disorganisation and 
cleavage of elastin, which could facilitate the migration of cells undergoing 
EndoMT[1, 2, 277, 278]. Up-regulation of the heart development pathway can, 
likewise, be attributed to the disease phenotype through the activation of 
developmental pathways such as EndoMT, a pathway significant in cardiac 
embryogenesis[33, 41, 57, 95].  
Although genes may not be differentially expressed to a statistically significant 
level in each grade of disease, trend analysis allowed for the identification of 
disease-relevant GO-terms such as those discussed above. These insights 
would otherwise remain unclear as identification of disease-relevant GO 
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terms with believable P-value associations and the separation of genes into up- 
and down-regulated groups was not possible in lower grade 1-2 diseased 
valves (Table 3-13 and Table 3-14). The identification of GO terms relevant to 
disease in trend analysis helps to show the advantage of this type of analysis 
over analysing genes changed by grade alone. Likewise, this study indicates 
that genes that can be detected as significantly altered in late-stage disease are 
changing in a progressive manner over the entire course of disease 
development. Furthermore, genes which show a progressive trend for change 
throughout disease and the GO terms associated with them are more likely to 
be involved in causing disease than those that are only associated with 
changes in gene expression in late grade valves. Thus this analysis helps to 
examine the study aim.  
Analysis by grade using IPA helped to identify various interesting pathways 
associated with disease at different stages. Canonical pathway analysis 
indicated Agranulocyte adhesion and diapedesis was the second and Hepatic 
fibrosis/hepatic stellate cell activation was the top pathway related to the gene 
lists submitted for grade 3 and 4 disease samples. The second suggested top 
upstream regulator in both grade 3 and 4 diseased samples, TNF, is involved 
in controlling agranulocyte adhesion and diapedesis [279, 280]. This pathway may 
also relate to the up-regulation of immune response noted in the DAVID GO 
term analysis. Likewise, TGFβ1, the top upstream regulator suggested for both 
grade 3 and 4 diseased valve samples, is involved in the control of Hepatic 
fibrosis/hepatic stellate cell activation pathway[184] and as a cytokine, it is linked 
with immune response pathways. Both TGFβ1 and TNF share many 
downstream targets making distinguishing which may be more important in 
disease pathogenesis difficult, although TGFβ1 does have the strongest 
associations. As described in Chapter 1 section 1.5.1, TGFβ signalling has 
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previously been implicated in the development of MMVD. TGFβ1 is 
commonly used to stimulate the activation of VICs into a myofibrotic 
phenotype in vitro [45, 60, 117]. Furthermore, TGFβ1 and 2 signalling have been 
implicated in the development of MMVD in both the dog and human. 
Increased TGFB1 and 2 gene expression and increased phosphorylated 
SMAD2/3 protein (activated downstream TGFβ signalling molecule) have 
been detected in canine MMVD[124, 126]. Likewise, increased TGFB1 gene 
expression and increased phosphorylated SMAD2/3 were observed in a 
human study and TGFB2 has been implicated in two transcriptomic studies in 
humans[27, 125, 131, 176]. Interestingly, when analysing the genes differentially 
expressed in grade 4 diseased samples with the FDR correction applied, the 
top upstream regulator was another member of the TGFβ signalling family, 
TGFβ3. This evidence along with the data presented here helps support a role 
for TGFβ, in particular TGFβ1, signalling in MMVD development in dogs. 
Network analysis associated the top disease and functions with each gene list 
for the different grades of disease. This indicated that the genes differentially 
expressed in grade 1 and 2 disease did not show any strong association with 
cardiovascular or tissue development functions, unlike grade 3 and 4 disease 
were these functions were both associated, suggesting cardiovascular 
development related pathways such as those involved in EndoMT are more 
relevant in late disease. This suggests that the changes to the cardiovascular 
system are a consequence rather than a cause of MMVD, since they only occur 
late in the progression of the disease. It did, however indicate that in all grades 
of disease as well as in the more stringent dataset analysis, there was an 
association with cell cycle or cell development, which could be related to the 
proliferation and transition of VICs into an activated phenotype discussed in 
Chapter 1 section 1.3.2.  
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As mentioned, one of the flaws in this study was the inability to use a suitable 
FDR correction for most analyses. Without it, there will be a higher rate of false 
positive error in the datasets. It was therefore imperative to validate the 
microarray results by an alternative method. The gold standard for this is by 
RT-qPCR which offers a wider dynamic range and the ability to detect lowly 
expressed genes[281, 282].  
The RT-qPCR results validate the microarray results for the genes analysed 
and help to add credence to the other results obtained from this study despite 
the lack of FDR correction. As mentioned in section 3.3.8, the minority of genes 
that showed significant differential expression by RT-qPCR compared to 
microarray analysis indicated a change in expression that was in keeping with 
the other results for that gene i.e. up-regulation of a gene where it is up-
regulated in all other grades of disease. This may be, due to the technical 
superiority of RT-qPCR being able to detect these more subtle changes, 
especially in the lower grade 1 and 2 valves.  
To conclude, this study aimed to investigate transcriptomic changes occurring 
as MMVD progresses across all breeds of dogs and to identify pathways that 
are causal in disease progression. To that end, cluster analysis tools were 
utilised to identify genes associated with progressive changes throughout the 
disease. Perhaps most importantly, pathways involved in the upstream 
regulation of disease were identified.  
Summary:  
- Genes showing a progressive change in expression throughout disease 
(including some hallmarks of disease) were associated with pathways 
including ERK1 and ERK2 cascade, metalloendopeptidase activity and 
proteinaceous extracellular matrix. 
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- Using dogs from various breeds may cause greater variation within 
groups making distinguishing gene changes relevant to disease 
difficult when using an FDR corrected dataset 
- By grade analysis identified TGFβ signalling as consistently important 
in disease regulation in later grade valves. In particular, TGFβ1 (which 
has previously been implicated in the literature) is suggested as the 
likely controller of disease.   
This study has therefore succeeded in its aim and has provided valuable 
insight into the pathogenesis of MMVD. However, it was not possible to 
elucidate a better understanding of the early pathogenesis of MMVD. As 
stated, this is likely due to the approach of the study using whole valves, which 
in the lower grades still contain large amounts of normal valve tissue. This will 
have the effect of dampening any discreet gene changes occurring in the 
diseased sections of the valve. Gaining an understanding of the transcriptomic 
changes occurring in these lower grade valves is necessary for identifying 
factors, such as TGFβ1, which could be the primary drivers of disease 
pathogenesis from the onset. As such, the Chapter 5 aims to investigate this 
issue. 
Another aspect that warrants further investigation is the effect of breed in 
MMVD development. Although using various breeds in this study posed its 
problems, it did allow for the identification of potential breed-specific 




















   Transcriptomic changes in CKCS 
4.1 Introduction 
The clinical development of MMVD is associated typically with small breed 
dogs, notably the Cavalier King Charles Spaniel (CKCS), as the disease begins 
to develop earlier in these breeds allowing for clinical symptoms to develop at 
an earlier age[23, 24, 212, 222]. This early-onset of MMVD has been shown to be 
heritable and breeding programmes have shown some success in reducing the 
frequency of early-onset disease suggesting a genetic component is 
involved[222, 283, 284]. 
As discussed in Chapter 1 section 1.6, genome wide association studies 
(GWAS) studies investigating potential genetic variants related to MMVD 
development have been performed in the dog[219-221]. Two of these studies were 
performed on CKCSs comparing dogs with early-onset and late-onset 
disease[219, 220]. One was unable to identify any genomic regions that were 
consistently different between the two groups[219]. The other identified two loci 
with a total of thirty-one protein-coding genes within these regions that could 
be affected[220]. However, despite this study being published several years ago, 
no further developments have followed this study and the thirty-one genes 
identified have not been made public. It has therefore been proposed that a 
single variant is not responsible for disease and it is polygenic in its 
development[33, 210].  
Furthermore, immunohistochemical analysis comparing CKCS to other breeds 
of dog with late-stage (grade 3-4) MMVD valve samples and to unaffected 
normal valves showed similar cellular changes in the two diseased groups[110]. 
This suggests that the resulting end-grade pathology of the disease is the same 
in CKCS as in other breeds. What is unknown is if there are different or 
124 
 
additional mechanisms responsible for the early development of MMVD in 
CKCSs.  
In this study, we aim to investigate the transcriptomic profiles of diseased, 
Whitney grade 3 and 4, CKCS and other breeds of dog. It is hypothesised that 
differences will exist in CKCS but the hallmark gene changes in disease will 
not be different due to a level of shared pathogenesis. Both the CKCS group 
and the other breeds of dog group will be compared to normal valves as well 
as one another to identify any differences and similarities.  
4.2 Materials and Methods 
4.2.1 Tissue collection, RNA quantification and quality control 
The valves used in this study are a subset of 17 valves used in Chapter 3 and 
are summarised in Table 4-1. For full details on tissue collection, see Chapter 
2 section 2.2.  
 
Table 4-1. Description of dogs used in this study 
Sample ID Date sampled Dog Breed Gender Age Whitney grade
B2G0 05/06/2015 BEAGLE MALE 4y 0
B4G0 05/06/2015 BEAGLE FEMALE 4y 0
PBT1G0 20/11/2015 'PITBULL TERRIER' TYPE MALE 2y9m 0
PBT3G0 01/04/2016 'PITBULL TERRIER' TYPE MALE 1y9m 0
PBT2G0 27/11/2015 'PITBULL TERRIER' TYPE MALE 3y 0
B26G0 26/10/2015 BEAGLE MALE 3y 0
BTG3 29/01/2016 BULL TERRIER FEMALE 10y 3
WHTG3 06/11/2015 WEST HIGHLAND TERRIER MALE 10y 3
JRG4 30/10/2015 JACK RUSSEL TERRIER FEMALE 11y 4
C1G4 19/02/2016 BORDER COLLIE MALE 13y 4
C2G4 08/07/2016 BORDER COLLIE MALE 13y 4
811M_024 16/01/2013 CAVALIER KING CHARLES SPANIEL MALE 12y 3
811M_019 20/12/2012 CAVALIER KING CHARLES SPANIEL MALE 11y 3
811M_023 16/01/2013 CAVALIER KING CHARLES SPANIEL MALE 12y 3
811M_017 20/02/2013 CAVALIER KING CHARLES SPANIEL FEMALE 10y 3
CKCSG4 21/03/2014 CAVALIER KING CHARLES SPANIEL MALE 16y 4
811M_016 20/12/2012 CAVALIER KING CHARLES SPANIEL FEMALE 12y 4
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4.2.2 RNA extraction, quantification and quality control  
Full details of the protocols followed for RNA extraction, quantification and 
quality control can be found in Chapter 2 section 2.3.1 and 2.3.3 with the results 
of this analysis presented in Chapter 3 section 3.3.2. As mentioned in Chapter 
3 section 3.2.2, almost all RNA extractions were performed by myself, with the 
exception of CKCS samples with the sample ID beginning 811M which were 
extracted by Dr. Chie Chien Lu prior to the start of this study. 
4.2.3 Affymetrix Canine Gene 1.1ST microarray analysis 
As in Chapter 3, microarray analysis was performed using two 16 well 
Affymetrix Canine Gene 1.1ST chips. RNA processing, hybridisation, post-
hybridisation quality control, summarisation file creation and differential 
gene expression analysis was performed as described in section 2.5 of Chapter 
2. A Benjamini-Hochberg false discovery rate (FDR) correction (Q-value <0.05) 
was applied to the comparisons of normal valves compared to CKCS valves 
and other breed diseased valves compared to CKCS valves. When comparing 
normal valves to the other breed diseased valves the FDR correction was 
relaxed to allow the inclusion of a greater number of genes for gene 
enrichment analysis.  
4.2.4 Gene enrichment analysis  
The network analysis tool Miru (version 1.4) was utilised as described in 
Chapter 2 section 2.6.1. A sample-to-sample comparison was performed with 
a Pearson correlation of r=0.97, this maximised the number of samples 
included whilst minimising the connection between samples. Meta-data 
(grade of disease, gender, breed etc.) applied to the dataset was then examined 
to see if this was having an effect on the association between samples. 
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The tools Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) and Ingenuity Pathway Analysis (IPA) were used as stated in 
Chapter 2 sections 2.6.2 and 2.6.3; default settings were used throughout. Gene 
list comparison was performed as outlined in Chapter 2 section 2.6.4 
4.3 Results 
4.3.1 Transcriptomic differences in Cavalier King Charles Spaniels  
The sample-to-sample analysis was performed in Miru (Pearson correlation 
r=0.97) and metadata was used to colour the nodes by grade of disease (Figure 
4-1A), as presented in Chapter 3 section 3.3.3 (Figure 3-7). It was noted that, 
although an expected clustering of samples based on the grade of disease was 
observed, a subset of grade 3 and 4 disease samples was separating from the 
main cluster of samples. Colouring the nodes by breed (Figure 4-1B) of dog 
showed that all of the samples located away from the main cluster of samples 





Figure 4-1. Sample-to-sample analysis showing samples coloured by grade 
of disease and by breed. (A) Normal samples are coloured green, grade 1 
brown, grade 2 black, grade 3 blue and grade 4 red. Highlighted by a red 
circle is a set of grade 3 and 4 disease samples clustering away from the main 
group of samples. (B) Sample-to-sample analysis showing samples coloured 
by breed. Brown - beagle, dark purple - Staffordshire bull terriers, light 
purple - collies, light grey - west highland terrier, dark grey - Rottweiler, 
black - bull terriers, cream - Pitbull terriers, orange - Jack Russel terrier and 
blue - CKCSs. The red circle shows that all the CKCS samples in the analysis 






4.3.2 CKCS differential gene expression 
As CKCSs are a breed predisposed to the development of MMVD at an early 
age, further analysis of the differences between this breed and other breeds 
was carried out. There was no significant difference in age between the 
diseased valve groups in this analysis and a similar, but small, number of 
valves were split between groups (6 CKCS (3 in either grade) and 5 other breed 
dogs (2 in grade 3 and 3 in grade 4)). The CKCS and other breed grade 3 and 
4 disease samples were separated and gene expression comparisons were 
performed with the normal valve samples for both groups. As well as this, 
comparison of the differential gene expression between the CKCS group and 
the other breed grade 3 and 4 disease samples was also performed. Using the 
same criteria as previously established (Chapter 3 section 3.2.3) without an 
FDR correction, 278 genes were differentially expressed (Figure 4-2A) between 
the other breed diseased and normal valve samples, with 165 up-regulated 
and 113 down-regulated. Comparing the CKCS samples to normal valves a 
FDR correction of Q-value <0.05 could be applied without the removal of all 
differentially expressed genes. With this criteria, 599 genes were differentially 
expressed (Figure 4-2B) between the CKCS and normal valve samples, with 
270 up-regulated and 329 down-regulated. Finally, comparing CKCS to other 
breed grade 3 and 4 valves, with FDR correction (Q-value <0.05), found 161 
genes differentially expressed (Figure 4-2C) with 27 genes up-regulated and 
134 down-regulated in the CKCS breed. Full gene lists can be found in 




Figure 4-2. Volcano plots of differentially expressed genes in other breeds 
compared to normal samples, CKCS compared to normal samples and other 
breed compared to CKCS. Red dots represent genes that were up-regulated 
in disease, green represent genes that were down-regulated and uncoloured 
are genes which do not pass the differential expression criteria. The X-axis 
shows fold change value and the Y-axis shows P-value. (A) Differentially 
expressed genes in normal and other breed disease samples with no FDR 
correction. (B) Differentially expressed genes between CKCS samples and 
normal valve samples with FDR correction. (C) Differentially expressed 
genes between CKCS and other breed disease samples with FDR correction. 
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To investigate the level of similarity between the CKCS and the other breed 
grade 3 and 4 samples in comparison to normal valve samples, the number of 
genes that share differential expression was calculated (Figure 4-3). In total 
120 of the genes differentially expressed when compared with normal valves 
were shared in both datasets. 158 genes were differentially expressed only in 
the other breed dataset and 479 genes were differentially expressed only in the 
CKCS dataset. Shared genes included known markers of disease phenotype 
such as ACTA2 and HTR2B, which are up-regulated in both of these datasets 
and not different when comparing CKCS samples to the other breed grade 3 
and 4 samples.  
 
Figure 4-3. Venn diagram illustrating the number of shared differentially 
expressed genes in the CKCS and other breed grade 3 and 4 valves when 
compared to normal valves. In the left orange circle is the number of 
differentially expressed genes for other breed grade 3 and 4 valves 
compared to normal only, and not shared with the CKCS dataset. In the right 
purple circle the number of differentially expressed genes for CKCS 
samples compared to normal only and not shared with the other breed 
dataset is shown. In the centre, the number of shared differentially 
expressed genes between the two datasets is shown. 
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4.3.3 DAVID GO term analysis of breed-specific pathways  
DAVID gene ontology enrichment was performed on each of the datasets with 
up- and down-regulated genes separated. When comparing other breed grade 
3 and 4 disease samples to normal valve samples 59 GO terms were associated 
with up-regulated genes and 28 with down-regulated genes. The top ten GO 
terms for up- and down-regulated genes for this dataset are summarised in 
Table 4-2 and included. CKCS samples compared to normal valve samples 
showed 49 GO terms associated with up-regulated genes and 96 with down-
regulated genes. The top ten GO terms for up- and down-regulated genes for 
this dataset are summarised in Table 4-3. Finally, when comparing the CKCS 
samples to other breed grade 3 and 4 valve samples only one GO term was 
associated with up-regulated genes and 70 associated with down-regulated 
genes. The top ten GO terms for up- and down-regulated genes for this dataset 
are summarised in Table 4-4. The GO terms for the CKCS compared with 
normal had a greater emphasis on immune response in comparison to the 
other breed compared with normal analysis. However, three terms were 
shared in both analyses for up-regulated genes (extracellular space, cell-cell 
signalling and positive regulation of ERK1 and ERK2 cascade) and down-
regulated genes (calcium ion binding, proteinaceous extracellular matrix and 




Table 4-2. Functional analysis chart summary of other breed grade 3 and 4 
disease samples compared to normal valves. The top 10 GO terms associated 
with genes up- and down-regulated in the other breed grade 3 and 4 disease 
samples compared to normal valves. 
Category Term Gene count P-value FDR
GOTERM_MF_DIRECT Calcium ion binding 14 9.81E-04 1.18887
GOTERM_BP_DIRECT Cardiac muscle fiber development 3 9.85E-04 1.49236
GOTERM_BP_DIRECT Positive regulation of angiogenesis 6 0.00118 1.79196
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 7 0.00177 2.66034
GOTERM_BP_DIRECT Cell-cell signaling 5 0.0039 5.78536
GOTERM_MF_DIRECT Structural constituent of muscle 3 0.00414 4.93182
GOTERM_BP_DIRECT Negative regulation of GPCR protein signalling 3 0.00521 7.65678
GOTERM_BP_DIRECT Positive regulation of cell proliferation 8 0.00679 9.87975
GOTERM_CC_DIRECT Extracellular space 16 0.00723 8.09541
GOTERM_CC_DIRECT Synapse 5 0.00996 10.9896
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 8 3.65E-05 0.03795
GOTERM_CC_DIRECT Integral component of plasma membrane 14 2.27E-04 0.2357
GOTERM_CC_DIRECT Extracellular matrix 6 2.33E-04 0.24233
GOTERM_MF_DIRECT Calcium ion binding 12 2.96E-04 0.33195
GOTERM_CC_DIRECT Integral component of membrane 36 3.21E-04 0.33397
GOTERM_BP_DIRECT Adenylate cyclase-activating GPCR signalling 4 9.27E-04 1.28441
GOTERM_MF_DIRECT GPCR activity 3 0.00221 2.45393
GOTERM_CC_DIRECT Cell surface 7 0.01138 11.2334
GOTERM_MF_DIRECT Metalloendopeptidase activity 4 0.02209 22.2049






Table 4-3. Functional analysis chart summary of CKCS disease samples 
compared to normal valves. The top 10 GO terms associated with genes up- 
and down-regulated in the CKCS disease samples compared to normal 
valves. 
 
Table 4-4. Functional analysis chart summary of CKCS compared to other 
breed grade 3 and 4 disease samples. The only GO term associated with 
genes up-regulated in the CKCS samples and the top 10 GO terms associated 
with down-regulated genes in the CKCS samples are shown. 
Category Term Gene count P-value FDR
GOTERM_BP_DIRECT Cell-cell signalling 7 3.96E-04 0.61136
GOTERM_BP_DIRECT Immune response 10 1.15E-03 1.76196
GOTERM_BP_DIRECT Inflammatory response 10 0.00152 2.32542
GOTERM_CC_DIRECT Extracellular space 25 0.00155 1.89913
GOTERM_BP_DIRECT Positive regulation of inflammatory response 5 0.00164 2.50471
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 8 0.00311 4.71581
GOTERM_MF_DIRECT CCR chemokine receptor binding 4 0.00378 4.79573
GOTERM_BP_DIRECT Lymphocyte chemotaxis 4 0.0048 7.18014
GOTERM_BP_DIRECT Neutrophil chemotaxis 5 0.00583 8.65707
GOTERM_BP_DIRECT Eosinophil chemotaxis 3 0.00598 8.86813
GOTERM_BP_DIRECT cardiac muscle contraction 8 2.29E-07 3.64E-04
GOTERM_BP_DIRECT Regulation of heart rate by cardiac conduction 8 2.29E-07 3.64E-04
GOTERM_CC_DIRECT Z disc 9 1.65E-05 0.02048
GOTERM_BP_DIRECT Sarcomere organization 6 1.98E-05 0.03144
GOTERM_CC_DIRECT Voltage-gated calcium channel complex 6 3.48E-05 0.0432
GOTERM_MF_DIRECT Calcium ion binding 24 7.96E-05 0.10617
GOTERM_BP_DIRECT Regulation of ventricular cardiac muscle action potential 4 4.13E-04 0.65443
GOTERM_BP_DIRECT Regulation of the force of heart contraction 4 4.13E-04 0.65443
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 11 6.32E-04 0.78217
GOTERM_CC_DIRECT Integral component of plasma membrane 26 0.00135 1.66305
Up-regulated 
Down-regulated
Category Term Gene count P-value FDR
Up-regulated GOTERM_BP_DIRECT L-methionine biosynthetic process from methylthioadenosine 2 0.00607 6.03855
GOTERM_CC_DIRECT Z disc 9 2.90E-08 3.31E-05
GOTERM_BP_DIRECT Sarcomere organization 6 4.26E-07 6.17E-04
GOTERM_BP_DIRECT Regulation of heart rate 5 1.39E-05 0.02004
GOTERM_BP_DIRECT Cardiac muscle contraction 5 5.12E-05 0.07401
GOTERM_CC_DIRECT Sarcoplasmic reticulum membrane 4 2.30E-04 0.26205
GOTERM_BP_DIRECT Skeletal muscle thin filament assembly 3 3.79E-04 0.54748
GOTERM_CC_DIRECT Voltage-gated calcium channel complex 4 6.12E-04 0.69548
GOTERM_CC_DIRECT Intercalated disc 4 0.00113 1.28114
GOTERM_BP_DIRECT Regulation of heart rate by cardiac conduction 4 0.00114 1.64204




4.3.4 IPA analysis of breed-specific pathways  
Datasets were submitted to IPA for further analysis. The number of genes that 
the programme was able to map to published articles for each dataset is shown 
in Table 4-5. 
 
Table 4-5. Mapped, unmapped and total number of genes submitted into 
IPA for each dataset. 
Canonical pathway analysis of each dataset showed the pathways associated 
with each set of analysis (P-value <0.05). The genes differentially expressed 
between other breed grade 3 and 4 disease compared to normal valve samples 
had 58 canonical pathways attributed to them. Analysis of the genes 
differentially expressed in CKCS compared to normal valve samples showed 
an association of 77 pathways. Finally, 28 pathways were associated with the 
differentially expressed genes in CKCS compared to other breed grade 3 and 
4 disease samples. A summary of the top three canonical pathways associated 
with the differentially expressed genes in each grade of disease is shown in 
Table 4-6. Other breed grade 3 and 4 valves compared to normal showed the 
same top canonical pathway as when samples were not separated by breed 
(Chapter 3 section 3.3.7), CKCS samples for both analyses showed calcium 
signalling as the top pathway.  
Analysis Mapped Genes Unmapped genes Total genes
Other breed Vs Normal 298 25 323
CKCS Vs Normal 645 36 681




Table 4-6. Summary of top three canonical pathways associated with each 
dataset. The number of genes up- and down-regulated in each pathway as 
well as the total number of genes changed in each pathway is shown. The 
P-value score shows the association of the gene list to the pathway. 
Upstream regulator analysis for each dataset comparing the effect of the CKCS 
breed was performed with a P-value cut-off (<0.05). The top four upstream 
regulators for each dataset analysed are summarised in Table 4-7. Z-scores for 
this showed that when comparing the diseased valve datasets to normal valve 
samples there was an activation of pathways whereas comparing CKCS to 
other breed grade 3 and 4 samples suggested an inhibition of pathways. There 
were 1937 molecules associated with the genes differentially expressed in 
other breed grade 3 and 4 disease samples when compared to normal valve 
samples. The molecule with the strongest association was again TGFβ1 with 
65 genes in the dataset being associated with this pathway and only 20 of these 
showing an inconsistent change in expression to what has previously been 
published (Figure 4-4). There were 1831 molecules suggested as potential top 
upstream regulators in CKCS samples compared to normal valve samples. The 
top upstream regulator here was F2 (prothrombin) which is later cleaved into 
Analysis Canonical Pathway Up-regulated genes Down-regulated genes Genes changed in pathway P-value
Hepatic Fibrosis / Hepatic Stellate Cell Activation 10 4 14/183 1.31826E-07
Caveolar-mediated Endocytosis Signaling 6 1 7/71 3.80189E-05
Agranulocyte Adhesion and Diapedesis 8 3 11/191 4.36516E-05
Calcium Signaling 6 17 23/179 7.94328E-11
Hepatic Fibrosis / Hepatic Stellate Cell Activation 8 12 20/183 2.39883E-08
Axonal Guidance Signaling 11 16 27/452 1.99526E-05
Calcium Signaling 0 10 10/179 6.45654E-06
LPS/IL-1 Mediated Inhibition of RXR Function 2 5 7/168 0.000977237
Gluconeogenesis I 0 3 3/22 0.001071519
Other breed Vs Normal
CKCS Vs Normal
CKCS Vs Other breed
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thrombin in the blood clotting cascade. 29 genes in the dataset were associated 
with this pathway (10 of these were inconsistent with the literature) (Figure 
4-5). Of note in this analysis is the presence of TNF and TGFβ1 in the top four 
upstream regulators. There were 377 molecules associated with the genes 
differentially expressed in CKCS samples compared to other breed grade 3 
and 4 disease samples. The top upstream regulator here was Myocyte-specific 
enhancer factor 2C (MEF2C), which is an important gene in the control of 
myogenesis and cardiac muscle cells development. A total of 11 genes in the 
dataset were associated with this pathway with all genes matching the change 
of expression expected in the literature (Figure 4-6). 
 
Table 4-7. Summary of the top four upstream regulators associated with the 
differentially expressed genes lists for each dataset. For each upstream 
regulator, the molecule type, Z-score and P-value are given. 
Analysis Upstream Regulator Molecule Type Activation Z-score P-value
TGFB1 Growth factor 2.228 1.69E-15
SRF Transcription regulator 3.769 3.43E-12
Cg Complex 1.358 1.36E-11
AGT Growth factor 2.307 5.26E-11
F2 Peptidase 1.503 2.2E-12
TNF Cytokine 1.892 2.18E-11
AGT Growth factor 2.018 1.15E-10
TGFB1 Growth factor 1.486 9.03E-10
MEF2C Transcription regulator -3.087 1.11E-09
MYOCD Transcription regulator -2.768 1.33E-07
2,3 butanedione monoxime Chemical drug -1.4 3.71E-07
DNMT3A Enzyme 1.667 6.27E-07
Other breed Vs Normal
CKCS Vs Normal




Figure 4-4. The network of genes that are differentially expressed in other 
breed grade 3 and 4 disease samples compared to normal valve samples that 
are downstream of TGFβ1 signalling. TGFβ1 is shown to have its effect from 
the extracellular space on the genes in their cellular location. Genes are 
coloured red and green to represent up- or down-regulation in the dataset. 
Dotted lines connecting TGFβ1 to these genes show the expected effect of 
TGFB signalling: orange - activation, blue - inhibition, yellow -result 




Figure 4-5. The network of genes that are differentially expressed in CKCS 
samples compared to normal valve samples that are downstream of F2 
signalling. F2 is shown to have its effect from the extracellular space on the 
genes in their cellular location. Genes are coloured red and green to 
represent up- or down-regulation in the dataset. Dotted lines connecting F2 
to these genes show the expected effect of F2 signalling: orange - activation, 





Figure 4-6. The network of genes that are differentially expressed in CKCS 
compared to other breed grade 3 and 4 disease samples valves that are 
downstream of MEF2C signalling. MEF2C is shown to have its effect from 
the extracellular space on the genes in their cellular location. Genes are 
coloured red and green to represent up- or down-regulation in the dataset. 
Dotted lines connecting MEF2C to these genes show the expected effect of 





Network analysis for the genes differentially expressed in other breed grade 3 
and 4 disease samples compared to normal samples highlighted top five 
disease and functions annotations assigned to this dataset (Table 4-8). The top 
network in this analysis is visualised in Figure 4-7. 
 
Table 4-8. Summary of disease and function networks associated with 
differentially expressed genes in other breed grade 3 and 4 disease samples 
compared to normal samples. Underlined is the network that is visualised 
in Figure 4-7. 
 
Top disease and function
Organismal Injury and Abnormalities, Renal and Urological Disease, Behavior
Cancer, Organismal Injury and Abnormalities, Reproductive System Disease
Cell Morphology, Cellular Movement, Hair and Skin Development and Function
Skeletal and Muscular System Development and Function, Cardiovascular System Development and Function, Organ Development




Figure 4-7. Schematic of the Organismal injury and abnormalities, renal and 
urological disease and behaviour network. Genes are shown in their protein 
cellular location with red indicating up-regulation, green down-regulation 
and un-coloured showing no change in the dataset. 
Network analysis for the genes differentially expressed in CKCS samples 
compared to normal samples highlighted the top five disease and functions 
annotations assigned to this dataset (Table 4-9). Amongst these were several 
networks that involved cardiovascular pathways. The third pathway in this 





Table 4-9. Summary of disease and function networks associated with 
differentially expressed genes in CKCS samples compared to normal 
samples. Underlined is the network that is visualised in Figure 4-8. 
 
Figure 4-8. Schematic of the Cardiovascular disease, cell death and survival 
and connective tissue disorders network. Genes are shown in their protein 
cellular location with red indicating up-regulation, green down-regulation 
and un-coloured showing no change in the dataset. 
Top disease and function
Cell Death and Survival, Cell Cycle, Cellular Movement
Cardiovascular System Development and Function, Cell Morphology, Organ Morphology
Cardiovascular Disease, Cell Death and Survival, Connective Tissue Disorders
DNA Replication, Recombination, and Repair, Cellular Movement, Cellular Assembly and Organization
Connective Tissue Disorders, Organismal Injury and Abnormalities, Skeletal and Muscular Disorders
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Network analysis for the genes differentially expressed in CKCS samples 
compared to other breed grade 3 and 4 disease samples highlighted the top 
five disease and functions annotations assigned to the dataset (Table 4-10). 
The top pathway in this analysis is visualised in Figure 4-9. 
 
Table 4-10. Summary of disease and function networks associated with 
differentially expressed genes in CKCS samples compared to other breed 
grade 3 and 4 disease samples. Underlined is the network that is visualised 
in Figure 4-9. 
 
Top disease and function
Skeletal and Muscular Disorders, Developmental Disorder, Hereditary Disorder
Carbohydrate Metabolism, Energy Production, Small Molecule Biochemistry
Lipid Metabolism, Small Molecule Biochemistry, Molecular Transport
Cellular Development, Cellular Growth and Proliferation, Organ Development




Figure 4-9. Schematic of the Skeletal and muscular disorders and 
developmental disorder and hereditary disorder network. Genes are shown 
in their protein cellular location with red indicating up-regulation, green 
down-regulation and un-coloured showing no change in the dataset. 
4.4 Discussion 
This study aimed to investigate the transcriptomic similarities and differences 
between CKCS diseased valve samples and other breed diseased valve 
samples. It is worth noting that almost all CKCS RNA samples in this analysis 
were isolated for a previous study (as stated in section 4.2.2) and the RNA had 
been stored at -80 C for several years. This may have played a role in the 
removal of one of the CKCS samples prior to analysis in this study (detailed 
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in Chapter 3 section 3.3). However, one of the CKCS samples, although from 
an older stored valve, was extracted for the current study and still clustered 
with the other CKCS valve samples away from the other samples. 
Additionally, the protocol for valve tissue extraction, tissue preparation and 
RNA extraction were performed using the same protocol as the previous 
student. It is therefore unlikely this caused the differences seen, but should be 
accepted as a potential flaw in the following analysis. 
It was initially hypothesised (Chapter 3 section 3.1) that by looking at multiple 
breeds, transcriptomic changes that occur in each grade of MMVD could be 
elucidated without breed bias. Breed specific differences were hypothesised 
not affect the analyses as previous studies have indicated that MMVD is 
polygenic in its development and broadly follows the same pathogenesis in all 
breeds[1, 2, 33, 110, 219]. Conflicting GWAS results have been published in CKCS 
with one small study of 18 cases and 18 controls unable to associate any 
genome region with MMVD and the other weakly associating two loci. A 
study in whippets also found two loci (different from those in CKCS) 
associated with disease[219-221]. Immunohistochemical analysis of CKCS MMVD 
samples compared to other breed MMVD samples and to unaffected other 
breed normal valves showed no difference between the two diseased groups 
suggesting there is shared pathology between breeds[110]. However, some 
reports have indicated there may be a genetic basis for CKCS developing 
disease earlier in life with a greater heritability of early onset (age 4-5 years) 
clinically significant MMVD found in CKCS[23, 222, 285]. Recent reports on 
Swedish and UK breeding programmes have shown that the prevalence of 
MMVD or at least the prevalence of early-onset MMVD can be reduced in 
CKCS following a breeding programme[283, 284]. Given this, the results reported 
in this study may be enlightening. 
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Comparing the genes differentially expressed in diseased valve samples from 
other breeds and the CKCS diseased valve samples to normal valve samples, 
a number of the same genes were found to be differentially expressed (section 
4.3.2). Of note were many of the genes described as hallmarks of MMVD (as 
discussed in Chapter 3 section 3.4) such as ACTA2 and HTR2B, giving 
credence to the previous report that the central pathology of MMVD in all 
breeds is the same[2, 110]. Supporting this view, similarities were observed in the 
gene enrichment analysis performed for these two datasets. DAVID analysis 
indicated four (two up-regulated and two down-regulated) GO terms were 
shared in the top 10 lists for each dataset compared to normal valves. These 
included GO terms previously associated with analysis, in Chapter 3 section 
3.3.5 and 3.3.6, for their relevance to disease; positive regulation of ERK1 and 
ERK2 cascade and down-regulation of proteinaceous extracellular matrix. 
Similarly, in IPA analysis of the diseased valve datasets compared to normal 
valve samples, matching pathways are seen in both the canonical pathway and 
top upstream regulator analysis. In agreement with the by grade analysis, in 
Chapter 3 section 3.3.7, the top canonical pathway suggested was the hepatic 
fibrosis/hepatic stellate cell activation pathway, this was the most significant 
pathway in the comparison with other breed samples and second in the CKCS 
analysis with calcium signalling being top. Interestingly, the second suggested 
canonical pathway in other breed samples was the up-regulation of genes in 
the Caveolar-mediated endocytosis signalling but this was not seen in CKCS. As 
this pathway is associated with the inhibition of TGFβ-activation of fibroblasts 
this may have some bearing on early development of disease in CKCS[164, 165]. 
TGFβ1 was also the top upstream regulator in the other breed analysis and the 
fourth most significant for the CKCS dataset. TNF was also implicated but F2 
(prothrombin) was suggested as the top upstream regulator. In network 
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analysis, there were also various disease functions that matched between these 
two analyses. This included those involved in cardiovascular development 
and dysfunction although these functions were suggested far more in the 
CKCS analysis. Overall, the similarities between CKCS and other breed grade 
3 and 4 suggest that there is a shared pathogenesis in the disease development 
(likely mediated by TGFβ1), in agreement with the previous literature[33, 110]. 
However, some differences in these datasets do exist and may be important.  
The immune-related GO terms in the by grade analysis (Chapter 3 section 3.3.5 
and 3.3.6) were only observed to be enriched in the CKCS compared to normal 
valve samples dataset, suggesting that this is enhanced in CKCS valve samples. 
This may be of interest as there is some evidence to suggest that CKCS are also 
pre-disposed to some inflammatory conditions such as inflammatory bowel 
disease and pancreatitis[286, 287]. However, what role this play in the early 
development of MMVD is highly speculative as the role of immune cells in 
MMVD is yet unknown[44]. As mentioned earlier, the top upstream regulator 
in the CKCS comparison to normal valve samples was the activation of 
prothrombin. Prothrombin is a factor related to blood coagulation, but it has a 
role in pro-inflammatory mediation as well as having downstream signalling 
activity in endothelial, smooth muscle and fibroblast cell types which can be 
related to MMVD[288]. Likewise, thrombin has also been shown to both induce 
and inhibit TGFβ1 signalling depending on the context[289, 290] However, 
prothrombin’s role in blood coagulation may be most relevant to MMVD 
development. As discussed in Chapter 1 section 1.6.1, CKCS are predisposed 
to platelet dysfunction and macro-thrombocytopenia, which has been 
associated with early MMVD development in humans[225, 226, 228]. Prothrombin’s 
role as a top upstream regulator in CKCS valves may indicate a presence or 
role for platelet interaction with the valve. If this were the case it would allow 
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for 5HT signalling to be enhanced in the valve which could lead to MMVD 
development, something which has been stipulated in the literature[171, 173, 229]. 
Additionally in this analysis, there is an enrichment for muscle conduction and 
muscle related GO terms in the down-regulated CKCS differentially expressed 
genes. This involvement of conduction and cardiac muscle related pathways 
was also seen in the IPA analysis with Calcium signalling being seen as the top 
canonical pathway in the CKCS dataset. Interestingly, differences in Calcium 
signalling and Cardiac muscle pathways were also seen when comparing CKCS 
to the other breeds in the grade 3 and 4 valve samples.  
When considering the results generated from comparing the CKCS to the other 
breed diseased valves, in agreement with the previous analysis, genes that are 
typical of disease were not differentially expressed between groups, further 
supporting a central pathogenesis shared between all dogs[110]. This includes 
the MMVD markers ACTA2 and HTR2B[2]. DAVID analysis centred around 
down-regulated GO terms with all involving muscle contractility and calcium 
signalling related pathways. This theme continued in IPA analysis with 
Calcium signalling again being the top canonical pathway suggested form this 
dataset. The top upstream regulator’s list for this dataset is dominated by the 
down-regulation of the activity of factors involved in cardiac muscle 
contraction control and differentiation[291-293]. Understanding how down-
regulation of cardiac muscle, smooth muscle related and calcium binding 
pathways relate to the early on-set or advanced progression of MMVD in 
CKCSs may provide clues to the early pathogenesis in CKCS and hence to 
possible breed-specific therapies. The consistent implication of a role of 
calcium binding and calcium signalling could be of interest when considering 
the role it may play in 5HT signalling. 5HT typically signals through G-protein 
q coupled receptors (such as 5HTR2B) which cause an influx of calcium into 
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the cell as part of their downstream signalling[172]. The heightened number of 
genes down-regulated in calcium related pathways may be indicative of either 
increased calcium signalling (potentially through 5HT signalling) through 
negative feedback of these genes in CKCS samples or that CKCS valves have 
something fundamentally different in capacity for calcium signalling. Both of 
these could result in downstream signalling that could enhance or cause early 
MMVD development. This is especially interesting given the recent reports 
implicating higher circulating 5HT in the platelets of CKCS compared to most 
other breeds and, as discussed, the potential role of dysfunctional platelets[225, 
226, 229]. However, more in-depth studies would be required to confirm this. It 
may also be that, although a transcriptomic difference exists, it is not related 
to disease pathogenesis, but this seems unlikely due to the heritability of early-
onset disease in this breed and the relevance that transcriptomic differences 
between breeds of dogs would have[222].  
The drug predominantly used to treat the symptoms of MMVD, pimobendan, 
is a calcium sensitiser and inotrope[259, 294]. Pimobendan primarily acts by 
reducing the size of the heart and having peripheral vasodilatory effects, 
resulting in a prolonged period before congestive heart failure takes effect[35, 
260, 294]. Given the implied involvement of calcium signalling in CKCS disease, it 
may be that reduced or enhanced calcium sensitisation and contractility in 
CKCS valves are involved in the early development or rapid progression of 
disease in this breed. Likewise, these changes could be symptomatic of a single 
or several unidentified change/s that have additional non-transcriptomic 
effects on the valve. These questions remain unanswerable with this current 
analysis which involved relatively small numbers, particularly of breeds other 
than CKCS with severe disease. Appreciation of what these results mean will 
require a far more in-depth analysis beyond the scope of this study. It would 
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be useful to have control CKCS unaffected samples, preferably age-matched, 
to compare with normal valves from other breeds as well as to the diseased 
valve samples. From this, further –omic or cell culture studies could be 
performed to generate hypotheses into the molecular reasons for early disease 
development, which might inform breeding programmes, or the development 
of appropriate therapies for at-risk dogs. In this context studies investigating 
if similar transcriptomic differences are present in the valves of other breeds 
predisposed to developing early-onset disease, such as the dachshund, would 
be beneficial [166].  
In conclusion, this study has analysed the transcriptomic similarities and 
differences between CKCS and other breed dogs with grade 3 and 4 disease. 
In doing so, potentially key pathways that may be important in the early 
development of MMVD in CKCS have been identified. 
Summary:  
- Transcriptomic differences exist between CKCS and other breed dogs with 
grade 3 and 4 disease 
- There is a shared central pathology in the development of MMVD regardless 
of breed 
-calcium signalling, muscle contraction and prothrombin may be important in 
the early development of MMVD in CKCS  
This study has therefore achieved its aim and established potentially 
important pathways that may cause the increased predisposition for MMVD 
in CKCS. However, there is a level of shared pathology across all breeds of 
disease implying the pathways identified are more enhancers rather than 
central drivers of disease pathogenesis. It may be the case that CKCS have 
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several of these pathways enhanced leading to early development. Regardless, 
investigating the central pathogenesis of disease shared in all dogs especially 
in early disease pathogenesis. As mentioned in Chapter 3, Chapter 5 aims to 
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   Region dependent changes in early MMVD  
5.1 Introduction 
The development of myxomatous mitral valve disease (MMVD) begins in 
discreet areas of the valve (that can be macroscopically identified), typically 
towards the free edge, that expands eventually encompassing the entire valve 
by end-stage disease[2, 4, 36]. A neglected area of MMVD research is that which 
focusses on events in early disease progression (Whitney grade 1 and 2). This 
makes discerning causal pathways responsible for MMVD difficult. As 
highlighted in Chapter 3, analysis of early disease is confounded by the 
presence of high proportions of normal tissue that can mask MMVD-specific 
pathways when the whole valve is included in the analysis. In this study, this 
issue is circumvented by separating the areas of overtly diseased and normal 
tissue from the same grade 2 valves. It is hypothesised here, that by comparing 
the transcriptome of the normal and diseased tissue regions, pathways 
involved in the early development of MMVD will be observed.  
This approach offers benefits over whole valve analysis as diseased valve 
tissue is compared directly to the normal tissue from the same valve in a paired 
analysis. This minimises the effect of confounding factors such as age and 
breed, as well as any differences in baseline expression of genes between 
individual animals. Additionally, this is a novel approach in MMVD research 
in any species. To my knowledge, only one previous study has used a 
dissection approach, similar to the one proposed here, in valve research. Nagy 
et al macroscopically dissected human aortic valves into normal, thickened 
and calcified regions before assessing gene expression by RT-qPCR[295]. This 
study was able to successfully show gene expression differences between the 
normal and thickened diseased areas or calcified diseased areas of the valve 
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and correlated gene expression with disease severity. This helps to justify the 
use of dissection as an appropriate technique to interrogate early disease 
development[295].  
This chapter aims to investigate transcriptomic profiles of diseased and 
normal areas of Whitney grade 2 valves from the dog and identify differences 
that may be important in the early development of MMVD. Additionally, this 
study aims to investigate if the normal regions of diseased valves are similar 
or different to the whole normal valves samples. 
5.2 Materials and methods 
5.2.1 Tissue collection 
For full details on tissue collection and dissection, see Chapter 2 section 2.2. 
Seven Whitney grade 2 valves were collected and the diseased and normal 
areas of the valve were macroscopically dissected. An additional four normal 
(grade 0) valves were collected and dissected following the same protocol with 
areas towards the free edge of the valve (were diseased lesions would typically 
begin to form) separated to compare to the rest of the valve tissue. Myself and 
another investigator in unison performed dissection and identification of 
diseased lesions on the valve. The description of the dogs used in this study is 
summarised in Table 5-1.  
 
Table 5-1. Summary of the dogs used in this study. 
Sample ID Date sampled Dog Breed Gender Age Whitney grade
SBT1G0 05/06/2017 STAFFORDHSIRE BULL TERRIER MALE 1y 0
JRG0 23/03/2018 JACK RUSSEL TERRIER MALE 4y 0
SBT2G0 04/05/2018 STAFFORDHSIRE BULL TERRIER MALE 6y 0
GSG0 18/05/2018 GERMAN SHEPHERD FEMALE 5y 0
JRG2 28/06/2016 JACK RUSSEL TERRIER MALE 3y 2
BCG2 07/10/2016 BORDER COLLIE MALE 3y 2
GSG2 26/08/2016 GERMAN SHEPHERD FEMALE 4y1m 2
SBT1G2 05/08/2016 STAFFORDHSIRE BULL TERRIER MALE 3y10m 2
SBT2G2 13/10/2017 STAFFORDHSIRE BULL TERRIER MALE 4y1m 2
ROTG2 22/09/2017 MASTIFF MALE 5y 2
BG2 14/04/2014 BEAGLE FEMALE 6y 2
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5.2.2 RNA extraction, quantification and quality control for microarray  
The extraction protocol followed for dissected valve RNA extraction is 
detailed in section 2.3.1 of Chapter 2. Quantification and quality control 
assessment of RNA for microarray analysis was performed as described in 
Chapter 2 section 2.3.3. RNA integrity numbers (RIN) were not assessed in the 
normal valve dissected samples as these were not used in microarray analysis.  
5.2.3 Affymetrix Canine Gene 1.1ST microarray analysis  
In this study, the majority of microarray analysis was performed on a single 
24 well Affymetrix Canine Gene 1.1ST chip, the remaining 12 wells on this chip 
were used in the study discussed in Chapter 6. The normal and diseased tissue 
samples from sample BG2 were analysed by microarray on one of the 16 well 
Affymetrix Canine Gene 1.1ST chips used in the analysis described in chapter 
3. RNA processing, hybridisation, post-hybridisation quality control, 
summarisation file creation and differential gene expression analysis was 
performed as described in section 2.5 of Chapter 2. Statistical analysis used 
paired sample analysis of variance (ANOVA) with differential gene 
expression determined as having a >±1.5 fold change difference in expression 
a >2.5 log signal intensity and with an adjusted P-value (Q-value) using a 
Benjamini-Hochberg false discovery rate (FDR) correction (Q-value <0.05).  
5.2.4 Gene enrichment analysis  
The network analysis tool Miru (version 1.4) was utilised as described in 
Chapter 2 section 2.6.1. A sample-to-sample comparison was performed with 
a Pearson correlation of r=0.9, this maximised the number of samples included 
whilst minimising the connection between samples. The tools Database for 
Annotation, Visualisation and Integrated Discovery (DAVID) version 6.8 and 
Ingenuity Pathway Analysis (IPA) were used as stated in Chapter 2 sections 
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2.6.2 and 2.6.3. Gene list comparison was performed as described in Chapter 2 
section 2.6.4. 
5.2.5 cDNA synthesis and RT-qPCR 
To validate the microarray analysis and the expression of genes of interest in 
normal valve samples that have been dissected, RNA samples were 
synthesised into complementary DNA (cDNA) and real-time quantitative 
polymerase chain reaction (RT-qPCR) was performed (Chapter 2 section 2.7). 
The primers used are listed in Table 5-2 and were designed and optimised 
following the protocol summarised in Chapter 2 section 2.7.2-2.7.6. All gene 
quantification was normalised to MRPS25, RPL32 and GAPDH. Statistical 
analysis used paired sample T-tests as detailed in Chapter 2 section 2.13.  
 
Table 5-2. Primers designed and optimised for use in this study.  
5.3 Results 
5.3.1 RNA quality assessment  
Extracted RNA samples from dissected regions of valve tissue were quantified 
and their concentrations, 260/280 and 260/230 ratio and RNA integrity 
numbers (RIN) were recorded and summarised in Table 5-3. RNA 
Gene Symbol Forward Primer Sequence Reverse Primer Sequence Product Length Optimum TM ºC Primer Efficiency %
ACTA2 5'CGGCTACTCCTTTGTGACG3' 5'CGTGGCCATCTCGTTCTC3' 100 58 102.2
HTR2B 5'CCAATCCAGGCCAATCAAAG3' 5'CAGGTGATGTTGCTTGGGTT3' 143 59 104.8
TAGLN 5'GACATGTTCCAGACCGTCGA3' 5'CAATGACGTGCTTTCCCTCC3' 199 59 106.7
ACTG2 5'TGCCAACAATGTCCTTTCCG3' 5'GCCTCCAATCCAGACTGAGT3' 148 60 93
HBEGF 5'CTGTGGTGCTGTCATCTGTC3' 5'TGGGAAGTAGTCATGCCTAACT3' 124 61 103.8
CDKN2A 5'CATGTTGGCTCAGAATCGGG3' 5'CTCACGTCCAAGGCACAAAA3' 125 60 90.6
SLC10A6 5'GCTGTTGGATGGGTTTCTCA3' 5'TCCAAGAAAGCACCAGTCTCT3' 147 58 101.7
CILP 5'TGCTCCAATTATACCGTGCG3' 5'CAGAACACTTGCTCCAGGGA3' 100 62 106.1
MMP12 5'GACACAATTCATGGACCCTGG3' 5'TCAAATACGTCAGGTCCTTGGA3' 129 63 110
ADAMTS5 5'GTTCCCAAATATGCAGGCGT3' 5'AGCTTCGAACCAATGATGCC3' 191 59 101.6
ADAMTS9 5'CACCGTGTCCTCTCTATGCT3' 5'AACCTCATTGCCTTTGTCCG3' 119 60 100
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concentration ranged 157.4-2183.2 ng/µl. When comparing the RNA 
concentrations of ‘normal’ (mean: 1140 ng/µL ±247 S.E.) to ‘diseased’ (mean: 
1360 ng/µL ±299 S.E.) regions of tissue from the normal valves did not 
demonstrate a statistical difference (P-value 0.117). Comparing the RNA 
concentration of ‘normal’ (mean: 854 ng/µL ±140 S.E.) and ‘diseased’ (mean: 
554 ng/µL ±93 S.E.) regions of tissue from the grade 2 valves, a statistical 
difference in concentrations was identified (P-value 0.034). Absorbance 
reading ratios were all within the acceptable reference range (>1.8) for both 
260/280 and 260/230, indicating uncontaminated RNA extractions. Gel 
electrophoresis images (Figure 5-1) display the 28S and 16S rRNA in each 
sample alongside the quantified RIN values. The majority of samples passed 
the accepted cut-off of RIN>7 for microarray analysis. Sample SBT1G2 
‘normal’ had a RIN of 6.6 but was deemed acceptable for analysis by 




Table 5-3. Concentration, 260/280 and 260/230 ratios and RIN for each 
‘diseased’ and ‘normal’ region of valve tissue.  
 
Figure 5-1. Gel electrophoresis images displaying the 28S (top band) and 16S 
(bottom band) rRNA intensities in each sample. The RIN for each sample is 
shown and colour coded with >8.2 given a green colour and 6.5-8.2 given a 
yellow colour. 
Sample ID RNA  [ng/µL] 260/280 260/230 RIN
SBT1G0 'normal' 978.9 2.1 2.22 -
SBT1G0 'diseased' 1157.3 2.1 2.27 -
JRG0 'normal' 806 2.11 2.22 -
JRG0 'diseased' 766.5 2.09 2.15 -
SBT2G0 'normal' 903.3 2.1 2.25 -
SBT2G0 'diseased' 1331.8 2.1 2.26 -
GSG0 'normal' 1873.1 2.07 2.23 -
GSG0 'diseased' 2183.2 2.06 2.23 -
JRG2 'normal' 649.97 2.12 2.22 8.4
JRG2 'diseased' 343.78 2.06 2.14 8.6
BCG2 'normal' 1178.93 2.09 2.2 7.7
BCG2 'diseased' 686.65 2.09 2.19 8
GSG2 'normal' 916.19 1.89 2.21 7.3
GSG2 'diseased' 532.2 2.11 2.16 8.6
SBT1G2 'normal' 616.95 2.12 2.04 6.6
SBT1G2 'diseased' 851.63 2.1 2.2 7.1
SBT2G2 'normal' 1235.56 2.09 2.21 8.3
SBT2G2 'diseased' 781.24 2.1 2.22 8.5
ROTG2 'normal' 1147.54 2.09 2.24 7.4
ROTG2 'diseased' 521.9 2.09 2.2 8.1
BG2 'normal' 235 2.09 2.15 8
BG2 'diseased' 157.4 2.08 2.15 7.1
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5.3.2 Microarray post-hybridisation quality control  
All wells on the array showed the correct concentration of spike in 
hybridisation and labelling controls indicated that no technical errors occurred 
on the plate. After Robust Multi-array Average (RMA) and gene-level 
normalisation, the log expression signal for the dissected normal, dissected 
diseased and whole valve normal samples are shown in Figure 5-2. The 
sample with the largest variability in the log expression signal was BG2 
‘normal’. Signal intensity distribution for these samples is shown as the log2 
signal line graph in Figure 5-3. A similar signal distribution pattern was seen 
for all samples ranging from 0-13.69. The initial peak, indicative of background 
noise, ranges from 0.93-2.5. This figure shows that to remove the effect of 
background on this dataset, genes expressed below 2.5 log signal intensity 
should be removed. 
 




Figure 5-3. Log2 signal line graph for samples. Each line represents a sample 
and a uniform pattern of expression can be seen here. 
Principal component analysis (PCA) in Affymetrix expression console and 
sample-to-sample analysis in Miru (r=0.9) was performed. Samples from 
‘normal’ and ‘diseased’ regions of the valve clustered away from one another 
(Figure 5-4). The dissected valve samples analysed on the microarray chip 
used in Chapter 3 (yellow squares) clustered away from the samples analysed 
on the chip described in this chapter (red and blue squares) indicative of a 
potential batch effect. Comparing the normal whole valve samples to the 
‘normal’ dissected valve regions, by PCA, indicated a slight difference 
between these two groups (Figure 5-5). Sample BG2 ‘normal’, the sample 
which had the largest variability in the log expression signal, was plotted the 
furthest away from the other samples, suggesting there may be an issue with 
the samples use. However, the sample-to-sample analysis in Miru showed that 
samples clustered together based on whether they were the whole normal 
valve, dissected ‘normal’ regions or dissected ‘diseased’ regions (Figure 5-6). 
Normal whole valve and dissected ‘normal’ samples shared more edges with 
each other than the normal whole valve and dissected diseased valve. BG2 
161 
 
‘normal’ in this analysis clustered with other dissected ‘normal’ samples. This 
coupled with the sample having a relatively good RIN value (7.1) it was 
decided not to remove this sample from the dataset. Ultimately, PCA and 
sample-to-sample analysis highlighted that there were transcriptomic 
differences between both the diseased regions and normal regions of grade 2 
valves as well as, to a lesser extent, between normal regions of grade 2 valves 
and whole normal valve samples.  
 
Figure 5-4. PCA plot comparing dissected ‘normal’ and dissected ‘diseased’ 
regions of the valve. Red squares represent ‘normal’ samples, blue squares 
represent ‘diseased’ regions and the yellow squares represent the dissected 




Figure 5-5. PCA plot comparing dissected ‘normal’ regions and normal 
whole valve samples. Red squares represent dissected ‘normal’ samples and 
blue squares represent normal whole valve samples. The red square with a 
black cross through it is the dissected ‘normal’ valve region from the 





Figure 5-6. Sample-to-sample correlation (r=0.9) of dissected ‘normal’, 
dissected ‘diseased’ and whole normal valve. Red nodes represent whole 
normal valve samples, blue nodes represent dissected ‘normal’ regions of 
valve samples and yellow nodes represent the dissected ‘diseased’ regions 
of whole valve samples.  
5.3.3 Differential expression of genes 
315 probes which could be assigned to 289 genes were found to be 
differentially expressed between dissected ‘normal’ and dissected ‘diseased’ 
regions of the valve samples (>1.5 or <-1.5 fold change, Q-value <0.05, >2.8 log2 
signal intensity). 170 genes were down-regulated and 119 genes were up-
regulated in dissected ‘diseased’ regions when compared to the dissected 
‘normal’ regions. When comparing the dissected ‘normal’ regions of valve to 
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normal whole valve samples, 238 probes which could be assigned to 202 genes 
were differentially expressed. 157 genes were up-regulated and 45 genes were 
down-regulated in dissected ‘normal’ regions compared to the normal whole 
valve samples. These two datasets are summarised in volcano plots in Figure 
5-7 and full gene lists can be found in Appendix III: Chapter 5 Tables S1 and 
2. 
 
Figure 5-7. Volcano plots showing differential expression of genes in 
dissected and whole valve samples. (A) Genes differentially expressed 
between dissected ‘normal’ and ‘diseased’ regions. (B) Genes differentially 
expressed between ‘normal’ dissected regions of valve and normal whole 
valve samples.  
To investigate the level of similarity between the two-dataset comparisons, the 
number of genes that shared differential expression was calculated. Out of the 
combined 472 genes differentially expressed in both datasets, 19 were found 
to be shared. This is illustrated in a Venn diagram in Figure 5-8. Of the 
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nineteen shared genes (listed in Table 5-4), only three shared whether they 
were up- or down-regulated in the two datasets.  
 
Figure 5-8. Venn diagram illustrating the number of shared differentially 
expressed genes in the two datasets. In the left orange circle, the number of 
differentially expressed genes for dissected ‘normal’ and dissected 
‘diseased’ regions of the valve samples is shown. In the right purple circle, 
the number of differentially expressed genes for dissected ‘normal’ regions 
of the diseased valves and normal whole valve samples is shown. In the 




Table 5-4. Shared differentially expressed genes in the two datasets. Genes 
in yellow share up- or down-regulation in both datasets. 
5.3.4 DAVID 6.8 gene enrichment  
DAVID GO term enrichment was performed on the up- and down-regulated 
genes from both of the datasets. The top ten GO terms suggested for the up- 
and down-regulated genes comparing dissected ‘normal’ and dissected 
‘diseased’ regions of valve samples are summarised in Table 5-5. The top ten 
up-regulated and the one down-regulated GO terms associated with genes 
differentially expressed between dissected ‘normal’ regions of valve and 
normal whole valve samples are summarised in Table 5-6. No shared GO 
terms were suggested between these two datasets and the degree of 
association of the GO terms in this analysis have was much lower, indicated 
by the higher P-value and FDR values.   























Table 5-5. Functional analysis chart summary of GO terms associated with 
up- and down-regulated genes differentially expressed in the ‘diseased’ 
regions of valve compared to ‘normal’ regions. 
 
Table 5-6. Functional analysis chart summary of GO terms associated with 
up- and down-regulated genes differentially expressed in the dissected 
‘normal’ regions of valve compared to normal whole valve samples. 
Category Term Gene count P-value FDR
GOTERM_BP_DIRECT Immune response 11 3.25E-07 4.66E-04
GOTERM_BP_DIRECT Neutrophil chemotaxis 7 1.01E-06 0.00145
GOTERM_BP_DIRECT Eosinophil chemotaxis 4 1.86E-05 0.02665
GOTERM_CC_DIRECT Integral component of membrane 44 5.14E-05 0.05463
GOTERM_CC_DIRECT External side of plasma membrane 8 1.13E-04 0.12021
GOTERM_BP_DIRECT Chemokine-mediated signaling pathway 5 1.28E-04 0.18394
GOTERM_MF_DIRECT CCR chemokine receptor binding 4 3.04E-04 0.34272
GOTERM_BP_DIRECT Lymphocyte chemotaxis 4 5.44E-04 0.77798
GOTERM_MF_DIRECT Chemokine activity 4 8.90E-04 1.00101
GOTERM_BP_DIRECT Monocyte chemotaxis 4 9.81E-04 1.39882
GOTERM_CC_DIRECT Extracellular space 28 1.25E-08 1.37E-05
GOTERM_CC_DIRECT Lipid particle 6 6.16E-05 0.06733
GOTERM_MF_DIRECT Heparin binding 7 1.76E-04 0.21874
GOTERM_CC_DIRECT Integral component of membrane 53 7.60E-04 0.8275
GOTERM_CC_DIRECT Extracellular exosome 35 0.0012 1.29825
GOTERM_BP_DIRECT Response to insulin 4 0.00161 2.38306
GOTERM_BP_DIRECT Lipid storage 4 0.00181 2.68488
GOTERM_BP_DIRECT Low-density lipoprotein particle clearance 3 0.00195 2.87493
GOTERM_CC_DIRECT Proteinaceous extracellular matrix 7 0.00478 5.1044
GOTERM_BP_DIRECT Glucose homeostasis 5 0.00755 10.7315
Up-regulated 
Down-regulated
Category Term Gene count P-value FDR
GOTERM_BP_DIRECT Translation 7 0.00274 3.81602
GOTERM_MF_DIRECT Structural constituent of ribosome 7 0.00669 7.56247
GOTERM_BP_DIRECT Intracellular protein transport 6 0.0136 17.6462
GOTERM_CC_DIRECT Cytosolic large ribosomal subunit 4 0.01496 15.6621
GOTERM_BP_DIRECT Transcytosis 2 0.03993 43.8971
GOTERM_BP_DIRECT Negative regulation of angiogenesis 3 0.04748 49.8405
GOTERM_CC_DIRECT Synaptic vesicle 3 0.05136 44.8855
GOTERM_BP_DIRECT Regulation of cellular senescence 2 0.05546 55.4804
GOTERM_BP_DIRECT Nucleoside triphosphate biosynthetic process 2 0.05546 55.4804
GOTERM_BP_DIRECT Angiogenesis 4 0.05882 57.6713




5.3.5 Ingenuity Pathway Analysis  
Both datasets were submitted for analysis in IPA with the number of mapped 
and unmapped genes in each dataset summarised in Table 5-7. 
 
Table 5-7. Mapped, unmapped and total number of genes submitted into 
IPA for each dataset. 
Canonical pathway analysis was performed and sixty-two and twenty-seven 
pathways respectively were associated with genes differentially expressed in 
‘diseased’ regions compared to ‘normal’ regions and ‘normal’ regions of 
dissected valve compared to normal whole valve samples (P-value <0.05). 
Comparing the two sets of analysis, it is apparent that stronger associations 
were obtained for the ‘normal’ and ‘diseased’ dissected regions comparison 
dataset. The top three canonical pathways associated with both sets of 
comparison are summarised in Table 5-8.  
 
Table 5-8. Summary of top three canonical pathways associated with each 
dataset. The number of genes up- and down-regulated in each pathway as 
well as the total number of genes changed in each pathway is shown. The 
P-value score shows the association of the gene list to the pathway. 
Dataset Mapped genes Unmapped genes Total genes 
Dissected valve sample comparison 270 19 289
Normal valve sample comparison 181 21 202
Dataset Canonical Pathway Up-regulated genes Down-regulated genes Genes pathway P-value
Hepatic Fibrosis/Hepatic Stellate Cell Activation 7 14 21/160 3.9811E-09
Granulocyte Adhesion and Diapedesis 11 6 17/132 1.6218E-07
Agranulocyte Adhesion and Diapedesis 10 6 16/135 1.1749E-06
TREM1 Signaling 5 0 5/75 0.00038905
Toll-like Receptor Signaling 5 0 5/76 0.00040738
Serine Biosynthesis 1 1 2/5 0.00066069
Dissected valve sample comparison
Normal valve sample comparison
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Upstream regulator analysis associated 2156 molecules with the ‘normal’ and 
‘diseased’ dissected regions dataset and 290 molecules with the ‘normal’ 
dissected regions of valve and normal whole valve samples dataset (P-value 
<0.05). The top three molecules for each dataset are summarised in Table 5-9 
with Tumour Necrosis Factor (TNF) and Reproductive Homeobox 5 (RHOX5) 
respectively being suggested as the most likely upstream regulator for genes 
differentially expressed in ‘diseased’ compared to ‘normal’ regions and 
‘normal’ regions of valve compared to normal whole valve. The genes 
downstream of TNF are summarised in Figure 5-9. One hundred and seven 
genes were associated with the pathway with eighty genes being differentially 
expressed in accordance with the literature and twenty-two not. One of the 
other pathways of interest in this dataset was the TGFβ1 signalling pathway, 
with the genes downstream of this molecule summarised in Figure 5-10. One 
hundred and one differentially expressed genes from the dataset were 
associated with this pathway with 75 of these changing their expression with 
what would be expected from the literature and 26 showing an unexpected 
change. Only four differentially expressed downstream genes were associated 
with RHOX5, three of which did not match the change in expression expected 
from the literature (Figure 5-11).  
 
Table 5-9. Summary of the top three upstream regulators associated with 
each dataset. For each upstream regulator, the molecule type, Z-score and P-
value are given. 
Dataset Upstream Regulator Molecule Type Activation Z-score P-value
TNF Cytokine 3.544 4.02E-26
TGFB1 Growth factor 0.926 1.79E-19
IFNG Cytokine 2.233 2.19E-18
Rhox5 Transcription regulator 0.277 7.54E-06
POLG Enzyme  0.0000495
ADCY7 Enzyme  0.0000635
Dissected valve sample comparison




Figure 5-9. The network of genes that are differentially expressed in 
‘diseased’ compared to ‘normal’ regions that are downstream of TNF 
signalling. TNF is shown to have its effect from the extracellular space on 
the genes in their cellular location. Genes are coloured red and green to 
represent up- or down-regulation in the dataset. Dotted lines connecting 
TNF to these genes show the expected effect of TNF signalling: orange - 





Figure 5-10. The network of genes that are differentially expressed in 
‘diseased’ compared to ‘normal’ regions that are downstream of TGFβ1 
signalling. TGFβ1 is shown to have its effect from the extracellular space on 
the genes in their cellular location. Genes are coloured red and green to 
represent up- or down-regulation in the dataset. Dotted lines connecting 
TGFβ1 to these genes show the expected effect of TGFβ signalling: orange - 





Figure 5-11. The network of genes that are differentially expressed in 
‘normal’ regions of dissected valve compared to normal whole valve 
samples that are downstream of RHOX5 signalling. RHOX5 is shown to 
have its effect from the nucleus on the genes in their cellular location. Genes 
are coloured red and green to represent up- or down-regulation in the 
dataset respectively. Dotted lines connecting RHOX5 to these genes show 
the expected effect of RHOX5 signalling: blue – inhibition and yellow -
result inconsistent. 
The signal intensity values from the microarray analysis for each of the three 
top upstream regulators suggested for the ‘diseased’ compared to ‘normal’ 
dissected regions dataset are shown in Table 5-10. TGFβ1 has approximately 
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a ten-fold greater signal intensity than TNF or IFNG. These results were 
corroborated when examining these factors expression in the whole valve 
analysis (Table 5-11).  
  
Table 5-10. Signal intensity values for each of the top upstream regulators 
for the dissected ‘normal’ compared to dissected ‘diseased’ regions dataset. 
 
Table 5-11. Signal intensity values for each of the top upstream regulators 
for the dissected ‘normal’ compared to dissected ‘diseased’ regions dataset 
in each grade of disease in whole valve analysis 
Network analysis was performed and highlighted the disease and function 
annotations associated with the genes differentially expressed for both 
datasets. The top three groups of disease and functions are summarised for 
both datasets in Table 5-12. The top groups for each dataset are also visualised 








Normal Grade 1 Grade 2 Grade 3 Grade 4
TNF 15.56 15.03 16.56 19.02 12.64
TGFβ1 121.09 143.01 134.36 139.1 142.02






Table 5-12. Summary of disease and function networks for both datasets. 
 
Figure 5-12. Schematic of the Tissue morphology, connective tissue 
development and function lipid metabolism disease and function network. 
Genes are shown in their protein cellular location with red indicating up-
regulation, green down-regulation and un-coloured showing no change in 
the dataset. 
 
Dataset Top Diseases and Functions
Tissue Morphology, Connective Tissue Development and Function, Lipid Metabolism
Connective Tissue Disorders, Organismal Injury and Abnormalities, Skeletal and Muscular Disorders
Cell-To-Cell Signaling and Interaction, Cell Signaling, Molecular Transport
Organismal Injury and Abnormalities, Renal and Urological Disease, Connective Tissue Disorders
Connective Tissue Disorders, Developmental Disorder, Hereditary Disorder
Cellular Function and Maintenance, Hematological System Development and Function, Humoral Immune Response
Dissected valve sample comparison




Figure 5-13. Schematic of the Organismal injury and abnormalities, renal and 
urological disease and connective tissue disorders disease and function 
network. Genes are shown in their protein cellular location with red 
indicating up-regulation, green down-regulation and un-coloured showing 
no change in the dataset. 
5.3.6 RT-qPCR validation of microarray analysis  
Validation of the microarray results was performed with RT-qPCR on selected 
genes of interest. The majority of these genes surpassed the FDR corrected Q-
value cut-off of <0.05, with the exception of ADAMTS5 and ACTG2 which were 
selected for their differential expression in the whole valve analysis, had 
surpassed ±1.5 fold change and had a Q-value <0.1. Additionally, RT-qPCR 
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was performed for these same genes of interest on samples from the dissected 
tissue of normal valves. This analysis compares the expression of these genes 
from areas where the disease would typically develop (towards the edge of 
the leaflet) to the rest of the valve. Fold change data for this analysis is 
summarised in Table 5-13. All RT-qPCR data comparing ‘diseased’ and 
‘normal’ valve regions were in agreement with the corresponding fold 
changes observed in the microarray analysis. There was no significant 
difference detected between the different normal regions of valve dissected 
out of the normal valves for any of these genes.  
 
Table 5-13. Summary of Microarray validation by RT-qPCR of the ‘diseased’ 
compared to ‘normal’ regions of the valve and RT-qPCR performed on 
dissected normal valves. Data presented as fold change compared to normal 
and associated P/Q-value. Normalised to GAPDH, MRPS25 and RPL32. 
5.4 Discussion  
This study aimed to investigate the transcriptomic profiles of overtly diseased 
and normal regions of Whitney grade 2 MMVD valves. It was hypothesised 
Fold change P-value Fold change Q-value Fold change P-value
ACTA2 3.12 0.001 1.79 0.043 2.44 0.157
HTR2B 2.64 <0.001 1.57 0.031 -2.64 0.982
ADAMTS5 -2.28 0.004 -1.6 0.072 3.39 0.186
ADAMTS9 -2.54 0.002 -1.56 0.013 2.29 0.112
SLC10A6 -1.92 0.004 -1.67 0.013 2.01 0.56
CDK2NA 4.96 0.034 1.99 0.04 -1.38 0.215
ACTG2 3.31 <0.001 1.93 0.065 -1.16 0.4
HBEGF 2.34 0.008 1.9 0.042 1.76 0.547
CILP -5.89 <0.001 -5.77 0.02 3.3 0.079
MMP12 2.59 0.002 1.67 0.019 1.65 0.724
Gene name
qPCR 'Diseased' compared to 'Normal' Microarray 'Diseased' compared to 'Normal' qPCR Normal valve dissection
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that differences in expression of genes between these two groups would give 
an indication to which pathways are fundamentally important in early disease 
development. Furthermore, this study attempted to compare the 
transcriptome of seemingly normal regions of Whitney grade 2 valves to that 
of the whole normal valve, to establish whether the normal regions from the 
dissected valves were also expressing genes related to disease pathogenesis. 
Additionally, to eliminate the possibility that the gene changes observed were 
purely based on regional differences in expression in the valve, dissections 
were performed on completely normal unaffected valves mimicking the 
dissections performed in the Whitney grade 2 valves. RNA extracted from 
these dissected normal valves was then assessed by RT-qPCR for genes 
differentially expressed between the diseased and normal regions of valves, 
serving as controls for the diseased dissected valve analyses. 
Prior to transcriptomic analysis, it was noted that there was significantly less 
RNA extracted from diseased regions of Whitney grade 2 valves compared to 
the normal regions of the same valve (section 5.3.1). This may be because the 
amount of diseased tissue from these valves was smaller than the remaining 
normal tissue. However, this difference in RNA concentration was not 
observed in the dissected normal valves, where the upmost effort was made 
to use similar sized pieces of tissue in each group as the Whitney grade 2 
valves. If the difference observed was caused by disease rather than a 
difference in tissue size it could be attributed to cells in this region producing 
less RNA, a decrease in the number of cells in this region or a combination of 
both. Previous reports in the literature indicate that even in myxoid regions of 
the spongiosa from early diseased valves, there is an overall decrease in cell 
number compared to the same regions in normal valves[44, 49]. However there 
is an increase in cell number in the sub-endothelial areas (atrialis and fibrosa) 
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so it may be the case that total cell number remains the same[48, 153]. Regardless 
of this potential difference, the concentration of as well as the quality of RNA 
extracted from dissected valves was adequate for further study, with all 
samples passing post-hybridisation quality control. This indicates that this is 
a feasible approach for future research. 
An advantage that this study has over the whole valve analysis of disease is 
that by comparing samples from the same valve, paired analysis can be 
performed. This minimises the effect of confounding factors such as breed and 
age of dog as well as baseline differences in gene expression between 
individual dogs within groups, which was shown to have an effect in Chapters 
3 and 4. This allowed for the more stringent FDR corrected Q-value to be used 
in this analysis, minimising the effect of false positives due to multiple-
comparisons[296]. The FDR corrected gene list produced for the comparison 
between regions of diseased and normal tissue included some hallmarks of 
disease, also noted in Chapter 3 and 4, such as ACTA2 and HTR2B, supporting 
the hypothesis that differentially expressed genes that are related to disease 
progression are detectable in the overtly diseased regions of valve[1, 2]. 
Furthermore, when comparing the normal regions of the diseased valves to 
whole normal valves, although differences did exist, these hallmark genes 
were not differentially expressed. In fact, only nineteen genes were 
differentially expressed in both datasets with only three sharing up-or down-
regulation in expression (all up-regulated) (section 5.3.3). This supports the 
view that the majority of genes differentially expressed in the normal regions 
of valve compared to whole normal valve samples were not diseased related. 
These findings help to support the hypothesis of this study and show that this 
approach is of use in future studies. 
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Nonetheless, differential gene expression was detected between the normal 
regions of dissected valves and the normal whole valve samples. This may 
indicate that normal regions of valve from Whitney grade 2 valves are 
different from completely unaffected valves. However, it is important to 
consider other factors that may be responsible for the differences observed. 
For example, batch effects, such as analysis being performed at different times 
on different array plates with different batches of reagents could be have been 
shown to have an effect on microarray analysis[297, 298]. The normal regions of 
dissected valve and normal whole valve samples were run on the same 
Affymetrix Canine Gene 1.1ST array platform on two separate occasions so 
batch effects could be responsible for differential expression. Methods do exist 
to account for these batch effects but were beyond the scope of this study[299, 
300]. Aside from batch effects, it is conceivable that the differentially expressed 
genes are due to regional differences in cell type and gene expression between 
normal regions from diseased valves and whole normal valves. For example, 
it is established that there is a greater number of adipose cells towards the 
proximal side of the valve[36]. The removal of the diseased region, which is 
typically located on the free edge of the valve, would allow for a stronger 
signal from these cells to be detected. In future studies, performing 
transcriptomic analysis comparing the normal regions from dissected diseased 
valves and the regions same valvular regions dissected from completely 
normal valves would help to clarify what genes are differentially expressed 
due to region and which are due to disease development. To investigate the 
gene changes detected in both datasets further and establish their potential 
role in disease gene enrichment analysis was performed. 
DAVID GO term analysis of the up- and down-regulated genes in the diseased 
regions of valve compared to the normal regions of valve indicated a role for 
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up-regulation of immune-related pathways and down-regulation of lipid and 
metabolism-related pathways in the diseased regions. As mentioned in 
Chapter 3, the up-regulation of immune-related genes may be attributed to the 
immune-cell-like qualities of the activated VIC population[45, 117]. Additionally, 
the mast cells present in the valve migrate to the periphery of the diseased 
region of the valve, although it is not known how if they contribute to 
disease[30]. The down-regulation of lipid and metabolism-related genes could 
be, as discussed earlier, due to the regional differences in the valve with a 
reduced presence of adipocytes towards the free edge of the valve[36]. Genes 
related to the GO term proteinaceous extracellular matrix were down-
regulated in this analysis similar to what was seen in the analysis of whole 
valves (Chapter 3). Comparing these GO terms to the GO terms associated 
with the genes differentially expressed between normal regions of diseased 
valves with normal whole valve samples showed there was no similarity. 
Interpreting what the GO terms associated with the normal sample 
comparison is problematic, as there does not appear to be a coherent set of 
similar GO terms suggested. This indicates that the gene differences detected 
in this comparison are not being caused by a specific stimulus but may, as 
suggested earlier, be a result of a technical effect such as batch effects.  
The analysis in IPA of both datasets (section 5.3.5) likewise garnered 
interesting results. Canonical pathway analysis of the genes differentially 
expressed in diseased regions of valve showed that the top three pathways 
matched with the top three pathways identified for grade 4 valve samples in 
Chapter 3, with hepatic fibrosis/hepatic stellate cell activation being the most 
significant. As discussed in Chapter 3, the involvement of these pathways in 
disease is not immediately clear, however, it can be related to the top upstream 
regulators TGFβ1 and TNF[184, 279, 280]. These were also the top upstream 
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regulators suggested for this dataset and will be discussed further later. 
Comparing these results to those suggested for normal regions of valve 
compared to normal whole valves, as with DAVID analysis, there was a 
marked decrease in the association of pathways with the differentially 
expressed genes in this dataset, as well as the number of genes associated with 
each pathway. The top two pathways suggested for this analysis are associated 
with the up-regulation of genes in immune-related pathways. This may 
suggest that the normal regions of the diseased valves are undergoing some 
form of immune response, which was not highlighted in the GO term analysis. 
However, due to the relatively low number of genes (5 each) associated with 
these pathways it is difficult to infer biological significance. As mentioned, the 
top three upstream regulators associated with the genes differentially 
expressed in the diseased regions of valve included TNF and TGFβ1 as well as 
IFNG. This, like the canonical pathway analysis, showed a similarity with the 
grade 3 and 4 analysis presented in Chapter 3. As discussed, there is a 
relevance for both molecules in disease progression, in particular TGFβ 
signalling[45, 60, 78, 117, 124-126, 131, 176]. However, the top upstream regulator was TNF 
with TGFβ1 suggested as the second most likely candidate. TNF also has a 
potential role in disease development with some indications it could act on 
valvular endothelial cells to induce endothelial-to-mesenchymal transition 
and so could contribute to the VIC population of the valve[90, 91]. In this study, 
the microarray signal intensities (section 5.3.5) for each of the top three 
upstream regulators in disease indicates that only TGFB1 is expressed at a 
biologically relevant level with signals for IFNG and TNF indistinguishable 
from background fluorescence. Likewise, this was also the case in the by grade 
analysis. Additionally, there has been no indication in the literature of 
increases in circulating TNF in dogs affected by MMVD[301, 302]. However, signal 
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intensity does not necessarily relate to the amount of active protein in the valve 
with this warranting further investigation (see Chapter 6). All of these 
observations support a more credible role for TGFβ1 in disease regulation.  
Upstream analysis of the normal regions of dissected valves compared to 
normal whole valve samples again showed less association of suggested 
pathways to the differentially expressed genes in the dataset. This can be seen 
with the top upstream regulator, RHOX5, only having an effect on four 
differentially expressed genes in the dataset, three of which did not change in 
a way predicted by the literature. Similarly to the previous gene enrichment 
analyses, it is difficult to attribute any of the suggested molecules to a function 
in disease progression. In contrast, in network analysis the normal regions of 
dissected diseased valves compared to normal whole valve samples, 
pathways that could be related to disease development were associated. This 
includes functions such as connective tissue disorder. This could suggest that the 
transcriptomic differences between normal regions of the Whitney grade 2 
valves and normal whole valves are diseased related implying that disease 
relevant changes are occurring in the grossly normal tissue. However, taking 
into account the previous gene enrichment analysis and the lack of shared 
differentially expressed genes between the two datasets this does not appear 
to be the case. It appears far more likely that, as previously asserted, the gene 
changes between the two normal tissue samples are caused by something 
other than disease progression, such as regional differences or batch effect. 
This analysis helps to address an aim of this study, showing support that 
normal regions of diseased valves do not appear to be undergoing 
transcriptomic changes reminiscent of disease progression.  
Network analysis, as with the DAVID analysis, highlighted a role for the 
down-regulation of lipid metabolism as part of the first group of disease and 
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functions group. Alongside this, disease and functions such as tissue 
morphology and connective tissue development were also associated with the 
diseased regions of valve. Disease and functions such as these can be related 
with the extracellular matrix remodelling that occurs in disease. The majority 
of these functions seem to be controlled by TNF adding support to a role for 
this molecule in disease. However, these changes likewise could be being 
controlled by other factors and influences. For example, TGFβ1 as previously 
discussed (Chapter 1 section 1.5.1) is also heavily involved in tissue 
morphological changes and extracellular matrix development, specifically in 
valves[107, 179, 181]. Equally, down-regulation of lipid metabolism is likely being 
associated, as previously discussed, due to a reduced presence of adipocytes 
in the regions typically were disease develops rather than due to the influence 
of TNF[36]. Additionally, TGFβ signalling has been shown to induce a reduction 
in lipid metabolism as well as other metabolic processes in murine hepatocytes 
in vitro which may implicate it in the results established here[303]. 
Finally, RT-qPCR on genes of interest selected from the differentially 
expressed genes in diseased areas was performed to validate the microarray 
data. Included in these selected genes was ADAMTS9 which, like its family 
member ADAMTS5, cleaves proteoglycans and has previously been 
implicated in the development of MMVD[17, 18]. Eight of the eleven genes 
analysed here were also used to validate the whole valve microarray analysis 
(Chapter 3). RT-qPCR confirmed the up- and down-regulation of the genes of 
interest in the RNA used for microarray analysis, validating the microarray 
analysis and gene enrichment discussed in this study.  
The RT-qPCR analysis comparing dissected regions of normal valves 
indicated that there was no significantly differentially expressed genes of 
interest in the free edge regions of the normal valve. This indicates that gene 
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changes present in diseased regions of valve are disease-related and not due 
to regional differences that exist in the normal valve. This helps to support the 
contention that the differentially expressed genes detected in the ostensibly 
diseased regions of the valve are truly representative of early disease 
development. However, this analysis is only being performed on a small 
number of genes of interest, which are associated with the disease. Ideally, in 
future studies, these dissected normal valves would also be examined 
transcriptomically allowing for the elimination of genes that may be only 
differentially expressed due to regional differences.  
To conclude, this study has met its aims by:  
- Establishing transcriptomic differences that are relevant to disease 
progression in diseased regions of Whitney grade 2 valves compared to 
normal regions of the same valve  
- Showing that the normal regions of the valve do not show 
transcriptomic changes that are disease relevant when compared to 
normal whole valves, indicating they are suitable for comparison with 
the diseased regions 
- Validating that gene changes in the diseased regions are not caused by 
regional differences that would be observed in the context of a normal 
valve 
- Showing that the dissection approach is feasible for more in-depth 
research of early disease development 
This study has therefore been able to elucidate transcriptomic changes 
occurring in early disease development. Furthermore, these changes are 
broadly in agreement with changes in the late-grade diseased valves 
established in Chapter 3. Of particular interest is the role of TGFβ1, which is 
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implicated as the leading candidate as a potential upstream regulator of 
disease in the studies presented in this thesis. As such, this factor warrants 
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   Transcriptomic profiling of VICs and the 
effect of TGFβ1 signalling 
6.1 Introduction 
Mitral valves comprise of layers of multiple cell types and cell composition 
can change drastically in MMVD due to events like EndoMT and the activation 
of valvular interstitial cells (VICs). As discussed in Chapter 1 section 1.3.2, 
VICs are the predominant cell type in mitral valves and VICs are proposed to 
play a pivotal role in the development of MMVD[45, 117, 304, 305]. Studying cells in 
2D culture is an inexpensive, easy to use and reproducible method that allows 
for interrogation of the molecular and signalling aspects identified in tissue 
study[186]. In this study, in vitro analyses were conducted using VICs isolated 
from both normal and diseased mitral valves. 
It has been shown that in MMVD the normally quiescent VICs (qVICs) are 
activated into a myofibrotic-like phenotype (aVICs) which are responsible for 
perpetrating many of the pathological signs of disease, including the 
deposition of extracellular matrix components such as proteoglycans[2, 43-45, 60, 61]. 
When activated aVICs begin to express markers including ACTA2/αSMA, 
MYH10/SMemb and TAGLN/SM22 (gene/protein) [43, 45, 60, 114-116]. Additionally, 
morphological differences are apparent between the two cell types in vitro 
with qVICs organised in an orthogonal, honeycomb-like pattern with an 
elongated spindle morphology and aVICs adopting a far more disorganised 
structure with varying morphologies including a large rhomboid and a hyper-
elongated morphology [45, 113]. Using proteoglycan deposition, activation 
markers and morphological characteristics to define the qVIC and aVIC 
populations allow for comparison studies to be performed in culture on qVICs 
isolated from normal valves and aVICs isolated from diseased valves.  
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However, previous in vitro VIC studies have been hampered by the 
spontaneous activation of qVICs into aVICs under standard culture conditions 
in 10% FBS[45, 121, 306]. Recently, an optimised protocol for human aortic VICs 
using a low serum (2%) and FGF2 supplemented medium was shown to be 
able to maintain qVIC phenotype in 2D culture[138]. If this protocol is also 
successful for canine VICs, a better fundamental understanding of the 
differences between these two phenotypes could be achieved and the effect of 
molecules hypothesised to be involved in disease can be assessed.  
From the work so far presented in this thesis, roles for TGFβ signalling, TNF 
and IFNγ in the upstream regulation of early disease have been proposed 
(Chapters 3-5). In particular, TGFβ1 signalling has been consistently 
implicated in disease progression. TGFβ signalling, notably via TGFβ1, has 
been identified as an activator of qVICs into an aVIC phenotype, not only in 
culture but also potentially in MMVD[43, 122, 125, 126, 131, 133, 174, 177]. Serotonin (5HT), 
as discussed in Chapter 1 section 1.5.2, has been associated with MMVD, both 
through the induction of disease in the presence of hyper-physiological levels 
of 5HT and the consistent up-regulation of aspects of the 5HT signalling 
mechanism such as 5HTR2B (consistently up-regulated in the canine 
disease)[33, 71, 133, 150, 170-173]. However, the exact mechanism through which these 
signalling pathways may be induced in MMVD and the downstream 
signalling consequences are not fully understood. Therefore, these are prime 
targets to be investigated further in vitro.  
This study aimed to investigate VICs from normal (qVICs) and diseased 
(aVICs) valves, which are cultured according to the optimised human cell 
culture protocol[138]. VIC phenotype and activation status would be 
determined by the expression of activation hallmark genes/proteins, 
deposition of proteoglycans and morphology. The secretion of TGFβ, TNF and 
189 
 
IFNγ molecules from VICs would be examined by ELISA, to determine the 
functional protein expression of these potential upstream regulators of MMVD. 
Furthermore, this study aimed to assess the effect of TGFβ1 and 5HT 
signalling in VICs by treating qVICs with each of these factors and treating 
aVICs with inhibitors of these pathways and observing the effect on 
phenotype. If these factors contribute to the development of MMVD, it was 
expected that treated qVICs would acquire the aVIC phenotype, while 
inhibitor-treated aVICs would revert to the qVIC phenotype. Finally, as the 
previous tissue microarray analysis indicated that TGFβ1 is the most 
important signalling molecule in the development of MMVD, transcriptomic 
profile analysis of four groups, qVICs, aVICs, qVICs +TGFβ1 and aVICs + 
TGFβRI kinase inhibitor (SB431542) (which inhibits canonical SMAD2/3 
signalling) would be performed[307, 308]. 
6.2 Materials and Methods 
6.2.1 Tissue collection and cell extraction 
Tissue collection and VIC extraction were performed as described in Chapter 
2 section 2.2.1, 2.2.2 and 2.4. The animals used in this study are shown in Table 
6-1. The majority (4/6) of samples were collected and cells extracted by Dr. 
Mengmeng Liu before this study began[121].  
 
Table 6-1. Description of VICs used in this study.  
Sample ID Date sampled Dog Breed Gender Age Whitney grade Sampler
B09 09/04/2015 BEAGLE FEMALE 2y7m 0 Dr. M. Liu
B10 09/04/2015 BEAGLE MALE 2y 0 Dr. M. Liu
B12 09/11/2015 BEAGLE MALE 2y9m 0 Dr. M. Liu
D1 - LABRADOR MALE 6y 2 Dr. M. Liu
D2 03/12/2017 COLLIE MALE 10y 3 G. Markby
D3 07/12/2016 CAVALIER KING CHARLES SPANIEL MALE 15y 4 G. Markby
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6.2.2 Cell culture conditions and treatments 
Cells were maintained in DLF media, following the protocol of Latif et al, as 
described in Chapter 2 section 2.4[138]. The treatment of cells for the assessment 
of TGFβ1 and 5HT signalling was performed as described in Chapter 2 
sections 2.11.1 and 2.11.2 respectively. VICs used for microarray analysis were 
all passage 3, for other experiments VICs were between passage 2 and 6.  
6.2.3 RNA extraction and quantification and quality control 
RNA extraction from cells was performed following the protocol detailed in 
Chapter 2 section 2.3.2. RNA quantification and quality assessment were 
performed on all samples as described in Chapter 2 section 2.3.3, quality 
control for microarray by assessment of 28S and 18S rRNA and calculation of 
RIN was reserved for the samples used in the transcriptomic analysis. 
6.2.4 Affymetrix Canine Gene 1.1ST microarray analysis 
This study was performed on the remaining 12 wells of the 24 well Affymetrix 
Canine Gene 1.1ST chip also used in Chapter 5 section 5.2.3. RNA processing, 
hybridisation, post-hybridisation quality control, summarisation file creation 
and differential gene expression was performed as described in Chapter 2 
section 2.5. Statistical analysis was performed using unpaired (between qVIC 
and aVIC phenotype) and paired (within phenotype with or without 
treatment) ANOVA with differential gene expression determined as 
having >±1.5 fold change in expression and P-value <0.05. No FDR adjustment 
was applied to the transcriptomic data in this chapter.  
6.2.5 Gene Enrichment analysis 
The network analysis tool Miru (version 1.4) was utilised as described in 
Chapter 2 section 2.6.1. A sample-to-sample comparison was performed with 
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a Pearson correlation of r=0.97, this maximised the number of samples 
included whilst minimising the connection between samples. The tools 
Database for Annotation, Visualisation and Integrated Discovery (DAVID) 
version 6.8 and Ingenuity Pathway Analysis (IPA) were used as stated in 
Chapter 2 sections 2.6.2 and 2.6.3, default settings were used throughout. Gene 
list comparison was performed as described in Chapter 2 section 2.6.4. 
6.2.6 cDNA synthesis and RT-qPCR 
cDNA synthesis and RT-qPCR was performed as described in Chapter 2 
section 2.7.2-2.7.6. The primers used to investigate genes of interest in this 
study are summarised in Table 6-2. ACTA2, HTR2B, TAGLN and MYH10 were 
used for VIC characterisation and assessment of 5HT signalling. For 
microarray validation, all genes of interest were investigated. All gene 
quantification was normalised to MRPS25, RPL32 and GAPDH. 
 
Table 6-2. Primers designed and optimised for use in this study. 
6.2.7 Protein extraction and quantification and western blotting 
Gene Symbol Forward Primer Sequence Reverse Primer Sequence Product Length Optimum TM ºC Primer Efficiency %
ACTA2 5'CGGCTACTCCTTTGTGACG3' 5'CGTGGCCATCTCGTTCTC3' 100 58 102.2
HTR2B 5'CCAATCCAGGCCAATCAAAG3' 5'CAGGTGATGTTGCTTGGGTT3' 143 59 104.8
TAGLN 5'GACATGTTCCAGACCGTCGA3' 5'CAATGACGTGCTTTCCCTCC3' 199 59 106.7
MYH10 5'TGCCAACAATGTCCTTTCCG3' 5'GCCTCCAATCCAGACTGAGT3' 148 59 93
HBEGF 5'CTGTGGTGCTGTCATCTGTC3' 5'TGGGAAGTAGTCATGCCTAACT3' 124 61 103.8
MAL 5'CTGCCCTGTTTTACCTCAGC3' 5'GGACCACGTACAGCAGAGT3' 141 61 99.1
BMPER 5'TTTCTGGCATATACTCGGGC3' 5'CAGTTGTCACAGGTCTTGGC3' 143 60 105.2
VCAM 5'GATGCGGGAGTGTACGAATG3' 5'GCACAATAAAGCACGAGTAGTTC3' 131 60 97.1
PDK4 5'CCAATTTCTCGTCTCTATGCCA3' 5'GGCTGATTTGTTAAAGACTGGGA3' 144 60 95.6
FAP 5'TCAAATGTGGGATAGCAGTGG3' 5'GGAGGCCCATGAATCGTTCT3' 81 60 106.3
SLC10A6 5'GCTGTTGGATGGGTTTCTCA3' 5'TCCAAGAAAGCACCAGTCTCT3' 147 58 101.7
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Protein extraction from cells, protein quantification and western blot 
assessment of αSMA, SM22 and β-actin expression were performed as 
described in Chapter 2 section 1.8.  
6.2.8 ELISAs 
Enzyme-linked immunosorbent assays (ELISAs) were performed on the 
media supernatants from cells cultured for 72 hours prior to collection. qVICs 
and aVICs were approximately 60-70% confluent when first plated and 80-90% 
confluent when supernatants were collected for assessment. The ELISA 
protocols for TNF, IFNγ, TGFβ1, 2 and 3 are described in Chapter 2 section 2.9 
(sub-sections 2.9.1-5 respectively) with values normalised to total cellular 
protein (per µg), measured by the Quick Start Bradford protein assay (Bio-Rad, 
Cat. No. 5000201) of the cell sample, from which the supernatant was obtained. 
A TGFβ1 assay was performed by Dr. Karen Tan, using the same method, 
except that the cells had been in culture for 120 hours.  
6.2.9 Proteoglycan assay 
Quantification of proteoglycan deposition in supernatants from cells in this 
study was performed as described in Chapter 2 section 2.10. Supernatants 
were collected from cells cultured for 72 hours. Where possible, values were 
normalised to the total cellular protein (µg) of the cell sample from which the 
supernatant was collected (sections 6.3.1 and 6.3.10). When samples were used 
for downstream microarray analysis, values were normalised to cell numbers 
(cellx105) of the sample from which the supernatant was collected (section 
6.3.9).  
6.2.10 Microscopy and image capture 
Microscopy and cell imaging were performed as described in Chapter 2 




6.3.1 qVIC and aVIC characterisation 
VICs isolated from normal valves (expected to be primarily composed of 
qVICs) and from diseased valves (expected to be mostly aVICs), were assessed 
for gene and protein level expression of activation markers (hallmarks of 
disease) as well as for the deposition of proteoglycans and cell morphology. 
Expression of ACTA2, TAGLN and MYH10 genes was assessed by RT-qPCR 
for the presumed qVICs and aVICs. All genes were found to be significantly 
up-regulated in the presumed aVICs in comparison to the presumed qVICs 
with a 40.7 fold increase in expression for ACTA2 (P-value 0.006) (Figure 6-1A), 
4.3 fold increase for TAGLN (P-value 0.006) (Figure 6-1B) and 4 fold increase 
for MYH10 (P-value 0.047) (Figure 6-1C). Protein expression of αSMA 
(ACTA2), SM22 (TAGLN) and β-actin were assessed by western blot (Figure 
6-1D). Bands were detectable for αSMA in the three presumed aVIC samples 
(particularly D3); likewise, bands were detectable for SM22 in all samples, 
strongly in D2 and D3, but also in B09. β-Actin expression indicated equal 
loading between samples. Proteoglycan (PG) deposition was significantly 
greater in the media of presumed aVICs compared to qVICS (P-value 0.002) 
(Figure 6-1E). Morphological assessment of the presumed qVICs (Figure 6-1F) 
and aVICs (Figure 6-1G) identified differences in morphology consistent with 
the phenotypes previously reported[45, 113], with the presumed qVICs being 
more spindle-like and having a more uniform honeycomb-like distribution, 
and the presumed aVICs having a disorganised structure with larger 
rhomboid and hyper-elongated cells present. Collectively, these differences 
were consistent with the literature and indicate that the cells in culture 
recapitulate the cells in vivo[2, 45, 113, 121]. Henceforth these cultured cells will be 




Figure 6-1. qVIC and aVIC characterisation. (A) Relative fold change 
expression in ACTA2. (B) Relative fold change expression in TAGLN. (C) 
Relative fold change expression in MYH10. (D) Western blot images for 
αSMA, SM22 and β-Actin in the qVICs (B09, B10 and B12) and aVICs (D1-
3). (E) Comparison of proteoglycan (PG) deposition between qVICs and 
aVICs. (F) Representative morphology image of qVICs. (G) Representative 
morphology image of aVICs. * = P-value <0.05, ** = P-Value <0.01, scale bar 
= 100µm. n=3 per group. 
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6.3.2 qVIC and aVIC secretion of TGFβ1-3, TNF and IFNγ 
ELISAs were performed on the supernatants from qVICs and aVICs, after 72 
hours in culture, to detect IFNγ, TNF, TGFβ1, TGFβ2 and TGFβ3. IFNγ was at 
an undetectable level, below the sensitivity of the assay, in both qVIC and 
aVIC supernatants suggesting little to no secretion of this factor from VICs. 
There was no significant difference in TNF, TGFβ1, TGFβ2 and TGFβ3 
expression comparing qVICs and aVICs (Table 6-3). However, the TGFβ1 
level exceeded any of the other molecules assessed. A TGFβ1 ELISA 
performed on the same primary lines of VICs after 120 hours by Dr Karen Tan 
showed a significant increase (P-value 0.024) of TGFβ1 deposited by aVICs 
(9.78 pg/mL/µg protein ±0.43 S.E.) in the supernatant compared to qVICs (3.19 
pg/mL/µg protein ±0.26 S.E.) (Figure 6-2).  
 
Table 6-3. Summary of ELISA data. Quantification of the concentration of 
TNF and TGFβ1-3 in the supernatants of qVICs and aVICs. n=3 per group. 
 
Figure 6-2. Bar chart of TGFβ1 ELISA performed after 120 hours in culture. 
n=3 per group. * = P-value <0.05 
Molecule qVICs [pg/ml/µg protein] aVICs [pg/ml/µg protein] P-value
TNF 0.14 ±0.0084 S.E. 0.11±0.029 S.E. 0.43
TGFβ1 1.12 ±0.14 S.E 1.8 ±0.51 S.E. 0.331
TGFβ2 0.31 ±0.0084 S.E. 0.4 ±0.12 S.E. 0.526
TGFβ3 0.05 ±0.0064 S.E. 0.04 ±0.0095 S.E. 0.372
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6.3.3 RNA quantification and quality assessment for microarray  
RNA to be used for microarray analysis of VICs was extracted from cells and 
quantified. The concentrations along with 260/280 and 260/230 absorbance 
ratios and RNA integrity number (RIN), were recorded in Table 6-4. RNA 
concentration ranged from 369.5 to 1358.5 ng/µL. A statistical difference was 
found when comparing average RNA concentrations of qVICs + vehicle (434.6 
±76 ng/µL) with qVICs + TGFβ1 (638.7 ±75.6 ng/µL) using a paired t-test (P-
value 0.015). However, no significant difference was observed when 
performing a t-test comparing qVICs + vehicle with aVICs + vehicle (993 ±187 
ng/µL) (P-value 0.109) or comparing aVICs + vehicle with aVICS + SB431542 
(1081 ±145 ng/µL) (P-value 0.481). Absorbance ratios were all within the 
acceptable reference range (>1.8) for both 260/280 and 260/230, indicating that 
the extractions did not contain contaminants. Gel electrophoresis images 
(Figure 6-3) displayed the 28S and 16S rRNA in each sample with RIN 
calculated and shown. All samples passed >7 cut-off for microarray analysis.  
  
Table 6-4. Concentration, 260/280 and 260/230 absorbance reading and RIN 
for each VIC sample.   
Sample ID RNA  [ng/µl] 260/280 260/230 RIN
B09 + Vehicle 586.1 2.1 2.06 10
B10 + Vehicle 369.5 2.04 1.96 10
B12 + Vehicle 348.1 2.06 1.96 10
B09 + TGFβ1 777.2 2.09 2.2 9.8
B10 + TGFβ1 621.7 2.1 2.08 10
B12 + TGFβ1 517.1 2.12 2.07 10
D1 + Vehicle 878.2 2.08 2.02 9.6
D2 + Vehicle 1358.5 2.08 2.1 9.3
D3 + Vehicle 742.6 2.1 1.93 10
D1 + SB431542 1157.9 2.09 2.19 10
D2 + SB431542 1285.2 2.08 1.96 10




Figure 6-3. Gel electrophoresis images visualising the 28S (indicated by the 
top arrow) and 16S (indicated by the bottom) rRNA intensity in each sample. 
6.3.4 Microarray post-hybridisation quality control 
Post-hybridisation analysis was performed to assess the quality of gene 
expression data generated from microarray analysis of the submitted samples. 
All wells on the array showed the correct concentration of spike in and 
labelling controls indicated that the arrays had been performed correctly. After 
Robust MultiArray Average (RMA) and gene-level normalisation, log 
expression signal was plotted (Figure 6-4). All samples showed a similar log 
expression signal. Signal intensity distribution for each of the samples was 
analysed and presented as a log2 signal line graph (Figure 6-5). This shows log 
signal intensity from 0-13.62 with a similar distribution pattern exhibited for 
all samples. There was a peak between 2-3.5 log signal intensity before a 
decline in genes expressing above this signal intensity until no genes were 
being expressed at a greater intensity than 13.62. This figure shows that to 
remove the effect of background on this dataset, genes expressed below 3.5 log 




Figure 6-4. Post-RMA signal intensity boxplots for each sample. 
 
Figure 6-5. Log2 signal line graph for samples. Each line represents an RNA 
sample with the X-axis plotting signal intensity and Y-axis plotting the 
number of probes on the array with that signal intensity. The higher the line 
is on the Y-axis, the greater the number of probes showing that signal 




Principal component analysis (PCA) and sample-to-sample analysis in Miru 
(r=0.97) were performed. In PCA analysis (Figure 6-6), qVICS + vehicle (red 
squares) and aVICs + vehicle (yellow squares) clustered the furthest apart for 
all samples. Treatment with TGFβ1 or SB431542 (TGFβRI kinase inhibitor) 
caused a change in the transcriptomic profile in the VICs with qVICs treated 
with TGFβ1 (blue squares) shifting towards aVIC + vehicle side of the plot and 
aVICs treated with SB431542 (green squares) shifting towards the qVIC + 
vehicle side of the plot. Likewise, in the sample-to-sample analysis (Figure 6-7), 
a similar distribution of the samples can be seen with samples within 
treatment and cell phenotype groups clustering together. Collectively these 
results indicate that all samples are suitable for downstream analysis. 
 
Figure 6-6. PCA plot comparing qVIC and aVIC samples with and without 
treatment. Red squares represent qVICs + vehicle, yellow squares represent 
aVICs + vehicle, blue squares represent qVICs + TGFβ1 and green squares 





Figure 6-7. Sample-to-sample correlation (r=0.97) of qVICs and aVICs with 
and without treatment. Red nodes represent qVICs + vehicle, yellow nodes 
represent aVICs + vehicle, blue nodes represent qVICs + TGFβ1 and green 
nodes represent aVICs + SB431542.  
6.3.5 Differential expression of genes  
Although various comparisons could be made between groups, the most 
pertinent for this study were between qVICs and aVICs and on the effect of 
TGFβ1 treatment or SB431542 treatment on qVICs and aVICs respectively. 
Differential gene expression for these groups is illustrated in Figure 6-8. There 
were 275 genes differentially expressed between qVICs treated with TGFβ1 
and qVICs with vehicle (144 down-regulated with TGFβ1 treatment and 131 
up-regulated) (Figure 6-8A). a total of 236 genes showed altered expression in 
aVICs treated with SB431542 compared to aVICs with vehicle (115 down-
regulated with SB431542 treatment and 121 up-regulated) (Figure 6-8B). there 
were 902 genes differentially expressed in aVICs compared to qVICs (406 
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down-regulated in aVICs and 496 up-regulated) (Figure 6-8C). The full gene 
lists for these analyses can be found in Appendix IV: Chapter 6 Tables S1-3. 
 
Figure 6-8. Volcano plots comparing qVICs to aVICs and the effect of 
treatments on VICs. Red dots represent up-regulated genes, green represent 
genes that were down-regulated and uncoloured are genes which do not 
pass the differential expression criteria. The X-axis shows fold change value 
and the Y-axis shows the P-value. (A) Genes differentially expressed 
between qVICs + vehicle and qVICs treated with TGFβ1. (B) Genes 
differentially expressed between aVICs + vehicle and aVICs treated with 
SB431542. C, Differentially expressed genes between qVICs and aVICs. 
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To investigate the similarity between genes differentially expressed in qVICs 
treated with TGFβ1 and aVICs with vehicle (both compared to qVICs with 
vehicle) gene lists were compared to one another. There were 102 genes found 
to be shared between the two datasets (Figure 6-9) with only one of these not 
showing the same direction of fold change (mastermind-like domain-
containing protein 1 (MAMLD1), down-regulated -1.52 fold in qVICs treated 
with TGFβ1 and up-regulated 1.56 fold in aVICs).  
 
Figure 6-9. Venn diagram illustrating the number of shared differentially 
expressed genes in qVICs treated with TGFβ1 and aVICs with vehicle. In 
the left orange circle, the number of differentially expressed genes for 
qVICs treated with TGFβ1 and not shared with aVICs is shown. In the right 
purple circle, the number of differentially expressed for aVICs samples and 
not shared with qVICs treated with TGFβ1 is shown. In the centre, the 
number of shared genes between the two datasets is shown. 
To complement the ELISA data presented earlier (section 6.3.2) further, the 
gene signal intensities of TNF, IFNγ and TGFβ1-3 were examined for each cell 




Table 6-5. Signal intensity values for each molecule examined by ELISA.  
6.3.6 DAVID GO term analysis 
DAVID GO term enrichment analysis of the gene lists derived was performed. 
The top ten GO terms for up- and down-regulated genes for qVICs treated 
with TGFβ1 compared to qVICs and vehicle are summarised in Table 6-6, 
highlighting a role for extracellular matrix regulation by these genes. The top 
ten GO terms for up- and down-regulated genes for aVICs treated with 
SB431542 compared to aVICs and vehicle is summarised in Table 6-7, 
highlighting a downregulation of mesenchymal related GO-terms. The top ten 
GO terms for up- and down-regulated genes for aVICs and vehicle compared 
to qVICs and vehicle are summarised in Table 6-8 highlighting an up-
regulation in DNA replication. Finally, the top ten GO terms for up-regulated 
genes and the one GO term associated with down-regulated genes for the 
shared genes in aVICs and TGFβ1 treated qVICs is summarised in Table 6-9, 
highlighting that the shared genes are associated with extracellular space and 
smooth muscle cell proliferation amongst other GO terms. 
qVIC + vehicle qVIC + TGFβ1 aVIC + vehicle aVIC + SB431542
TNF 4.89 4.72 4.5 4.78
IFNG 5.16 7.26 4.85 5.13
TGFβ1 296.11 385.34 359.53 344.89
TGFβ2 537.45 442.64 359.53 250.73






Table 6-6. Functional analysis chart summary of the top ten GO terms 
associated with up- or down-regulated genes in qVICs treated with TGFβ1 
compared to qVICs and vehicle.  
Category Term Gene count P-value FDR
GOTERM_BP_DIRECT Positive regulation of release of cytochrome c from mitochondria 4 2.64E-04 0.38132
GOTERM_CC_DIRECT Extracellular matrix 5 0.00387 4.2409
GOTERM_CC_DIRECT Extracellular space 12 0.01687 17.3279
GOTERM_BP_DIRECT Cholesterol metabolic process 3 0.01837 23.5133
GOTERM_BP_DIRECT Osteoblast differentiation 4 0.01841 23.5522
GOTERM_MF_DIRECT Acylglycerophosphocholine O-acyltransferase activity 2 0.02591 26.6683
GOTERM_MF_DIRECT GTPase activator activity 5 0.02659 27.2671
GOTERM_CC_DIRECT Extracellular exosome 22 0.02729 26.6109
GOTERM_CC_DIRECT Collagen trimer 3 0.03073 29.4616
GOTERM_CC_DIRECT Cytoplasm 25 0.03698 34.3791
GOTERM_BP_DIRECT Actomyosin structure organization 4 7.14E-04 1.05707
GOTERM_CC_DIRECT Cell surface 10 8.44E-04 0.96142
GOTERM_CC_DIRECT Integral component of plasma membrane 15 0.00108 1.23267
GOTERM_BP_DIRECT Positive regulation of Ras protein signal transduction 3 0.0048 6.90528
GOTERM_BP_DIRECT Cardiac conduction system development 2 0.01617 21.529
GOTERM_MF_DIRECT E-box binding 3 0.01709 18.5306
GOTERM_CC_DIRECT Extracellular space 13 0.01817 18.9324
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 5 0.01976 25.684
GOTERM_CC_DIRECT Cell body 3 0.02099 21.5577






Table 6-7. Functional analysis chart summary of the top ten GO terms 
associated with up- or down-regulated genes in aVICs treated with 
SB431542 compared to aVICs and vehicle. 
Category Term Gene count P-value FDR
GOTERM_CC_DIRECT Lysosome 6 0.001142 1.24282
GOTERM_BP_DIRECT Angiogenesis 5 0.00706 9.51341
GOTERM_BP_DIRECT Positive regulation of TOR signaling 3 0.01016 13.4181
GOTERM_BP_DIRECT Nephron tubule epithelial cell differentiation 2 0.013912 17.9349
GOTERM_CC_DIRECT Mitochondrial membrane 3 0.01667 16.8095
GOTERM_MF_DIRECT Creatine kinase activity 2 0.019243 20.4883
GOTERM_CC_DIRECT Gtr1-Gtr2 GTPase complex 2 0.0197 19.5725
GOTERM_BP_DIRECT Renal tubule morphogenesis 2 0.020796 25.6583
GOTERM_BP_DIRECT Epithelial cell proliferation involved in renal tubule morphogenesis 2 0.020796 25.6583
GOTERM_BP_DIRECT Glomerulus morphogenesis 2 0.020796 25.6583
GOTERM_BP_DIRECT Collagen fibril organization 6 1.28E-06 0.00187
GOTERM_MF_DIRECT Extracellular matrix structural constituent 5 6.49E-05 0.07331
GOTERM_BP_DIRECT Positive regulation of epithelial to mesenchymal transition 4 6.09E-04 0.88332
GOTERM_CC_DIRECT Extracellular space 14 0.001122 1.25424
GOTERM_CC_DIRECT Stress fiber 4 0.001916 2.13231
GOTERM_CC_DIRECT Extracellular matrix 5 0.002899 3.21056
GOTERM_BP_DIRECT Transforming growth factor beta receptor signaling pathway 4 0.004864 6.85297
GOTERM_BP_DIRECT Positive regulation of release of cytochrome c from mitochondria 3 0.007117 9.87749
GOTERM_CC_DIRECT Focal adhesion 7 0.008523 9.17272






Table 6-8. Functional analysis chart summary of the top ten GO terms 
associated with up- or down-regulated genes in aVICs and vehicle 
compared to qVICs and vehicle. 
 
Table 6-9. Functional analysis chart summary of the top ten GO terms 
associated with up-regulated genes and the GO term associated with down-
regulated genes shared in aVICs with vehicle and TGFβ1 treated qVICs.  
Category Term Gene count P-value FDR
GOTERM_MF_DIRECT ATP binding 73 8.12E-13 1.13E-09
GOTERM_BP_DIRECT DNA replication initiation 11 8.27E-11 1.33E-07
GOTERM_BP_DIRECT Chromosome segregation 14 1.53E-10 2.45E-07
GOTERM_CC_DIRECT Kinesin complex 13 3.38E-09 4.46E-06
GOTERM_BP_DIRECT Mitotic sister chromatid segregation 9 1.37E-08 2.20E-05
GOTERM_BP_DIRECT Microtubule-based movement 14 1.54E-08 2.47E-05
GOTERM_CC_DIRECT Midbody 15 3.16E-08 4.17E-05
GOTERM_CC_DIRECT Nuclear chromosome, telomeric region 15 9.51E-08 1.26E-04
GOTERM_CC_DIRECT Nucleoplasm 67 2.13E-07 2.82E-04
GOTERM_BP_DIRECT Cell division 11 5.07E-07 8.14E-04
GOTERM_CC_DIRECT Intracellular 36 3.71E-06 0.00466
GOTERM_CC_DIRECT Lysosome 12 6.38E-05 0.08019
GOTERM_BP_DIRECT Small GTPase mediated signal transduction 15 7.56E-05 0.12256
GOTERM_BP_DIRECT PDGF receptor signaling pathway 6 9.44E-05 0.15311
GOTERM_BP_DIRECT intracellular signal transduction 18 1.61E-04 0.26021
GOTERM_MF_DIRECT Guanyl-nucleotide exchange factor activity 7 9.98E-04 1.33324
GOTERM_MF_DIRECT Semaphorin receptor activity 4 0.00208 2.753
GOTERM_BP_DIRECT Vasculogenesis 6 0.00263 4.18228
GOTERM_MF_DIRECT Rho guanyl-nucleotide exchange factor activity 7 0.00295 3.88544
GOTERM_CC_DIRECT Endosome 9 0.00815 9.77246
Up-regulated 
Down-regulated
Category Term Gene count P-value FDR
GOTERM_BP_DIRECT Retina vasculature morphogenesis in camera-type eye 2 0.01613 19.6781
GOTERM_CC_DIRECT Cell surface 5 0.02198 20.9497
GOTERM_BP_DIRECT Insulin-like growth factor receptor signaling pathway 2 0.02569 29.5769
GOTERM_CC_DIRECT Plasma membrane 11 0.04139 36.0558
GOTERM_CC_DIRECT Microtubule 3 0.04523 38.7122
GOTERM_CC_DIRECT Extracellular space 7 0.04575 39.0637
GOTERM_BP_DIRECT Positive regulation of smooth muscle cell proliferation 2 0.06301 58.3991
GOTERM_BP_DIRECT Regulation of multicellular organism growth 2 0.06606 60.1855
GOTERM_CC_DIRECT Intracellular 6 0.07053 53.8688
GOTERM_BP_DIRECT Response to heat 2 0.07212 63.5318




6.3.7 IPA analysis  
IPA analysis was performed on TGFβ1-treated qVICs compared to vehicle-
treated qVICs, the SB431542-treated aVICs compared to aVICs and vehicle, 
aVICs and vehicle compared to qVICs and vehicle and the shared genes in the 
aVIC and TGFβ1-treated qVICs datasets. In the shared analysis, both fold 
change differences associated with each gene was uploaded in the same 
analysis (i.e. fold change associated with aVICs and fold change associated 
with TGFβ1-treated qVICs). The numbers of mapped and unmapped genes in 
these analyses are summarised in Table 6-10. 
 
Table 6-10. Mapped unmapped and total number of genes submitted to IPA 
for analysis for each dataset. 
Canonical pathway analysis was performed with 29, 37, 32 and 44 pathways 
being statistically significantly (P-value <0.05) associated with the TGFβ1-
treated qVICs compared to qVICs and vehicle, the SB431542-treated aVICs 
compared to aVICs and vehicle, aVICs with vehicle compared to qVICs with 
vehicle and the shared genes in the aVIC and TGFβ1-treated qVICs datasets, 
respectively. The top three pathways associated with each of the four datasets 
are shown in Table 6-11. 
Analysis Mapped Genes Unmapped genes Total genes
TGFβ1 treated qVICs 273 2 275
SB431542 treated aVICs 200 36 236
aVICs compared to qVICs 855 47 902




Table 6-11. Summary of top three canonical pathways associated with each 
dataset. The number of genes up- and down-regulated in each pathway as 
well as the total number of genes changed in each pathway is given. The P-
value score gives the association of the gene list to the pathway. 
Upstream regulator analysis likewise found an association for 1015, 837, 991 
and 1034 molecules with the TGFβ1-treated qVICs compared to qVICs and 
vehicle, the SB431542-treated aVICs compared to aVICs and vehicle, aVICs 
and vehicle compared to qVICs and vehicle and the shared genes in the aVICs 
and TGFβ1-treated qVICs datasets respectively (P-value <0.05). The top three 
molecules associated with each dataset are shown in Table 6-12. In both 
treatment datasets, the top predicted upstream regulator was TGFβ1, with its 
activation seen in the qVICs treated with TGFβ1 and inhibition observed in 
the aVICs treated with SB431542. These two pathways are schematised in 
Figure 6-10 and Figure 6-11. The top upstream regulators in aVICs compared 
to qVICs are predominately involved in cell cycle control and apoptosis, 
including E2F4 (number 1), CDKN1A (number 2) and TP53 (number 5). E2F4 
was predicted as the top upstream regulator and is schematised in Figure 6-12, 
but no predictions could be made as to the effect it would have on genes in the 
Analysis Canonical Pathway Up-regulated genes Down-regulated genes Genes changed in pathway P-value
Hepatic Fibrosis/Hepatic Stellate Cell Activation 6 4 10/160 0.00076
Integrin Signaling 3 8 11/196 0.00102
Role of Tissue Factor in Cancer 2 6 8/112 0.00107
Superpathway of Cholesterol Biosynthesis 10 0 10/22 1E-12
Cholesterol Biosynthesis I 0 7 7/11 1.3E-10
Cholesterol Biosynthesis II 0 7 7/11 1.3E-10
Cell Cycle Control of Chromosomal Replication 15 0 15/49 1.7E-09
Role of BRCA1 in DNA Damage Response 15 0 15/73 5.9E-07
Mitotic Roles of Polo-Like Kinase 12 1 13/60 1.7E-06
Superpathway of Cholesterol Biosynthesis 3 0 3/28 0.0002
Zymosterol Biosynthesis 2 0 2/6 0.00025
Axonal Guidance Signaling 4 4 8/457 0.00059
TGFβ1 treated qVICs
SB431542 treated aVICs
aVICs compared to qVICs
Shared aVICs and TGFβ1 treated qVICs
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dataset. CDKN1A was also schematised (Figure 6-13) illustrating an overall 
inhibition of this pathway. The upstream regulators associated with genes 
shared in the aVICs and TGFβ1-treated qVICs showed TNF and TGFβ1 to be 
among the top suggested pathways. TNF showed a slight inhibition (-0.244 Z-
score) whereas TGFβ1 showed an activation (2.009 Z-score), and this pathway 
is illustrated in Figure 6-14.  
 
Table 6-12. Summary of the top three upstream regulators associated with 
the differentially expressed genes lists for each dataset. For each upstream 
regulator, the molecule type, Z-score and P-value are given. 
Analysis Upstream Regulator Molecule Type Activation Z-score P-value
TGFB1 Growth factor 4.029 2.04E-12
TNF Cytokine 1.18 1.38E-11
HGF Growth factor -0.623 1.47E-11
TGFB1 Growth factor -3.946 3.06E-12
GATA4 Transcription regulator 1.525 4.95E-10
AGT Growth factor -0.808 1.48E-09
E2F4 Transcription regulator  5.85E-33
CDKN1A Kinase -2.669 2.75E-28
dextran sulfate Chemical drug 0.422 3.98E-28
TNF cytokine -0.244 1.31E-08
TGFB1 growth factor 2.009 1.39E-08
dexamethasone chemical drug 0.861 3.52E-08
Shared aVICs and TGFβ1 treated qVICs
TGFβ1 treated qVICs
SB431542 treated aVICs




Figure 6-10. The network of genes that are differentially expressed in qVICs 
treated with TGFβ1 compared to qVICs and vehicle that are downstream of 
TGFβ1 signalling. TGFβ1 is shown to have its effect from the extracellular 
space on the genes in their cellular location. Genes are coloured red and 
green to represent up- or down-regulation in the dataset. Dotted lines 
connecting TGFβ1 to these genes show the expected effect of TGFβ1 
signalling: orange - activation, blue - inhibition, yellow - result inconsistent 




Figure 6-11. The network of genes that are differentially expressed in aVICs 
treated with SB431542 compared to aVICs with vehicle that are downstream 
of TGFβ1 signalling. TGFβ1 is shown to have its effect from the extracellular 
space on the genes in their cellular location. Genes are coloured red and 
green to represent up- or down-regulation in the dataset. Dotted lines 
connecting TGFβ1 to these genes show the expected effect of TGFβ1 
signalling: orange - activation, blue - inhibition, yellow - result inconsistent 




Figure 6-12. The network of genes that are differentially expressed in aVICs 
with vehicle compared to qVICs with vehicle that are downstream of E2F4. 
E2F4 is shown to have its effect from the nucleus on the genes in their 
cellular location. Genes are coloured red and green to represent up- or 
down-regulation in the dataset. Grey lines connecting E2F4 to these genes 




Figure 6-13. The network of genes that are differentially expressed in aVICs 
with vehicle compared to qVICs with vehicle that are downstream of 
CDKN1A. CDKN1A is shown to have its effect from the nucleus on the 
genes in their cellular location. Genes are coloured red and green to 
represent up- or down-regulation in the dataset. Lines connecting CDKN1A 
to these genes show the expected effect of CDKN1A signalling: orange - 





Figure 6-14. The network of genes that are shared in aVICs with vehicle and 
qVICs treated with TGFβ1 that are downstream of TGFβ1 signalling. TGFβ1 
is shown to have its effect from the extracellular space on the genes in their 
cellular location. Genes are coloured red and green to represent up- or 
down-regulation in the dataset. Dotted lines connecting TGFβ1 to these 
genes show the expected effect of TGFβ1 signalling: orange - activation, 





The network analysis highlighted the disease and function annotations 
associated with each of the datasets. The top five associated with the genes 
differentially expressed between TGFβ1-treated qVICs compared to qVICs 
with vehicle are shown in Table 6-13. The Cellular movement, cardiac arrhythmia 
and cardiovascular disease functions are also schematised in Figure 6-15. The top 
five disease and function networks associated with the genes differentially 
expressed between aVICs treated with SB431542 compared to aVICs with 
vehicle are given in Table 6-14, and the cardiovascular disease, hereditary disorder, 
organismal injury and abnormalities disease function are further schematised in 
Figure 6-16. The top five networks associated with the genes differentially 
expressed between aVICs with vehicle and qVICs with vehicle are shown in 
Table 6-15, with cell cycle, cellular movement and Cancer schematised in Figure 
6-17. Lastly, the top five disease and function networks associated with genes 
shared between aVICs with vehicle and qVICs treated with TGFβ1 and are 
shown in Table 6-16, and cell morphology, cardiovascular disease and development 










Table 6-13. Summary of the top five disease and function networks 
associated with the genes differentially expressed between TGFβ1 treated 
qVICs compared to qVICs with vehicle. 
 
Figure 6-15. Schematic of the Cellular movement, cardiac arrhythmia and 
cardiovascular disease function network. Genes are shown in their protein 
cellular location with red indicating up-regulation, green down-regulation 
and un-coloured showing no change in the dataset. 
Top disease and function
Cancer, Endocrine System Disorders, Organismal Injury and Abnormalities
Cellular Movement, Organismal Survival, Cancer
Cellular Movement, Cardiac Arrythmia, Cardiovascular Disease
Cancer, Organismal Injury and Abnormalities, Reproductive System Disease




Table 6-14. Summary of the top five disease and function networks 
associated with the genes differentially expressed between SB431542 
treated aVICs compared to aVICs with vehicle. 
 
Figure 6-16. Schematic of the Cardiovascular disease, hereditary disorder, 
organismal injury and abnormalities function network. Genes are shown in 
their protein cellular location with red indicating up-regulation, green 
down-regulation and un-coloured showing no change in the dataset. 
Top disease and function
Dermatological Diseases and Conditions, Inflammatory Disease, Organismal Injury and Abnormalities
Drug Metabolism, Small Molecule Biochemistry, Cellular Assembly and Organization
Cardiovascular Disease, Hereditary Disorder, Organismal Injury and Abnormalities
Cell Morphology, Glomerular Injury, Organ Morphology




Table 6-15. Summary of the top five disease and function networks 
associated with the genes differentially expressed between aVICs with 
vehicle compared to qVICs with vehicle. 
 
Figure 6-17. Schematic of the Cell cycle, cellular movement and Cancer 
function network. Genes are shown in their protein cellular location with 
red indicating up-regulation, green down-regulation and un-coloured 
showing no change in the dataset. 
Top disease and function
Cell Cycle, Cellular Movement, Cancer
Cell Cycle, Reproductive System Development and Function, Cellular Assembly and Organization
Cellular Assembly and Organization, Connective Tissue Disorders, Developmental Disorder
Cellular Assembly and Organization, DNA Replication, Recombination, and Repair, Cell Cycle




Table 6-16. Summary of the top five disease and function networks 
associated with the genes shared between aVICs with vehicle and qVICs 
treated with TGFβ1.  
 
Figure 6-18. Schematic of the Cell morphology, cardiovascular disease and 
development disorder disease and function network. Genes are shown in 
their protein cellular location with red indicating up-regulation, green 
down-regulation and un-coloured showing no change in the dataset 
Top disease and function
Cell Morphology, Cardiovascular Disease, Developmental Disorder
Cancer, Endocrine System Disorders, Organismal Injury and Abnormalities
Connective Tissue Disorders, Organismal Injury and Abnormalities, Cell Death and Survival
Cellular Movement, Cellular Development, Cellular Growth and Proliferation
Cell-To-Cell Signaling, Hematological System Development and Function, Hematopoiesis
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6.3.8 RT-qPCR microarray validation 
Validation of the microarray results by RT-qPCR was performed on selected 
genes of interest that showed a significantly different expression in at least one 
of the comparisons performed in the microarray analysis. Genes were selected 
based on their relevance to the disease myofibroblastic phenotype and 
activation (ACTA2, TAGLN and MYH10), differential expression described in 
the previous chapters (HTR2B, HBEGF and SLC10A6) or relative high fold 
change difference (BMPER, VCAM1, PDK4 and FAP). The microarray results 
for these genes are shown in Table 6-17 and the corresponding RT-qPCR 
results are shown in Table 6-18. Almost all results were in agreement between 
microarray and RT-qPCR with differences only seen in aVICs compared to 
qVICs, which are highlighted in yellow in the two tables. The HTR2B 
expression did not reach significance in the microarray analysis but did by RT-
qPCR. BMPER did the opposite with significance reached in microarray 
analysis but not in RT-qPCR analysis.  
 
Table 6-17. Microarray fold change and P-value for genes selected for 
microarray validation. Highlighted in yellow are instances where the 
significance of these results did not match with RT-qPCR validation.  
Fold change P-value Fold change P-value Fold change P-value
ACTA2 1.95 0.0437 -6.36 0.0184 7.69 0.0051
TAGLN 2.1 0.0228 -2.58 0.034 3.78 0.0088
MYH10 -1.13 0.7948 -1.34 0.5271 2.18 0.0297
HTR2B 3.71 0.0176 -5.16 0.0308 3.35 0.1184
HBEGF -1.73 0.0209 2.1 0.0003 -1.67 0.0085
BMPER -3.09 0.0064 1.6 0.4142 -3.98 0.0257
VCAM1 -1.83 0.0004 1.59 0.1007 -2.79 0.0076
PDK4 -5.11 0.0021 -1.78 0.2011 -7.89 0.0009
FAP 4.71 0.0032 -6.94 0.0141 6.73 0.0063
SLC10A6 -1.96 0.0481 -1.17 0.993 -2.14 0.0109
Gene name




Table 6-18. RT-qPCR fold change and P-value for genes selected for 
microarray validation. Highlighted in yellow are instances where the 
significance of these results did not match with microarray data. Normalised 
to GAPDH, MRPS25 and RPL32. 
6.3.9 Cell morphology and proteoglycan deposition in samples submitted 
for microarray  
To further characterise the effects of TGFβ1 and SB431452 on the VIC 
phenotypes, cell morphology and proteoglycan deposition were assessed. 
Morphologically, qVICs treated with TGFβ1 (Figure 6-19B) showed a far more 
disorganised, clustered structure and hyper-elongated morphology 
(reminiscent of the aVIC morphology observed in section 6.3.1) compared to 
qVICs treated with vehicle (Figure 6-19A). aVICs treated with SB431452 
(Figure 6-19D) showed a more organised structure and less elongation of cells 
(reminiscent of the qVIC morphology observed in section 6.3.1) compared to 
the aVICs treated with vehicle (Figure 6-19C). Proteoglycan deposition was 
increased significantly in qVICs treated with TGFβ1 compared to qVICs with 
vehicle (5.13 fold increase, P-value 0.02) (Figure 6-20A). Likewise, aVICs 
treated with SB431542 showed a significant decrease in proteoglycan 
Fold change P-value Fold change P-value Fold change P-value
ACTA2 6.01 0.03 -22.36 0.021 37.4 0.003
TAGLN 2.84 0.043 -2.72 0.042 3.92 0.028
MYH10 -1.74 0.086 -1.07 0.572 2.9 0.05
HTR2B 2.43 0.043 -9.34 0.042 2.33 0.029
HBEGF -2.69 0.44 2.95 0.035 -2.5 0.021
BMPER -5.28 0.008 2.31 0.12 -4.2 0.092
VCAM1 -2.83 0.049 2.78 0.065 -6.93 0.007
PDK4 -6.88 0.005 3.89 0.09 -74.07 0.012
FAP 7.64 0.002 -5.71 0.001 8.54 0.026
SLC10A6 -2.65 0.013 2.07 0.237 -4.53 0.042
Gene name
qVIC treated with TGFβ1 aVIC treated with SB431542 aVIC compared to qVIC
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deposition compared to aVICs with vehicle (2.82 fold decrease, P-value 0.012) 
(Figure 6-20B). Comparing aVICs with vehicle to qVICs with vehicle a 
significant difference was also found in proteoglycan deposition (3.03 fold 
increase, P-value 0.42) (Figure 6-20C). The data show treatment of qVICs with 
TGFβ1 promotes the aVIC phenotype while treatment of aVICs with the 
TGFβRI kinase inhibitor reverses activation and supports a reversion to the 
qVIC phenotype. 
 
Figure 6-19. Cell Morphology of VIC phenotypes under treatment of TGFβ1 
or SB431542. (A) Representative image of qVICs treated with vehicle. (B) 
Representative image of qVICs treated with TGFβ1. (C) Representative 
image of aVICs treated with vehicle. (D) Representative image of aVICs 




Figure 6-20. Proteoglycan deposition in VICs under treatment of TGFβ1 or 
SB431542. (A) Effect of TGFβ1 treatment of qVICs on proteoglycan 
deposition compared to qVICs with vehicle. (B) Effect of SB431542 
treatment of aVICs on proteoglycan deposition compared to aVICs with 
vehicle. (C) Comparison of proteoglycan deposition between qVICs with 
vehicle and aVICs with vehicle. * = P-value <0.05. n=3 per group. 
6.3.10 5HT signalling effect on gene expression and proteoglycan 
deposition 
To assess the effect of 5HT signalling in VICs, qVICs were treated with 5HT 
and aVICs were treated with two different concentrations of the 5HTR2B 
antagonist LY272015. Two-time points (4 days and 7 days) were assessed for 
the gene expression of myofibroblast markers and HTR2B. Additionally, 
proteoglycan deposition was measured at 7 days. At day 4, gene expression 
for all conditions was not significantly different apart from an unexpected 1.9 
fold increase (P-value 0.025) in HTR2B expression in the aVICs treated with 
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100 nM LY272015 (Table 6-19). At day 7, HTR2B expression was increased by 
2.09 and 2.84 fold (P-value 0.024 and 0.003) in aVICs treated with 100 nM and 
1 µM LY272015 respectively (Table 6-20). Likewise, an increase in expression 
of MYH10 was seen for both concentrations of LY272015 at this time point 
reflecting a 1.52 fold (P-value 0.009) and 2.84 fold (P-value 0.001) change for 
100 nM and 1 µM respectively. No significant changes were observed for 5HT 
(P-value 0.653), 100 nM (P-value 0.936) and 1 µM (P-value 0.458) LY272015 
treatment in the deposition of proteoglycans from VICs on day 7 (Figure 6-21).  
 
Table 6-19. Gene expression in 5HT signalling on day 4. Fold change and 
associated P-value for genes of interest in qVICs treated with 1 µM 5HT, 
aVICs treated with 100 nM LY272015 and aVICs treated with 1 µM LY272015.  
 
Table 6-20. Gene expression in 5HT signalling on day 7. Fold change and 
associated P-value for genes of interest in qVICs treated with 1 µM 5HT, 
aVICs treated with 100 nM LY272015 and aVICs treated with 1 µM 
LY272015. 
Fold change P-Value Fold change P-Value Fold change P-Value
ACTA2 -1.42 0.728 1.05 0.713 -2.6 0.341
TAGLN 1.33 0.662 1.08 0.871 1.17 0.621
MYH10 -1.59 0.242 2.31 0.167 1.53 0.428
HTR2B 1.13 0.811 1.9 0.025 2.07 0.383
qVICs treated with 5HT aVICs treated with 100nm LY272015 aVICs treated with 1µM LY272015
Gene
Fold change P-Value Fold change P-Value Fold change P-Value
ACTA2 1.97 0.289 -2.26 0.244 -1.39 0.575
TAGLN 2.91 0.093 -1.27 0.217 -1.24 0.61
MYH10 1.07 0.9 1.52 0.009 2.84 0.001
HTR2B 1.54 0.421 2.09 0.024 2.84 0.003
Gene




Figure 6-21. Proteoglycan deposition in VICs under treatment of 5HT or 
LY272015. (A) Effect of 5HT treatment of qVICs on proteoglycan deposition 
compared to qVICs with vehicle. (B) Effect of 100 nM LY272015 treatment of 
aVICs on proteoglycan deposition compared to aVICs with vehicle. (C) 
Effect of 1 µM LY272015 treatment of aVICs on proteoglycan deposition 
compared to aVICs with vehicle. 
6.4 Discussion 
This study aimed to build upon data presented in previous chapters and 
investigate MMVD in vitro. Myxomatous mitral valves present with activated 
VICs[2, 43, 57]. Using monocultures of primary VICs, proposed to be the main 
drivers of MMVD progression, examining VIC molecular events and 
signalling pathways can be achieved[1, 2, 43, 60]. In this study, both qVICs from 
normal valves and aVICs from diseased valves were cultured in a low serum 
culture system that has previously been shown to maintain these phenotypes 
in human aortic VIC cultures[138]. As the importance of TGFβ1 signalling was 
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identified in the valve tissue studies, investigation of the effects of exogenous 
TGFβ1 on qVICs and the inhibition of TGFβ signalling in aVICs with the 
TGFβRI kinase inhibitor SB431542 was undertaken. In addition, the role of 
5HT signalling in MMVD was investigated in a similar way with the 
exogenous delivery of 5HT to qVICs and the inhibition of the 5HTR2B 
signalling with LY272015.  
Initially, it was important to establish the phenotype of VICs isolated from 
normal and diseased valves. This was performed by examining the gene and 
protein expression of hallmarks of MMVD, proteoglycan deposition and cell 
morphology (section 6.3.1)[43, 45, 113]. It was shown that all of these markers 
indicated that qVICs from the normal valves and aVICs from the diseased 
valves had been isolated. Furthermore, their phenotype could be maintained 
in culture for several passages (at least passage 6) with the use of the optimised 
media conditions, which had previously not been possible[45, 138]. 
ELISAs for TNF and IFNγ, both previously implicated in disease pathogenesis 
(Chapter 3 and 5), indicated they were secreted from both populations of VICs 
at very low levels with IFNγ below the detection limits of the ELISA kit. This 
is in agreement with the gene expression detected for these factors both in 
VICs (section 6.3.2) and in tissue (Chapter 5 section 5.3.5), indicating that gene 
and protein level are similar. Together, these results indicate that TNF and 
IFNγ are only present at a minimal level in the valve. This is in spite of some 
reports indicating TNF has potential as an EndoMT stimulating factor[90]. 
However, these results, coupled with reports in the literature indicating that 
there is no association for an increase in the circulation of these molecules in 
MMVD dogs, makes it unlikely that they play an important role in disease 
development[301, 302]. It is more likely that their prominence in the analysis, in 
227 
 
particular TNF, is due to a cross-over in similar downstream targets to TGFβ 
signalling, as indicated in Chapter 3 section 3.3.7. 
TGFβ1 ELISA data from qVICs and aVICs showed it to have the highest level 
of secretion out of the three TGFβs, and although not significant after 72 hours 
in culture, after 120 hours a significant increase in TGFβ1 was detected (data 
provided by Dr. Karen Tan). Supporting these data, TGFβ1 gene expression 
was detected at a level well above the background cut-off in VICs (section 
6.3.5) and in tissue (Chapter 5 section 5.3.5). Comparative ELISA data for both 
TGFβ2 and TGFβ3 found a much lower secretion than TGFβ1, with no 
significant difference detected between qVICs and aVICs at 72 hours or 120 
hours (pers. comm. Dr. Karen Tan; data not shown). Surprisingly, the gene 
expression intensity for these two factors was at a similar or slightly higher 
level to that for TGFB1. This suggests that either post-transcriptional/post-
translational events are preventing the translation or secretion of these factors 
from the cell, or that they are being cleared from the supernatant and 
extracellular space at a far greater rate than TGFβ1. TGFβ1-3 undergo several 
post-translational events prior to their secretion in a latent form bound to 
latent TGFβ binding proteins (LTBPs)[180]. It may be events during this process 
are involved in the reduced secretion of TGFβ2 and TGFβ3. What relevance, if 
any, this disparity between gene level and protein secretion may have to 
MMVD is unknown and warrants future research. However, this is beyond 
the current scope of this study to investigate. It could also be argued that the 
higher secretion of TGFβ1 is because of its relevance to valve homeostasis as 
it is the activation of the extracellular latent forms of TGFβ that controls its 
activity and action[180]. It has been previously shown, in tissue using 
immunohistochemistry that TGFβ1 and TGFβ3 are expressed at relatively 
high levels in normal and MMVD valves, with a relatively low expression of 
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TGFβ2, and in agreement with the results presented here, only TGFβ1 was 
detected in the extracellular space[174]. The significantly higher level of TGFβ1 
detected in aVIC cultures compared to qVICs complements the data presented 
in previous chapters, and the wider literature, indicating its importance in 
MMVD [126, 133, 136, 174, 175].  
When performing differential gene expression analysis no FDR correction 
could be applied to any of the datasets without the loss of all differentially 
expressed genes. This included when using a paired ANOVA, similar to 
Chapter 5, between treatment groups. This is likely due to the low number 
(n=3) of samples per group, as well as a degree of naturally occurring 
biological variability between samples inherent in using primary cell 
cultures[309]. Technical variability was minimised by performing all 
experiments at the same time, by the same person, using the same culture 
plastics and passage matching all cells. As discussed in Chapter 3 section 3.4, 
methods for improving future studies would be to try and minimise variability 
within sample groups by using the same breed and age of dog for cell 
extraction, which was performed for the qVIC phenotype, as well as increasing 
the number of samples. Nonetheless, valuable insights into the role of TGFβ1 
signalling in VICs could still be identified and interpreted through gene 
enrichment analysis of the datasets without FDR correction.  
Differential gene expression, PCA and sample-to-sample analysis (sections 
6.3.4 and 6.3.5) all highlighted transcriptomic differences between each of the 
groups with qVICs treated with TGFβ1 showing more similarity with aVIC 
phenotype, and SB431542 treated aVICs showing more similarity with qVICs. 
Of the 102 shared differentially expressed genes between TGFβ1-treated 
qVICs and aVICs only one gene, encoding mastermind-like domain-
containing protein 1 (MAMLD1), was found to show a different expression 
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pattern between the two groups. MAMLD1  is primarily involved in the 
gonadal development and its differential expression is likely inconsequential 
to MMVD[310]. As such this gene was excluded from downstream gene 
enrichment analysis.  
In qVICs treated with TGFβ1 up-regulated DAVID GO terms (section 6.3.6) 
included extracellular matrix and extracellular space which relates to MMVD 
pathogenesis where expansion of the extracellular space is a hallmark of 
disease[2, 3, 61]. Down-regulated GO terms in this group’s analysis included 
cardiac conduction system development and positive regulation of ERK1 and 
ERK2. The former of these can be related to the phenotypic switch that appears 
to be happening in the qVICs treated with TGFβ1 and has been suggested to 
change the cardiac potential in these cells[43]. The association of positive 
regulation of ERK1 and ERK2 cascade with the down-regulated genes in the 
TGFβ1 treated qVICs is difficult to explain. It is in contrast with the data 
reported in Chapters 3 and 4 where this GO term was associated with up-
regulated genes in diseased valves, as well as reports of activation of ERK1 
and ERK2 signalling in human MMVD[1, 133]. This may reflect the activation of 
a negative feedback loop in VICs in response to acute exposure to exogenous 
TGFβ1.  
Examining the effects of SB431542 treatment on aVICs identified GO terms 
associated with down-regulated genes relevant to MMVD. Extracellular 
matrix, stress fiber, positive regulation of cell migration and focal adhesion can 
all be related to the aVIC phenotype[45, 113, 117]. Down-regulation of genes 
suggests that an attenuation of the aVIC phenotype is generated with 
SB431542 treatment. This implies that the signalling through TGFβRI is in part 
responsible for these disease phenotype traits. When comparing aVICs to 
qVICs amongst the GO terms associated with up-regulated genes there 
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appears to be a large number that are involved in cell division and DNA 
replication, (as seen in Chapter 3). This could be related to a more proliferative 
morphology seen in aVICs in culture as well as a moderate increase in the 
proliferation marker KI-67 in tissue [43, 45, 113]. When analysing the genes shared 
between TGFβ1-treated qVICs and aVICs GO terms associated with up-
regulated genes can be more directly related to MMVD such as the previously 
mentioned extracellular space.  
IPA analysis in this study (section 6.3.7), as with the previous chapters, gave 
insight into the underlying mechanisms responsible for the gene changes 
observed. Canonical pathway analysis showed that in TGFβ1-treated qVICs 
differentially expressed genes were most associated with the Hepatic 
fibrosis/hepatic stellate cell activation. This is in agreement with the results 
obtained in the tissue analysis (Chapters 3-5) and as discussed earlier, can be 
related to the activation of TGFβ1 signalling[184]. As such, this helps to add 
credence to the hypothesis that TGFβ1 signalling is being activated in MMVD. 
In support of the GO term analysis, canonical pathway analysis of the genes 
differentially expressed in aVICs compared to qVICs showed that the majority 
of the top associated pathways were involved in cell proliferation, again 
supporting the view that the aVICs have a more proliferative phenotype than 
qVICs[45, 113]. Both the differentially expressed genes in aVICs treated with 
SB431542 and the shared differentially expressed genes in aVICs compared to 
qVICs and qVICs treated with TGFβ1 were associated with cholesterol 
biosynthesis related pathways in canonical pathway analysis. Although these 
pathways have not previously been directly implicated in MMVD there is 
some evidence that TGFβ1 can play a role in cholesterol synthesis in 
keratinocytes[311]. However, what role this may play in MMVD development, 
if any, remains unclear. 
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Upstream regulator analysis, as expected, suggested the activation and 
inhibition of TGFβ1 signalling as being the most important pathway involved 
in the differentially expressed genes in the TGFβ1-treated qVICs and 
SB431542-treated aVICs respectively. This suggests that the other forms of 
gene enrichment analysis performed on these datasets are looking at the 
effects of changes in TGFβ1 signalling. This finding is particularly important 
in the SB431542-treated aVICs as this it inhibits TGFβRI kinase and so the gene 
changes related to this could be through signalling of TGFβ1-3 as well as 
potentially activin and nodal but not the BMP[307, 308]. These results suggest 
however that the gene changes caused by SB431542 treatment are due to 
inhibition TGFβ1 related canonical SMAD2/3 signalling specifically. 
Additionally, in the TGFβ1-treated qVICs analysis, TNF is the second 
upstream regulator associated with these genes, as was the case in Chapter 3. 
This further supports the view that TNF is identified as it shares many 
downstream targets with TGFβ1 and not because it is directly involved in 
disease pathogenesis.  
Genes differentially expressed between aVICs and qVICs were associated 
primarily with pathways involved in the down-regulation of apoptotic 
pathways. This is an interesting finding as there is a narrative in the literature 
for the role of anti-apoptosis in MMVD, and specifically in aVICs[45, 126]. aVICs 
in normal circumstances, such as wound healing, would undergo apoptosis 
after injury had been resolved [177]. However, it has been suggested that in a 
chronic condition, such as MMVD, this apoptosis may not happen and aVICs 
are allowed to persist in the valve[45]. There is evidence for this in tissue with 
an increase in interstitial cells as the disease progresses, but only a moderate 
increase in KI-67, as well as evidence to show apoptosis is undertaken, but not 
completed in MMVD, and that this effect is under the control of TGFβ1[43, 126]. 
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The data here seems to support these reports and further investigation of 
apoptosis in MMVD is warranted.  
Upstream analysis showed that the genes sharing differential expression in 
aVICs and qVICs treated with TGFβ1 were associated with both TNF and 
TGFβ1. However, TGFβ1 showed activation as opposed to inhibition of TNF. 
This implies there is a positive role for TGFβ1 signalling not only in the qVICs 
treated with TGFβ1 but also in the aVICs isolated from naturally occurring 
diseased valves, further supporting TGFβ1 role in disease pathogenesis.  
Network analysis of the top disease and functions associated with the genes 
differentially expressed in the qVICs treated with TGFβ1 and aVICs treated 
with SB431542 are pathways involved in cardiovascular disease. This indicates 
that gene changes induced by TGFβ1 signalling in these samples also play a 
role in cardiovascular disease. The genes differentially expressed in aVICs 
compared with qVICs were associated, similarly to previous analysis, with cell 
cycle-related disease and functions. The majority of the components were 
found to be upregulated, and as previously discussed this supports the role 
for a proliferative phenotype of aVICs in MMVD[45]. Analysis of the genes 
shared between aVICs compared to qVICs and qVICs treated with TGFβ1 
showed a number of relevant disease and functions. The top disease and 
function biological terms included cell morphology, cardiovascular disease and 
development disorder these would appear relevant to MMVD where 
morphological changes in qVICs differentiating to aVICs, and reactivation of 
developmental pathways such as EndoMT are cardinal features of the disease 
[2, 43, 57]. Other interesting and potentially relevant disease and functions related 
shared group of genes found with cell death and survival and cellular growth and 
proliferation. These can both be linked to previous analyses implicating anti-
apoptotic signalling and cell proliferation in MMVD pathogenesis. The fact 
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that these pathways can be associated with genes found in both spontaneously 
activated VICs and qVICs treated with TGFβ1 further implicates the role of 
TGFβ1 in MMVD.  
The transcriptomic analysis showed that treatment of qVICs with TGFβ1, for 
only 72 hours, induces an aVIC-like transcriptomic phenotype. Conversely, 
inhibition of TGFβ signalling with SB431542 in aVICs, for 96 hours, reduces 
the expression of genes that are involved in the aVIC phenotype and disease-
related processes. Comparison of aVICs to qVICs indicated a role for 
proliferative and anti-apoptotic pathways in disease, something which has 
been previously speculated in the literature[43, 45, 126]. However, when analysing 
the shared differentially expressed genes in aVICs and qVICs treated with 
TGFβ1, a role for TGFβ1 signalling in spontaneously occurring aVICs was 
found.  
RT-qPCR validated 28 out of 30 the gene changes occurring in the microarray 
data, despite the lack of FDR correction (section 6.3.9). In addition, 
morphological analysis and proteoglycan deposition indicated that TGFβ1 
treatment induced an aVIC phenotype in qVICs and SB431542 treatment 
attenuated the aVIC phenotype (section 6.3.10). This indicates that the gene 
changes analysed in this study relate to tangible changes in phenotype which 
are associated with MMVD, further establishing the role for TGFβ1 signalling 
in disease. 
Comparison between aVICs and qVICs showed the increased gene expression 
of the hallmarks aVIC phenotype (ACTA2, TAGLN and MYH10) was detected 
both by microarray and RT-qPCR. MYH10 expression was not significantly 
altered by treatment of either the qVICs or aVICs. This result is of interest 
given the sub-populations of aVIC (αSMA+, SMemb+ and αSMA/SMemb+) 
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described in canine MMVD valves (Chapter 1 section1.3.2)[2, 43, 110]. These results 
suggest either MYH10 expression is induced by another factor, other than 
TGFβ1, involved in activation of VICs and disease progression, or MYH10 
expression is altered later in the phenotypic change of VICs. It has been 
postulated that the co-expression of αSMA and SMemb is indicative of a 
heightened differentiation state and so possibly the result of a later phenotypic 
change in these cells[2, 110]. Furthermore, aVICs which co-express αSMA and 
SMemb have been shown to express 5HT to a greater extent than the other 
aVIC sub-populations[43]. If this occurs in late-stage disease, it suggests the 
increased 5HT expression is primarily a result of heightened TGFβ signalling. 
Interestingly, HTR2B expression was significantly altered, in both microarray 
and RT-qPCR analysis, in treatment groups, with increased expression in 
qVICs treated with TGFβ1 and down-regulation in aVICs treated with 
SB431542, as well as by RT-qPCR in aVICs. These novel findings indicate that 
the expression of HTR2B is under the control of TGFβ1 signalling. This is 
important as the up-regulation of HTR2B expression in canine disease has 
been used to support the hypothesis that 5HT signalling is responsible for 
MMVD pathogenesis[71, 133, 170-172]. However, in this study, when investigating 
the direct effect of 5HT signalling on qVICs, no significant changes in the 
expression of ACTA2, TAGLN, MYH10 or HTR2B was detected at 4 or 7 days 
as well as no change in proteoglycan secretion after 7 days (section 6.3.11). 
Additionally, the use of the 5HTR2B antagonist LY272015 on aVICs did not 
induce a reduction of these genes, which would be indicative of a reversion in 
phenotype. Instead, an increase in MYH10 was seen on day 7 and HTR2B on 
days 4 and 7. No significant change in proteoglycan deposition was detected 
at day 7 with the use of LY272015. These results contrast with the results 
obtained when investigating TGFβ1 signalling implying that at least in short-
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term culture TGFβ1 has more relevance as the inducer of MMVD. 
Additionally, these results contrast with a report where LY272015 induced a 
trend for reduction in HTR2B and ACTA2 expression in canine ex vivo valves 
in a dynamic culture, and partially block valve remodelling in mice[171]. No 
publications have looked at the effect of 5HT on canine qVIC phenotype in 
vitro. It has been suggested that 5HT could be signalling through 5HTR2B to 
induce greater expression of TGFβ1, causing autocrine signalling and 
activation of VICs[133]. 5HT has been shown to induce greater expression of 
TGFβ3 in avian embryonic hearts[169] but whether or not this happens in canine 
VICs is yet to be elucidated and warrants future research. Regardless of the 
potential role that 5HT may have in MMVD the results presented here, along 
with the data from previous chapters show a clear role for TGFβ1 signalling 
in MMVD. Additionally, inhibition of this pathway can result in some 
reversion of phenotype in vitro indicating that targeting TGFβ signalling may 
be of therapeutic value in future (see Chapter 7).  
In conclusion, this study aimed to investigate the role of TGFβ1 signalling in 
VICs in vitro. Using optimised cell culture techniques the secretion of various 
factors implicated in disease was assessed, the effect of exogenous TGFβ1 on 
qVICs and TGFβ signalling inhibition was investigated through 
transcriptomic profiling, RT-qPCR, whole cell morphology and proteoglycan 
deposition, and the effect of 5HT signalling were also examined. The results 
support a role for TGFβ1 signalling in the development of the phenotypic 







- TGFβ1 was secreted from both qVICs and aVICs in greater quantities 
than TGFβ2 and 3, with a significant increase of secretion found 
between qVICs and aVICs after 5 days 
- TGFβ1 treatment of qVICs induced an aVIC phenotype after 3 days of 
treatment 
- SB431542 treatment of aVICs helped attenuate the aVIC phenotype and 
reduce association with MMVD traits 
- 5HT signalling, at least in short-term culture, does not appear to be able 
to induce an aVIC phenotype in qVICs 
This study succeeded in its aim to investigate the role of TGFβ1 signalling in 
VICs in vitro. The data reported here support the results in previous chapters 
indicating a central role for TGFβ1 signalling in MMVD pathogenesis and that 
the partial attenuation of the spontaneously developed aVIC phenotype is 







   Final conclusions and future prospective 
7.1 Overview of the results 
This project aimed to improve the understanding of the overall pathogenesis 
of canine MMVD. It was hypothesised that clear and discernible changes in 
gene expression will occur dependent on the Whitney grade of the disease and 
will be related to MMVD development. A primary focus was establishing 
what pathways were likely to be causal in disease progression, as this was 
lacking in previous studies. To achieve this aim and answer the hypothesis, 
transcriptomic analysis was performed on valves spanning the entire 
pathogenesis of disease (Whitney grade 0-4; Chapter 3 and 4), as well as early 
(Whitney grade 2) diseased valves that had been dissected into overtly 
diseased and normal regions (Chapter 5). Collectively these analyses, 
alongside various other findings, indicated a central role for TGFβ1 signalling 
in both early and late-stage disease. The TGFβ1 signalling pathway was then 
interrogated further in vitro (Chapter 6). TGFβ1 was shown to activate qVICs 
leading to the acquisition of a MMVD-like phenotype, and inhibition of 
canonical downstream SMAD2/3 signalling, using a TGFβRI kinase inhibitor 
in aVICs, was shown to attenuate this phenotype. This project has therefore 
succeeded in its goal in confirming the primary pathway that is important in 
the overall pathogenesis of the disease.  
The consistent finding that TGFβ1 signalling was involved in MMVD 
development was not wholly unexpected, as previous studies (detailed in 
Chapter 1 section 1.5.1) have shown it to play a role in the activation of qVICs 
into aVICs. In addition, it has been shown that there is up-regulation of TGFβ1 
protein and increased phosphorylation of downstream signalling components 
such as SMAD2/3, ERK1 and ERK2 suggestive of increased TGFβ1 signalling 
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in diseased valve tissue[43, 45, 60, 71, 124, 126, 133, 174-176]. In human transcriptomic 
analysis, TGFβ2 has been implicated in the changes in gene expression 
associated with disease valves as well as the TGFβ superfamily member 
BMP4[125, 131, 163]. Likewise, the two previous microarray studies performed in 
the dog found some gene expression changes that were indicative of upstream 
TGFβ signalling, for example BMP6 and endoglin[33, 150]. However, these 
studies had focused on comparing normal and late-stage disease so could not 
evaluate TGFβ signalling’s role in MMVD initiation and progression.  
Whole valve analysis of Whitney grade 1 and 2 valves (Chapter 3) did not 
show the anticipated early disease-related gene expression changes sufficient 
for meaningful downstream analysis and causal pathway identification when 
analysed on a by-grade basis. However, valuable insights were still gained 
when considering the level of expression of genes that showed significant 
differential expression in at least one grade of disease. This analysis showed 
that the small changes in expression detected in early disease, altered 
progressively throughout the disease process until ultimately this lead to the 
more significant changes detected in the latter grades of MMVD. This 
highlighted that several of the GO pathways (such as metalloendopeptidase 
activity, ERK1 and ERK2 cascade and heart development) that were seen in 
later disease, were also enriched over the entire progression of disease. 
To further understand the role of differential gene expression, a study of 
MMVD in CKCS, a breed predisposed to the early onset disease, was 
undertaken (Chapter 4). Data presented in Chapter 4 indicates that enhanced 
or altered prothrombin, muscle contractility and calcium signalling (possibly 
the result of 5HT signalling through 5HTR2B) potentially might be involved 
in the predisposition to early MMVD development in CKCS. These results also 
suggest that dysfunctional platelets, which is a common disorder in CKCS, 
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may also be involved in early disease development in this breed through 
enhanced 5HT signalling [225-227]. 
Examining the molecular basis of early disease pathogenesis was revisited in 
Chapter 5 with the use of valvular dissection. This was shown to be a valuable 
approach as it allowed for the identification of genes that are associated with 
early disease-related pathways while using a high stringency statistical cut-off 
(FDR), and thereby improving on the Grade 1 and 2 data presented in Chapter 
3. Additionally, evidence was found that the normal regions of the valve do 
not have disease-related gene changes and that the disease-related changes are 
localised to the overtly abnormal regions of these valves. The study found that 
the overtly diseased regions of Whitney grade 2 valves shared differential 
expression of genes and pathways that were also seen in the late grade whole 
valves, albeit showing lower fold changes than in late-stage disease. This fold 
difference is interesting as it suggests a linear relationship between gene 
expression and the severity of the disease. 
A final experimental approach used in this study was to explore gene 
expression in cultured cells isolated from diseased and normal valves. The 
downstream analysis presented in Chapter 6 allows for further understanding 
of TGFβ1 signalling in MMVD. In agreement with previous accounts in other 
species TGFβ1 was able to induce the aVIC-like phenotype in qVICs and, 
supporting the role for this phenotype in disease, both the spontaneously 
derived aVICs and the TGFβ1-treated qVICs shared downstream signalling 
events which are important in the development of MMVD such as 
extracellular matrix deposition[45, 60, 85, 117]. Inhibition of the TGFβRI kinase, and 
subsequent canonical SMAD2/3 signalling indicated that this downstream 
signalling pathway and the ensuing gene expression changes are important 
for the MMVD-related biological functions seen in these cells. This 
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corroborates observations in human MMVD tissue[176]. However, in the 
timescale of these in vitro inhibitor experiments there was only a partial 
attenuation of the aVIC phenotype indicating that the role of other signalling 
pathways cannot be excluded. This includes the role of ERK1 and ERK2 
cascade (a non-canonical signalling pathway downstream of TGFβ1 and other 
factors) that was consistently associated with up-regulated genes in tissue in 
this project (Chapter 3), a finding that has been reported in other canine and 
human valves studies[133, 168, 171, 173]. Interestingly, as discussed in Chapter 6 
section 6.4, ERK1 and ERK2 cascade was associated with down-regulated 
genes in TGFβ1-treated qVICs from normal valves. However, this may be 
indicative of transient activation of this pathway and a resultant negative 
feedback loop in the normal repair process, rather than reflecting chronic 
signalling in disease. Other pathways such as 5HT signalling may also be 
activating the ERK1 and ERK2 cascade, which has been reported previously 
in MMVD. However, 5HT-treated qVICs and 5HTR2B antagonism in aVICs 
indicated, at least in the confines of the in vitro system utilised here, that this 
pathway on its own is not capable of inducing the MMVD phenotype. These 
findings do not eliminate 5HT signalling’s potential involvement in late-
disease progression, but further studies are required to elucidate its role.  
7.2 Integration of transcriptomic analysis 
To explore microarray datasets further, comparisons (as described in Chapter 
2 section 2.6.4) of the differentially expressed genes in the diseased dissected 
regions to the Whitney grade 4 valves or the Whitney grade 2 valve set were 
performed. This analysis is summarised in Figure 7-1 and Figure 7-2. Eleven 
and 75 genes were shared in the dissected diseased regions and the whole 
Whitney grade 2 and 4 valve analysis respectively. Seven of the 11 shared 
genes (Appendix V: Table S1) in the Whitney grade 2 dissected and whole 
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valves shared up- or down-regulation, whereas 42 and 23 genes shared up-or 
down-regulation with the grade 4 valves respectively. The 42 shared up-
regulated genes could be attributed to 26 GO terms in DAVID analysis with 
the top ten shown in (Appendix V: Table S2). These include pathways which 
were implicated in late-stage disease (Chapter 3), such as neutrophil 
chemotaxis, extracellular space, integrin binding and positive regulation of 
ERK1 and ERK2 cascade. This analysis indicated that the gene expression 
changes occurring in diseased regions of early-stage disease were similar to 
those present in late-stage disease.  
 
Figure 7-1. Venn diagram illustrating the number of shared differentially 
expressed genes in diseased dissected regions of Whitney grade 2 valves and 
whole Whitney grade 2 valves. In the left orange circle, the number of 
differentially expressed genes for diseased dissected regions not shared 
with whole Whitney grade 2 valves is shown. In the right purple circle, the 
number of differentially expressed genes for whole Whitney grade 2 valves 
not shared with dissected diseased regions of valves is shown. In the centre, 




Figure 7-2. Venn diagram illustrating the number of shared differentially 
expressed genes in diseased dissected regions of Whitney grade 2 valves and 
whole Whitney grade 4 valves. In the left orange circle, the number of 
differentially expressed genes for diseased dissected regions not shared 
with whole Whitney grade 4 valves is shown. In the right purple circle, the 
number of differentially expressed genes for whole Whitney grade 4 valves 
not shared with dissected diseased regions of valves is shown. In the centre, 
the number of shared genes between the two datasets is shown. 
Further informative dataset comparisons were made by considering the 
microarray analysis performed on the TGFβ1-treated qVICs. Comparisons of 
these treated cells to the diseased regions of dissected Whitney grade 2 valves 
or to the whole Whitney grade 4 valves (Figure 7-3 and Figure 7-4 respectively) 
showed a relatively small number of gene cross-over between the valve and 
cell datasets. However, the majority of the shared genes showed similar up- or 
down-regulation trends and GO term analysis (Appendix V: Tables S3-5) of 
the genes up-regulated in grade 4 valves and TGFβ1-treated qVICs showed 
many terms related to MMVD. These GO terms included extracellular 
space/matrix as well as terms such as regulation of cell proliferation. This 
analysis directly associates in vitro TGFβ1 treatment with several 
characteristics involved in the development of disease in tissue. This also 
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substantiates the cell proliferation findings in the aVIC phenotype analysis in 
Chapter 6 in MMVD development of tissue as well.  
Examining the genes that have differential expression, but do not show similar 
up- or down-regulation can also give some informative perspectives. For 
example, pre-microRNA 214 is up-regulated in TGFβ1-treated qVICs, but 
down-regulated in Whitney grade 4 valves. This is of interest as this 
microRNA plays a role in the development of fibrosis and its antagonism helps 
halt fibrosis developing in the kidney[312]. TGFβ signalling is a powerful 
inducer of fibrosis and up-regulation of pre- microRNA 214 suggest fibrotic 
pathways may be being induced in this in vitro system. In contrast, and 
although a fibrotic response is observed in human MMVD, this is absent in the 
canine disease[1, 2, 84]. This warrants future study as to the role of microRNA 214 
in the tissue and cell culture response.  
 
Figure 7-3. Venn diagram illustrating the number of shared differentially 
expressed genes in diseased dissected regions of Whitney grade 2 valves and 
TGFβ1-treated qVICs. In the left orange circle, the number of differentially 
expressed genes for diseased dissected regions not shared with TGFβ1-
treated qVICs is shown. In the right purple, circle the number of 
differentially expressed genes in TGFβ1-treated qVICs not shared with 
dissected diseased regions of valves is shown. In the centre, the number of 




Figure 7-4. Venn diagram illustrating the number of shared differentially 
expressed genes in Whitney grade 4 valves and TGFβ1-treated qVICs. In the 
left orange circle, the number of differentially expressed genes for diseased 
dissected regions not shared with Whiney grade 4 valves is shown. In the 
right purple circle the number of differentially expressed genes TGFβ1-
treated qVICs not shared with Whitney grade 4 valves is shown. In the 
centre, the number of shared genes between the two datasets is shown.  
7.3 A model for the initiation and development of MMVD 
The results presented in this project strongly suggest a central role for TGFβ1 
signalling in all dogs with MMVD and that this signalling pathway controls 
various key aspects of the disease process. In culture, TGFβ1 was secreted into 
the extracellular matrix at a greater level than its sub-family members in the in 
vitro ELISA analysis in Chapter 6, consistent with results previously reported 
in the literature[174]. However, how the latently secreted form of TGFβ1 is 
activated in the valve to initiate disease progression remains uncertain. As 
discussed in Chapter 1 section 1.5.1, various conditions and factors can 
activate latent TGFβ1, with many of these occurring or present in the normal 
mitral valve. This includes stretch, tensile and shear stress, reactive oxygen 
species, thrombospondin, thrombin and 5HT signalling[169, 172, 179, 180, 205, 290]. 
Within the general population of the dog, it is likely that a combination of these 
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factors induces initial TGFβ1 signalling. Activation may then become 
sustained and pathological, due to higher or chronic secretion and 
accumulation of latent TGFβ1 from aVICs (Chapter 6), the increased 
proliferation and reduced apoptotic capability of aVICs (Chapters 3 and 6), 
alteration of the extracellular matrix composition by aVICs (Chapters 3-6) 
and/or persistent aberrant signalling during the natural ageing process. For 
predisposed breeds results presented in Chapter 4 support a role for the 
enhancement of one or more of the latent TGFβ1 activating agents (in the case 
of CKCS this could be through prothrombin and 5HT signalling) resulting in 
the early development of the disease. Platelet dysfunction and dysregulated 
calcium signalling could also be involved in the CKCS predisposition (Chapter 
4). While the trigger for TGFβ1 signalling in MMVD remains speculative, 
identifying it as the major pathway in disease progression is of major benefit, 
especially in terms of identifying future therapeutic approaches to this disease. 
It appears likely that many of the GO terms, canonical pathways and disease 
and functions suggested in the microarray gene analysis are consequent of 
TGFβ1 signalling being initiated. This includes pathways such as 
proteinaceous extracellular matrix, hepatic fibrosis/hepatic stellate cell activation 
and extracellular matrix/space. Not only are many of these pathways 
suggested after TGFβ1 treatment of qVICs (Chapter 6), but have also been 
shown in the literature to be a consequence of the aVIC phenotype and TGFβ1 
signalling[46, 56, 142, 174, 179, 313]. In addition, developmental pathways (indicating 
EndoMT) seemed to be isolated to grade 3 and 4 valves (Chapter 3 section 
3.3.7). This suggests that EndoMT is only present in later disease, and so is 
consequential to initial VIC activation and TGFβ1 signalling. However, as 
many of the genes involved in EndoMT (such as HAS2 and CD31) did not 
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show differential expression in any of these datasets further investigation into 
what grade of disease EndoMT occurs in is warranted.  
Some pathways, as highlighted in section 7.1, could also be a result of other 
signalling mechanisms being activated in the valve such as the ERK1 and ERK 
2 cascade (possibly triggered by 5HT signalling) or immune cell-mediated 
inflammatory/immune response. Nevertheless, the identification of these 
pathways throughout pathogenesis of the disease is of interest, both in 
understanding the disease process and identifying targets that may be useful 
for future therapeutic approaches. 
Likewise, the finding that gene expression changes that occur in diseased 
regions of early and late stages of disease are ostensibly the same (section 7.2) 
is of interest. This suggests that the disease progresses through the spread of 
these changes in gene expression from the early nodules to the entire valve, 
rather than through changes in expression of different sets of genes over the 
disease course. This particular finding is of importance when considering the 
development of new therapeutics as it means that a drug that targets one of 
these important causal pathways could work at any stage of the disease. A 
proposed model for MMVD development derived from the results of this 





Figure 7-5. Proposed general model for MMVD progression. Initiation of 
MMVD is induced by latent TGFβ1 activation causing activation of a small 
number of aVICs, these then propagate as the disease progresses through 
Whitney grades resulting in deterioration of the valve and end-stage disease. 
7.4 Proposals for future research 
Although this project was able to give a range of  insights into the pathogenesis 
of MMVD, both in tissue and in vitro, there are various aspects of the disease 
that remain unexplored, as well as new questions generated from the data 
presented here, in part because of the limitations of the approaches used. 
Suggestions for additional research that could overcome these issues and 
further elucidate the molecular pathogenesis of the disease in both humans 
and dogs are outlined below. 
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Transcriptomic analysis with microarrays has provided a very useful resource 
that allows for a broad base of knowledge to be generated and new hypotheses 
to be developed. However, as discussed in Chapter 2 section 2.1, the 
technology, although robust, more amenable to analyse and cheaper than 
similar alternatives, cannot give the depth of detail that using a technique such 
as RNA-seq could[264]. Using RNA-seq in this project would have led to similar 
conclusions to those presented here (since validation by qRT-PCR indicated 
that the expression microarray data were a robust quantification of gene 
expression), yet may have given greater insights into the underlying 
mechanisms occurring in disease development, especially when considering 
the breed specific changes in CKCS presented in Chapter 4. RNA-seq would 
have given information of any transcript variants (arising for example from 
alternative splicing or different promoter usage) specific to CKCS compared 
to other breeds that could have supported the propositions that altered 
calcium signalling, prothrombin or contractile related pathways are important 
in CKCS predisposition for MMVD. In this regard, as mentioned in Chapter 4 
section 4.4, further research into the role these pathways play in early MMVD 
development in CKCS, especially into activation of latent TGFβ1, is needed, as 
well as more comprehensive histological comparison of normal CKCS valves 
to normal other breed valves, to establish if there are any differences between 
breeds.  
Transcriptomic analysis by any method is limited as it only examines the level 
of RNA expression, which can be used to infer but not confirm active protein 
levels and the functional consequences of any changes. Limited proteomic 
studies have been performed in both the dog and human, with both ultimately 
indicating that the major proteomic changes occurring in MMVD, 
unsurprisingly, are related to the extracellular matrix and the increased 
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presence of proteoglycans and GAGs (supporting the findings in this thesis)[51, 
140]. Having now established pathways of interest through the transcriptomic 
analysis, future research should have a focus on establishing the downstream 
signalling events in these pathways.  
Downstream signalling events can be elucidated in tissue through the analysis 
of gene and protein expression and localisation by in situ hybridisation and 
immunohistochemistry respectively. However, interrogation of these 
pathways is perhaps best achieved in vitro primarily because of the 
reproducibility of results and the ability to interfere with specific pathways in 
question. This was shown in Chapter 6, with these results indicating that 
further interrogation of the downstream signalling events of TGFβ1 signalling 
in VICs, and the potential role of anti-apoptotic pathways and cellular 
proliferation, is warranted. However, there are a number of limitations to the 
in vitro system presented in Chapter 6. In a 2D static mono-culture system, the 
cell environment contrasts greatly with that in vivo. This will not only affect 
cell phenotype but also how these cells react to stimuli, such as TGFβ1 which, 
as discussed in Chapter 1 section 1.5.1, is known to produce highly context-
specific signalling[178, 179]. Although the results presented in Chapter 6 did 
indicate the important role TGFβ1 signalling plays in VIC activation in a 
culture system, it was not able to completely recapitulate all events seen in the 
tissue analysis. This includes the failure to detect changes in the expression of 
microRNA 214, ADAMTS and MMPs (ADAMTS5, ADAMTS9 and MMP12), 
which are thought to play an important role in disease. These discrepancies 
may be due to the monoculture of VICs in the absence of VECs or the lack of a 
suitable 3D extracellular environment which may be simulated in culture with 
the use of fibrin or polyethylene based hydrogels[314-316]. A 3D extracellular 
environment alongside low serum culture conditions helps maintain the qVIC 
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phenotype [314-316]. Likewise, it has been shown that important reciprocal 
signalling occurs between VECs and VICs [42, 93]. With the adoption of a 3D co-
culture, a better understanding of the signalling events downstream of TGFβ1 
could be elucidated in comparison to 2D culture. Tensile strain or shear stress 
could also then be employed to these 3D valve models to investigate what role 
these may play in the initiation or sequestering of MMVD related pathways.  
In addition to giving insights into the molecular mechanisms behind disease 
development, an in vitro model could be used in the testing and application of 
new therapeutics which are currently lacking in both human and canine 
MMVD treatment[244]. These could come in the form of drugs that specifically 
target downstream aspects of the TGFβ1 signalling pathway or the 
myofibroblastic aVIC cell population. Regardless of how TGFβ1 signalling is 
triggered initially in MMVD, its role throughout disease pathogenesis is clear 
and the partial attenuation of aVIC phenotype in Chapter 6 should not go 
understated. The use of drugs such as SB431542, however, is not suitable as 
TGFβ1 plays various important roles throughout the body and its global 
inhibition would cause serious side effects. If a system of delivery could be 
directed specifically to the mitral valves, this might prove very useful for the 
future therapeutic treatment of MMVD. Drug targeting of more unique 
receptors on myofibroblasts, such as platelet-derived growth factor receptors 
(PDGFR-β in the mitral valve), integrins, mannose-6-phosphate/insulin-like 
growth factor-II receptor, FAP (up-regulated in aVICS and TGFβ1-treated 
qVICS in Chapter 6) or retinol binding protein receptor might be feasible[317]. 
Receptor-recognizing peptides, for example PDGFR-β recognizing peptide, or 
antibodies may be coupled via linkers or carriers to a drug-like small molecule 
TGFβRI kinase inhibitor (such as SB431542) to improve drug pharmacological 
stability, specificity and delivery in vivo. Targeting and eliminating aVICs 
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specifically could be another way to treat MMVD. Biosurfactant di-
rhamnolipid has been shown to target myofibroblasts preferentially to 
fibroblasts in skin in vitro and in vivo, with limited toxicity to surrounding cells, 
hence aiding the reduction of scar formation[318]. Future research goals could 
include investigations into pharmaceutical approaches such as these to 
provide a discrete effect on TGFβ1 signalling or aVICs. 
Likewise, the in vitro platform could give insights into the mechanisms of 
action of the limited number of current therapeutics in the dog, such as 
pimobendan and spironolactone. It has recently been indicated that both these 
drugs can potentially slow the progress of canine MMVD[35, 260, 261]. This may be 
through their compensatory action on heart muscle contractility, which itself 
may implicate biomechanical stresses in MMVD development, but also could 
potentially be due to a direct effect of these drugs on the valve cells themselves. 
By treating cells in vitro with the active metabolites of these drugs it can be 
assessed if they have an effect on cell phenotype or extracellular matrix 
production. Additionally, as suggested in Chapter 4 section 4.4, the possible 
effects the drugs could have on different breeds (such as the CKCS) could be 
investigated. This could then help inform future treatment strategies including 
whether these drugs should be given earlier in MMVD development.  
Beyond these proposals, further objectives could aim to examine in greater 
detail the differences and similarities between canine and human MMVD. This 
includes the predisposition for the development of fibrosis in human valvular 
disease but not in canine disease, which could lead to wider reaching 
understanding of fibrotic diseases as a whole[1]. A major issue in human 
MMVD research is the lack of both normal and early disease samples. As 
shown in Chapter 5, the dog offers a more readily available source of early 
diseased valves which can give insights into early disease pathogenesis. Also, 
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long-term longitudinal imaging and biomarker studies could be performed on 
a cohort of dogs to provide vital information into the changes that may occur 
during the induction of MMVD. In gaining a greater comparative 
understanding of the disease, therapeutics tested in vitro could then be further 
developed in vivo in the dog before testing in humans. This would serve as an 
efficient drug development model, as opposed to using a model species where 
the disease has to be induced experimentally, with both species benefitting 
from such an approach. 
7.5 Conclusion 
This study of MMVD using both tissue specimens and cells isolated from 
normal and diseased valves has highlighted the essential role of the TGFβ1 
signalling pathway in the initiation and progression of the disease. Further 
work is required to elucidate the precise mechanisms by which TGFβ1 acts 
and the causes of the initial dysregulation of TGFβ1 levels. This study opens 
the way for the development of drugs targeted to the mitral valve for the 
amelioration or prevention of this devastating disease, both in dogs and 
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Appendix V: List of shared genes and associated GO terms from 
Chapter 7 
 
Table S1. Genes shared between dissected diseased regions of grade 2 
valves and whole Whitney grade 2 valves. Genes in yellow share up- or 
down-regulation in both datasets 
 
Table S2. Functional analysis chart summary of the top ten GO terms 
associated with up-regulated shared genes in dissected diseased regions and 
whole Whitney grade 4 valves.  
Grade 2 Dissected 
Fold Change Fold Change
LOC476900 Uncharacterised -4 -3
CDKN2A Cyclin-dependent kinase inhibitor 2A 1.62 2.49
MARCH1 Mitochondrial amidoxime reducing component 1 1.64 -2.23
CRLF1 Cytokine receptor-like factor 1 1.67 2.61
CLEC5A C-type lectin domain family 5, member A 1.69 1.68
NRXN1 Neurexin 1 -3.4 1.74
GPD1 Glycerol-3-phosphate dehydrogenase 1 2.14 -7.81
SLC22A1 Solute carrier family 22 member 1 2.16 -8.91
CSTA Cystatin A 2.27 2.38
LOC608320 Uncharacterised 3.29 4.23
LOC612122 Uncharacterised 3.31 4.22
Gene Symbol Full Gene Name
Category Term Gene count P-value FDR
GOTERM_BP_DIRECT Neutrophil chemotaxis 4 1.52E-04 0.19483
GOTERM_BP_DIRECT Positive regulation of cytokine secretion 3 4.14E-04 0.52992
GOTERM_BP_DIRECT Positive regulation of ERK1 and ERK2 cascade 4 0.00261 3.2984
GOTERM_CC_DIRECT Extracellular space 7 0.0112 9.89786
GOTERM_BP_DIRECT Positive regulation of angiogenesis 3 0.01284 15.282
GOTERM_BP_DIRECT Eosinophil chemotaxis 2 0.0174 20.1661
GOTERM_CC_DIRECT Extracellular matrix 3 0.02248 18.9797
GOTERM_BP_DIRECT Innate immune response 3 0.03594 37.4701
GOTERM_MF_DIRECT Integrin binding 2 0.03806 30.8271




Table S3. Genes shared between dissected diseased regions and TGFβ1-
treated qVICs. Genes in yellow share up- or down-regulation in both 
datasets. 
TGFβ-treated Dissected
qVICs Fold Change Fold Change
NDP Norrie disease -4.41 1.74
EBF2 Early B-cell factor 2 -2.2 -1.57
F2RL2 Coagulation factor II recptor-like 2 -2.13 -2.17
SELL Selectin L -2.07 1.95
SLC10A6 Solute carrier family 10 member 6 -1.96 -1.67
LIFR Leukemia inhibitory factor receptor -1.76 -1.76
HBEGF Heparin binding EGF like growth factor -1.73 1.9
ADH4 Alcohol dehydrogenase 4 -1.62 -1.73
LYVE1 Lympahtic vessel endotehlial hyluronan receptor 1 -1.52 -1.61
CTHRC1 Collagen triple helix repeat containing 1 1.55 1.72
PLAUR Plasminogen activator urokinase receptor 1.74 1.6
ENSCAFG00000002086 Uncharacterised 1.79 1.58
ACTA2 Actin alpha 2 smooth muscle 1.95 1.79
TUBB3 Tubulin beta III 2.29 2.07
CH25H Cholesterol 25-hydroxylase 2.68 1.7
HTR2B 5HT receptor 2B 3.71 1.57




Table S4. Genes shared between Whitney grade 4 valves and TGFβ1-treated 
qVICs. Genes in yellow share up- or down-regulation in both datasets. 
TGFβ-treated Grade 4 
qVICs Fold Change Fold Change
SCARA5 Scavenger receptor class A member 5 -2.41 -1.59
F2RL2 Coagulation factor II receptor like 2 -2.13 -1.62
TNFRSF19 TNF receptor member 19 -2.01 -1.8
SLC10A6 Solute carrier family 10 member 6 -1.96 -1.67
EPHA3 EPH receptor A3 -1.95 3.19
VCAM1 Vascular cell adhesion molecule -1.83 1.73
AHNAK2 AHNAK nucleoprotein 2 -1.78 1.68
SLC2A12 Solute carrier family 2 member 12 -1.75 -1.72
SLC22A23 Solute carrier family member 23 -1.67 -1.7
PLCB1 Phospholipase C Beta 1 -1.67 1.52
SYNDIG1 Synapse differentiation inducing 1 -1.6 1.55
TPX2 TPX2 microtubule associated -1.58 1.52
ANLN Anillin actin binding protein -1.57 1.67
BMP6 Bone morphogenetic protein 6 1.52 2.19
BTK Bruton agammaglobulinemia tyrosine kinase 1.64 1.81
TPM2 Tropomyosin 2 1.66 2.83
ENSCAFG00000002086 Uncharacterised 1.79 3.2
SERPINE1 Serpin peptidase inhibitor clade E 1 1.88 4.34
ACTA2 Actin alpha 2 smooth muscle 1.95 3.24
LIF Leukemia inhibitory factor 1.96 1.53
WFDC5 WAP four disulfide core 5 2.01 -3.68
ENSCAFG00000010877 Uncharacterised 2.01 -1.57
MFSD2A Major facilitator superfamily 2A 2.13 1.9
LTBP2 Latent TGF beta binding protein 2 2.3 1.84
ENSCAFG00000027039 Uncharacterised 2.48 -1.58
PAPPA Pregnancy associated plasma protein A 2.5 2.05
ST5 Suppression of tumorigenecity 5 2.53 1.55
MIR214 MicroRNA 214 2.61 -2.73
LOC486400 Uncharacterised 3.19 2.35
HTR2B 5HT receptor 2B 3.71 3.11
TNC Tenascin C 3.75 1.64
RGS1 Regulator of G-protein signalling 1 5.81 2.41




Table S5. Functional analysis chart summary of the nine GO terms 
associated with up-regulated shared genes in Whitney grade 4 valves and 













Category Term Gene count P-value FDR
GOTERM_CC_DIRECT Extracellular matrix 3 0.00309 2.48202
GOTERM_CC_DIRECT Extracellular space 5 0.00394 3.14982
GOTERM_BP_DIRECT Positive regulation of cell proliferation 3 0.013 14.3349
GOTERM_CC_DIRECT Extracellular region 3 0.0265 19.578
GOTERM_BP_DIRECT Positive regulation of endothelial cell proliferation 2 0.03751 36.3796
GOTERM_CC_DIRECT Extrinsic component of plasma membrane 2 0.04559 31.5178
GOTERM_BP_DIRECT Osteoblast differentiation 2 0.06538 55.0582
GOTERM_BP_DIRECT Positive regulation of gene expression 2 0.09994 71.2176
GOTERM_BP_DIRECT Regulation of cell proliferation 2 0.09994 71.2176
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Disease (MMVD). Greg R. Markby, Kim M. Summers, Vicky MacRae and 
Brendan M. Corcoran. Poster, Heart Valve Society Scientific Meeting, New 
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Pathogenesis in Canine Myxomatous Mitral Valve Disease. Greg R. Markby, 
Kim M. Summers, Vicky MacRae and Brendan M. Corcoran. 20-minute 
presentation, Companion Animal Genetic Health meeting, Edinburgh 14-15th 
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A Role for TGFβ1 in the Pathogenesis of Canine Myxomatous Mitral Valve 
Disease (MMVD. Greg R. Markby, Kim M. Summers, Vicky MacRae and 
Brendan M. Corcoran. Poster presentation, Cardiovascular science 
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